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Adverse drug effects are unintended and undesirable effects of medicines, causing attrition of 
molecules in drug development and harm to patients. To anticipate potential adverse effects 
early, drug candidates are commonly screened for pharmacological activity against a panel of 
protein targets. However, there is a lack of large-scale, quantitative information on the links 
between routinely screened proteins and the reporting of adverse events (AEs). This work 
describes a systematic analysis of associations between AEs observed in humans and 
bioactivities of drugs while taking into account drug plasma concentrations. 
In the first chapter, post-marketing drug-AE associations are derived from the United States 
Food and Drug Administration Adverse Event Reporting System using disproportionality 
methods, while applying Propensity Score Matching to reduce confounding factors. The 
resulting drug-AE associations are compared to those from the Side Effect Resource, which are 
primarily derived from clinical trials. The analysis reveals that the datasets generally share less 
than 10% of reported AEs for the same drug and have different distributions of AEs across 
System Organ Classes (SOCs). 
Using the drugs from the two AE datasets described in the first chapter, the second chapter 
integrates corresponding bioactivities, i.e. measured potencies and affinities from the ChEMBL 
database and ligand-based target predictions obtained with the tool PIDGIN, with drug plasma 
concentrations compiled from literature, such as Cmax. Compared to a constant bioactivity cut-
off of 1 µM, using the ratio of the unbound drug plasma concentration over the drug potency, 
i.e. Cmax/XC50, results in different binary activity calls for protein targets. Whether deriving 
activity calls in this way results in the selection of targets with greater relevance to human AEs 
is investigated in the third chapter, which computes relationships between targets and AEs 
using different measures of statistical association. Using the Cmax/XC50 ratio results in higher 
Likelihood Ratios and Positive Predictive Values (PPVs) for target-AE associations that were 
previously reported in the context of secondary pharmacology screening, at the cost of a lower 
recall, possibly due to the smaller size of the dataset with available plasma concentrations. 
Furthermore, a large-scale quantitative assessment of bioactivities as indicators of AEs reveals 
a trade-off between the PPV and how many AE-associated drugs can potentially be detected 
from in vitro screening, although using combinations of targets can improve the detection rate 
in ~40% of cases at limited cost to the PPV. The work highlights AEs most strongly related to 
bioactivities and their SOC distribution. 
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Overall, this thesis contributes to knowledge of the relationships between in vitro bioactivities 
and empirical evidence of AEs in humans. The results can inform the selection of proteins for 
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1.1 Adverse drug effects  
 
Medicines can, in addition to their therapeutic effects, have unintended effects, and when these 
are harmful they are referred to as ‘adverse drug effects’, defined as “an adverse outcome that can 
be attributed, with some degree of probability, to an action of a drug” (1, 2). Adverse drug effects 
are experienced by patients as adverse drug reactions (ADRs), but both terms refer to the same 
phenomenon (1). For example, the patient information leaflet of diclofenac tablets, a painkiller 
from the non-steroidal anti-inflammatory drug class, lists possible side effects according to 
frequency (Table 1.1). Some ADRs occur with the normal doses used for therapy (3), whereas 
other effects can arise with off-label use, overdose, misuse, abuse, and medication errors (2, 4).  
Table 1.1 Examples of possible side effects listed on a patient information leaflet for diclofenac 
tablets 
Adapted from (5). 
Frequency Example of listed side effect 
Uncommon (may affect up to 1 in 100 people) Sudden and crushing chest pain (signs of 
myocardial infarction or heart attack) 
Rare (may affect up to 1 in 1,000 people) Any sign of bleeding in the stomach or intestine 
Very rare (may affect up to 1 in 10,000 people) Fits 
Unknown Chest pain, which can be a sign of a potentially 
serious allergic reaction called Kounis syndrome 
 
 When monitoring patients, a causal link between the drug exposure and adverse outcomes may 
not be established, thus the more inclusive terms ‘adverse event’ (AE), or ‘adverse experience’ are 
used (1). Therefore, the United States (US) Food and Drug Administration (FDA) distinguishes 
between an AE, defined as: “any untoward medical occurrence associated with the use of a drug 
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in humans, whether or not considered drug related”, and an adverse reaction, defined as “any 
adverse event caused by a drug” (1, 6).   
 
ADRs can harm patients by leading to life-threatening injury, prolonged hospital stays, disability 
and mortality (7, 8). While the exact incidence of ADRs is difficult to determine (2, 9), one study 
estimated the incidence of serious ADRs among hospitalised patients in the US to be 6.5% (10). 
The percentage of hospital admissions in Europe due to ADRs ranged from 0.5% to 12.8% in 
different studies (8), whereas a study in England estimated that 4% of hospital beds are occupied 
due to ADRs (11). In patients admitted due to ADRs, mortality attributed to the ADR was 2.3% 
(11). Thus, ADRs account for considerable harm to patients and costs to healthcare systems (11). 
 
Safety issues are also a major obstacle in the development of new drugs. Waring et al. investigated 
drug candidates developed by four major pharmaceutical companies between 2000 and 2010 that 
were terminated, i.e. not progressed into further clinical studies (12). Among early candidate 
compounds, 59% of terminations were due to failure in preclinical toxicology (12). In phase I and 
phase II clinical trials, 25% of terminations were caused by a lack of clinical safety, making this the 
leading and second leading causes of attrition in these phases, respectively (12). Similarly, an 
analysis of project closures in AstraZeneca between 2005 and 2010 showed that 62% of phase I 
and 35% of phase II projects were terminated due to clinical safety issues (13). These statistics 
highlight that drug safety and adverse drug effects are a major challenge in drug development and 
that there is a need for early and accurate prediction of adverse drug effects. 
1.1.1 Types of adverse drug reactions 
ADRs can broadly be categorised in type A and type B reactions (Table 1.2). In this classification, 
type A reactions are dose-dependent and predictable from the primary, secondary and safety 
pharmacology (1, 14, 15). Type B reactions are not dose-related and not predictable from the 







Table 1.2 Classification of ADRs 




Type A • Dose-dependent 
• Predictable from primary, secondary and 
safety pharmacology 
• Mechanism related to pharmacology 
Relatively frequent (usually 
>1 in 100 users) 
Type B • Not related to dose 
• Not related to pharmacology 
• Not predictable, unexpected 
• Mechanism often not known 
Minority (often <1 in 1000 
users) 
Type C • Long-term adaptive changes 
• Increased frequency of a disease in 
population 
• Not predictable, unexpected 
• Mechanism uncertain 
Not reported 
 
Effects arising from the primary pharmacology, i.e. on-target effects, are those due to interaction 
with the primary therapeutic target of the drug, which is the protein believed to be responsible for 
the therapeutic effect of the drug (18, 19). An example is hypoglycaemia due to sulphonylurea used 
in diabetes (14). In contrast, off-target effects arise from unintended interaction with secondary 
targets, such as QT prolongation caused by inhibition of the human ether-a-go-go-related gene-
encoded voltage-dependent potassium channel (hERG) by a variety of drugs, e.g. terfenadine (19, 
20). The mediation of cellular effects due to on-target and off-target interactions is illustrated in 
Figure 1.1. In contrast, an example of a type B reaction, which are not caused by pharmacological 




Figure 1.1 Schematic illustration of drugs interacting with primary and secondary pharmacological 
targets which may result in different effects. Secondary target interactions may cause undesirable 
effects. 
Reprinted from Jenkinson et al. (22) with permission from Elsevier. 
The A/B classification is imperfect and there exist numerous ADRs that do not match the 
descriptions of the categories (1). As such, extensions to the classification have been proposed, 
although the ADR incidence for these classifications is not available (1). For example, the A/B 
classification was extended with type C reactions (Table 1.2), referring to effects of long-term use, 
especially an increase in the frequency of a disease that is already relatively common in the 
population (1, 16, 17). An example is cardiovascular events related to rofecoxib (17). However, the 
dose-relatedness of type C reactions has not been described, illustrating how the ADRs categories 
can overlap (1). Another review categorized drug-induced toxicities in five groups: hypersensitivity 
and related immunological reactions; on-target pharmacology; off-target pharmacology; biological 
activation to toxic metabolites; and idiosyncratic toxicities, where idiosyncratic effects were 
regarded as rare occurrences of the former mechanisms (23). 
 
A meta-analysis of the incidence of ADRs in hospitalised patients or leading to hospital admissions 
reported that ~75% of ADRs were type A reactions and ~25% type B reactions (10). These 
statistics give a broad idea of the importance of pharmacology in causing ADRs and the potential 
to predict ADRs from pharmacological interactions (15, 24). 
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1.1.2 Medical Dictionary for Regulatory Activities (MedDRA) hierarchy 
The Medical Dictionary for Regulatory Activities (MedDRA) is the main standardised medical 
vocabulary currently in use for recording ADRs in regulatory submissions and the study of ADRs 
(25).  
 
The vocabulary is organised as a hierarchy with five levels. At the highest, most general level are 
the 27 System Organ Classes (SOCs) (Figure 1.2). The most specific terms are the Lowest Level 
Terms (LLTs), which can be interpreted as synonyms that are mapped to a Preferred Term (26). 
A Preferred Term (PT) is defined as “a distinct descriptor (single medical concept) for a symptom, 
sign, disease diagnosis, therapeutic indication, investigation, surgical or medical procedure, and 
medical social or family history characteristic” (27). Directly above the PT level is the High Level 
Term (HLT), grouping related PTs (27). In turn, HLTs are grouped in High Level Group Terms 
(HLGT) under the SOC. To illustrate this hierarchy, the path from the SOC Cardiac disorders to 
the PT ‘Torsade de pointes’ (TdP) is shown in Figure 1.3. 
 
Figure 1.2 The 27 SOCs in the MedDRA (version 21.1). These form the highest, most general 
level in the hierarchy. 
Blood and lymphatic system disorders
Cardiac disorders
Congenital, familial and genetic disorders








Injury, poisoning and procedural complications
Investigations
Metabolism and nutrition disorders
Musculoskeletal and connective tissue disorders
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nervous system disorders
Pregnancy, puerperium and perinatal conditions
Product issues
Psychiatric disorders
Renal and urinary disorders
Reproductive system and breast disorders
Respiratory, thoracic and mediastinal disorders
Skin and subcutaneous tissue disorders
Social circumstances





Figure 1.3 The path from the SOC 'Cardiac Disorders' to the PT TdP in the MedDRA hierarchy 
(version 21.1). 
1.2 Pharmacokinetics 
In most instances, the effect of drugs is dependent on their concentration at the molecular sites of 
action, such as a receptor (28, 29). Pharmacokinetics are concerned with (1) the relationship 
between dose and the unbound drug concentration at the site of action and (2) the drug 
concentration over time (29, 30).  
 
The concentration at the site of action depends on the dose of the drug administered and on the 
drug’s disposition, which encompasses the processes of absorption, distribution, metabolism and 
elimination (ADME) (28, 30). These factors combined result in changes of the drug concentration 
over time (28, 29). Different drugs have different ADME properties, and individuals also differ, 
for example in their metabolic capacity, which is why the exposure of the tissue or target site is 
important rather than the dose of the drug (31, 32). 
 
While concentrations at the site of action can typically not be measured, drug plasma 
concentrations can be measured more easily (29). A generic time course of the drug concentration 
in plasma is shown in Figure 1.4. The drug concentration in plasma can be measured at different 
intervals after drug administration to derive exposure parameters such as maximum concentration 
Cmax and area under the plasma concentration-time curve (AUC) (28, 30). The Cmax refers to the 
maximum concentration reached during a dosing interval (30). The AUC is the total area under 
the plasma drug concentration time-curve and can be used to understand the systemic exposure 
to the drug (Figure 1.4) (30, 31).  
Cardiac arrhythmias










Rate and rhythm disorders NEC
Supraventricular arrhythmias




























Figure 1.4 Generic plasma concentration-time plot and pharmacokinetic parameters 
Reproduced from Rolan and Molnár (29) with permission from John Wiley and Sons Ó 2013. 
The plasma concentration can differ from the concentration in various tissues and the brain, but 
the since the latter cannot be measured non-invasively, it is common to use plasma concentrations 
as a surrogate measurement (22, 31, 33). 
 
In the blood, drugs reversibly bind to plasma proteins, i.e. plasma protein binding (PPB) and 
similar processes happen in tissues in vivo (32). Only the unbound (free) drug is available for 
interaction with proteins and therefore most directly related to a drug’s pharmacological effects, 
although there are some exceptions to this (31, 32).  
 
The extent of PPB varies between drugs, thus to derive the relevant free concentration, this must 
be taken into account. The unbound concentration is derived by multiplying the total 
concentration by the free drug fraction: 
 
!! = !" ∗ 	%! (1.1) 
 
where Cu is the unbound concentration, Ct is the total concentration, and  fu is the fraction unbound 
(30, 32). 
1.3 Pharmacodynamics and drug action 
 
Pharmacodynamics is concerned with the relationship between the unbound drug concentration 
at the site of action and the drug response, such as therapeutic or toxic effects (30). Drugs can 
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bind to different types of proteins, such as enzymes, ion channels, transporters, and receptors, of 
which receptors are the largest class of drug targets (18). 
 
Compounds that produce similar effects at receptors as endogenous signalling molecules are called 
agonists (28, 34). Compounds that bind to the receptor but do not produce any direct cellular 
effect are called antagonists, which can reduce the action of the receptor by preventing the 
endogenous ligands from binding (28, 34, 35). Agonism at a protein target can have different or 
opposite effects to antagonism (19). 
 
Agonists that are able to elicit a full functional response as they bind to the target are full agonists, 
whereas those that are only able to elicit a partial response, even at high concentrations, are partial 
agonists, as illustrated in Figure 1.5. Thus, partial agonists have lower intrinsic efficacy than full 
agonists, and antagonists lack efficacy (35, 36). Efficacy is the extent of functional change or 




Figure 1.5 Partial agonists have a lower capacity to elicit a cellular response, i.e. lower intrinsic 
efficacy, than full agonists. 
Antagonists that compete with the endogenous ligand for the same binding site are competitive 
antagonists (36). Inverse agonism is similar to competitive antagonism, but happens when the 
receptor is constitutively active and the ligand has higher affinity for the inactive state than the 
active state of the receptor, reducing the overall activity level (Figure 1.6). This is in contrast with 












Figure 1.6 Effect on inverse agonists on the level of receptor activation 
Adapted from (35). 
Allosteric antagonists bind to a separate binding site on the protein, the allosteric binding site, 
causing a decrease in the affinity of the protein for the endogenous agonist (36). This is referred 
to as non-competitive antagonism (36). Alternatively, allosteric modulation that potentiates the 
endogenous agonist’s response is achieved by allosteric agonists (36). Another mechanism of 
functional non-competitive antagonism is due to covalent binding or very slow dissociation from 
the main binding site (36), although this has also been called irreversible competitive antagonism 
(35). Lastly, uncompetitive inhibition refers to an inhibitor binding only to the enzyme-substrate 
complex (37, 38), and sometimes uncompetitive antagonism is used to describe antagonists that 
can only bind to receptors upon activation of the receptor by the agonist (38, 39). 
 
The bioactivity of drugs can be quantified as their potency, which is the amount of drug required 
to produce an effect of given intensity (40). Two common measures of potency are the half-
maximal effective concentration (EC50/AC50) for agonists and half-maximal inhibitory 
concentration (IC50) for antagonists or enzyme inhibitors (37, 40). These measures refer to the 
concentration required to reach 50% of the maximal effect of the compound on a biochemical 








Constitutive level of receptor activation 
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Figure 1.7 Concentration-effect curve of the intensity of the response against the logarithm of 
the drug concentration, and position of the EC50, a common measurement of potency. 
Adapted from (28). 
 
 
Figure 1.8 Concentration-effect curve of the intensity of the response against the logarithm of the 
drug concentration, and position of the IC50, a common measurement of potency. 
 
Potency is influenced by the affinity and the efficacy of the drug, and the receptor density (28).  
Affinity refers to the binding of the drug to a receptor as a result of chemical forces, which can be 
quantified by the equilibrium dissociation constant, Kd, of the drug-receptor complex, and 
corresponds to the concentration achieving 50% receptor binding site occupancy (28, 41). The 
binding affinity of competitive antagonists can be quantified with the inhibition constant, Ki (36). 
Measurements of IC50 and EC50 depend on experimental conditions such as the concentration of 
















However, determining affinities may be more time-consuming, and less indicative of tissue and 
organ-level effects than potency measurements (42, 43).  
 
Whilst it is clear that measurements such as Ki, EC50, IC50 etc. are different from one another, in 
practice, different affinity and potency measures have been pooled in order to maximise the 
amount of usable bioactivity data derived from varied sources, such as for modelling, and one 
study found that this only moderately increases noise in the combined data (18, 40, 44). 
 
Polypharmacology, or compound promiscuity, refers to a single compound interacting with 
multiple protein targets, i.e. the extent of affinity for multiple targets (45, 46). For example, clinical 
candidates and marketed drugs are generally active at more than one target; one study found that 
35% of marketed drugs are active (< 10 µM) against 2 to 5 targets, and most other drugs against 
a higher number, although the extent of polypharmacology varies between drugs (46, 47). While 
the unintended interaction of drugs with off-targets such as hERG can cause adverse drug effects, 
it is recognised that the polypharmacology of various approved drugs is essential to their 
therapeutic efficacy (48, 49). For example, the action of antipsychotic drugs at multiple protein 
targets is thought to play a role in their efficacy (50). Similarly, some oncology drugs achieve a 
beneficial synergistic effect by inhibiting multiple targets simultaneously (48, 49, 51). Furthermore, 
it might be possible to reduce adverse effects mediated through on-target interactions when drugs 
act through multiple pathways simultaneously, as is the case for some analgesics (48). In 
conclusion, while it remains important to avoid unintended off-target activities, polypharmacology 
is also of increasing interest for improving therapeutic efficacy and safety (48, 49, 51). 
 
1.4 Overview of safety assessment during drug discovery and 
development 
 
The discovery and development of drugs is a lengthy process, of which some of the traditional 
stages are illustrated in Figure 1.9. In the earliest phases of drug discovery, thousands or millions 
of molecules may be screened for their activity against a biological target of interest e.g. in a high-
throughput screening campaign. These are then narrowed down to a limited set of hit compounds 
to be further optimised into lead compounds, before a final candidate is chosen for the first animal 
studies and ultimately clinical studies involving human participants (52–55). After marketing 




Figure 1.9 Traditional phases of drug discovery and development 
Adapted from (22, 53). 
 
The following sections will further introduce the safety-related studies in each of the drug 
discovery and development phases, focusing on in vitro pharmacological profiling and the analysis 
of post-marketing surveillance data, since these are of direct relevance to the current work. 
1.4.1 Early drug discovery 
1.4.1.1 In silico and in vitro screening 
In the 1990s, several drugs were withdrawn from the market due to AEs, for example the appetite 
suppressant fenfluramine was associated with heart valve disease and the antihistamine astemizole 
carried an increased risk of arrhythmia (57). Upon detailed analysis, these adverse effects were 
found to be related to specific interactions of the drugs with human targets: agonism at the cardiac 
serotonin receptor 2B (5-HT2B) was found to induce heart valve disease and inhibition of hERG 
causes prolongation of the QT interval on the electrocardiogram, with the potential to cause life-
threatening arrhythmias (58, 59). These discoveries led to the introduction of additional regulatory 
requirements for both in vitro testing, such hERG channel inhibition, and in vivo testing, i.e. a battery 
of mandatory safety pharmacology investigations in animals (15, 59). These developments, 
together with the high cost of late-stage failures, also motivate the wider trend to assess potential 
safety issues early in drug discovery during lead selection and optimisation (15, 19, 52). In silico and 
in vitro techniques play an important role in this ‘front-loading’ (15, 52).   
 
In silico models exist to predict genotoxicity, protein target interactions such as with hERG and the 
bile salt export pump (BSEP), and sometimes more complex endpoints such as phospholipidosis 
that have some dependence on physicochemical parameters (52). The types of studies done in vitro 
include cytotoxicity, genotoxicity, interaction with metabolic enzymes, as well as tissue-specific cell 
culture models (52).  However, one of the most widely used techniques is in vitro secondary 
pharmacological profiling, which refers to screening compounds against a variety of protein targets 
with possible links to adverse effects (19, 20, 22). Some screening panels are dedicated to specific 






target classes such as kinases or ion channels, or on establishing the general promiscuity, which 
has been associated with toxicity (19, 60). In vitro secondary pharmacology screening has also been 
referred to as selectivity screening, pharmacological profiling, and in vitro safety profiling (19, 20, 
22).  
1.4.1.2 Published secondary pharmacology screening panels 
A number of safety pharmacology profiling panels have been published (Table 1.3). Generally, the 
targets included on such panels include G protein-coupled receptors (GPCRs), ion channels, 
enzymes, transporters and nuclear receptors. One panel published by Bowes et al. consists of 44 
proteins which was compiled as the consensus set of targets screened by major pharmaceutical 
companies, intended to be used as a minimal set of targets to be screened (19). This panel is also 
available commercially as the Cerep-44 panel (61). Whitebread et al. compiled a set of 36 targets 
focused on cardiovascular toxicity (20). The panel used at Abbvie includes over 70 targets (62), 
whereas a list of targets used at Novartis has also been published (63). Authors from Amgen 
suggested a panel of 70 targets for application in pharmaceutical development (64). More recently, 
an optimised panel of 50 targets was published that was tailored to screening needs at Roche (65). 
The specific targets in three published panels are shown by target class in Table 1.4. The overlap 
in targets between these three panels is roughly between 30 and 80%. 
Table 1.3. Overview of published safety target panels 




effects, phenotypes or 
ADRs 
Reference 
Bowes et al. (2012) Minimal consensus 
panel from four 
companies / Cerep-44 
44 Yes, with references (19) 
Lounkine et al. 
(2012) 
Novartis 73 No (63) 




36 Yes, without references (20) 
Lynch et al. (2017) Abbvie – focus on 
pathology 
70 Yes, with references (62) 
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Deaton et al. (2019) Amgen 70 Yes, partial references (64) 
Bendels et al. (2019) Roche 50 No (65) 
 
Regarding the selection of targets included on safety target panels, the focus in most is on human 
targets although targets from other organisms are sometimes included (20, 62). One cited 
important criterion for including targets is an established association with clinical ADRs, where 
serious and frequent ADRs are prioritised (66). This results in a prominent representation of 
targets explored as therapeutic drug targets, such GPCRs (Table 1.4), since there is more clinical 
experience and knowledge of such targets (19, 20, 66, 67). The emphasis on severe effects is 
reflected in the focus on targets related to the cardiovascular, respiratory, and nervous systems (19, 
64). In contrast to requiring established associations with clinical effects, Bendels et al. decided to 
focus on the general promiscuity across targets, including a large share of targets that lacked 
established knowledge of adverse effects (65). However, Jenkinson et al. suggest that including 
targets without strong evidence of in vivo effects may have questionable value for decision-making 
(22).  
 
Another consideration for target inclusion is the redundancy in active compounds between targets, 
for instance, often a target family representative is included rather than multiple members of a 
family (19, 64, 68). A cut-off of 80% ligand overlap or protein sequence similarities have been used 
for this (64, 66). The optimised panel for screening at Roche was derived by statistical analysis of 
assay hit rates and iterative comparison of the overlap of active ligands between assays, in order to 
select the most non-redundant set of assays (65). 
 
Technical aspects of in vitro assay development also influence the selection of targets, for example 
ion channels are more difficult to screen in a high-throughput fashion, resulting in a historic 
underrepresentation of ion channels on safety pharmacology panels (19). 
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Table 1.4 Targets in three published safety target panels by target class. The target class is the second level of the ChEMBL target hierarchy if available 
otherwise only the first level is shown. 
Target class Bowes et al. (19) Lynch et al. (62) Whitebread et al. (20) 
Electrochemical 
transporter 
• Dopamine transporter 
• Norepinephrine transporter 
• Serotonin transporter 
• Dopamine transporter 
• Norepinephrine transporter 
• Serotonin transporter 
None 
Family A G protein-
coupled receptor 
• Adenosine A2a receptor 
• a-1a adrenergic receptor 
• a-2a adrenergic receptor 
• b-1 adrenergic receptor 
• b-2 adrenergic receptor 
• Cannabinoid CB1 receptor 
• Cannabinoid CB2 receptor 
• Cholecystokinin A receptor 
• d opioid receptor 
• Dopamine D1 receptor 
• Dopamine D2 receptor 
• Endothelin receptor ET-A 
• Histamine H1 receptor 
• Histamine H2 receptor 
• k opioid receptor 
• Adenosine A1 receptor 
• Adenosine A2a receptor 
• Adenosine A2b receptor 
• Adenosine A3 receptor 
• a-1a adrenergic receptor 
• a-1b adrenergic receptor 
• a-2a adrenergic receptor 
• a-2b adrenergic receptor 
• Angiotensin II type 2 (AT-2) receptor 
• b-1 adrenergic receptor 
• b-2 adrenergic receptor 
• Bradykinin B2 receptor 
• Cannabinoid CB1 receptor 
• Cannabinoid CB2 receptor 
• Cholecystokinin A receptor 
• Adenosine A1 receptor 
• Adenosine A2a receptor 
• Adenosine A3 receptor 
• a-1a adrenergic receptor 
• a-1b adrenergic receptor 
• a-2a adrenergic receptor 
• a-2b adrenergic receptor 
• a-2c adrenergic receptor 
• b-1 adrenergic receptor 
• b-2 adrenergic receptor 
• Bradykinin B1 receptor 
• Bradykinin B2 receptor 
• Dopamine D1 receptor 
• Endothelin receptor ET-A 
• Endothelin receptor ET-B 
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• µ opioid receptor 
• Muscarinic acetylcholine receptor M1 
• Muscarinic acetylcholine receptor M2 
• Muscarinic acetylcholine receptor M3 
• Serotonin 1a (5-HT1a) receptor 
• Serotonin 1b (5-HT1b) receptor 
• Serotonin 2a (5-HT2a) receptor 
• Serotonin 2b (5-HT2b) receptor 
• Vasopressin V1a receptor 
• d opioid receptor 
• Dopamine D1 receptor 
• Dopamine D2 receptor 
• Endothelin receptor ET-A 
• Endothelin receptor ET-B 
• Histamine H1 receptor 
• Histamine H2 receptor 
• k opioid receptor 
• Melatonin receptor 1B 
• µ opioid receptor 
• Muscarinic acetylcholine receptor M1 
• Muscarinic acetylcholine receptor M2 
• Muscarinic acetylcholine receptor M3 
• Muscarinic acetylcholine receptor M4 
• Muscarinic acetylcholine receptor M5 
• Neurokinin 1 receptor 
• Neurokinin 2 receptor 
• Neuropeptide Y receptor type 1 
• Platelet activating factor receptor 
• Prostanoid EP2 receptor 
• Serotonin 1a (5-HT1a) receptor 
• Serotonin 1b (5-HT1b) receptor 
• Serotonin 2a (5-HT2a) receptor 
• Ghrelin receptor 
• Histamine H3 receptor 
• Muscarinic acetylcholine receptor M1 
• Muscarinic acetylcholine receptor M2 
• Muscarinic acetylcholine receptor M3 
• Muscarinic acetylcholine receptor M4 
• Neuropeptide Y receptor type 1 
• Serotonin 2b (5-HT2b) receptor 
• Serotonin 4 (5-HT4) receptor 
• Thromboxane A2 receptor 
• Type-1 angiotensin II receptor 
• Vasopressin V1a receptor 
• Vasopressin V1b receptor 
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• Serotonin 2b (5-HT2b) receptor 
• Serotonin 2c (5-HT2c) receptor 
• Serotonin 4 (5-HT4) receptor 
• Serotonin 7 (5-HT7) receptor 
• Type-1 angiotensin II receptor 
• Urotensin II receptor 
• Vasopressin V1a receptor 
Family B G protein-
coupled receptor 
None • Calcitonin gene-related peptide type 1 
receptor 
• Vasoactive intestinal polypeptide receptor 
1 
• Calcitonin gene-related peptide type 1 
receptor 
Hydrolase 
• Acetylcholinesterase • Acetylcholinesterase 





• Acetylcholine receptor protein achain 
• GABA receptor a-1 subunit 
• Glutamate (NMDA) receptor subunit 
zeta 1 
• Neuronal acetylcholine receptor protein 
a-4 subunit 
• Serotonin 3a (5-HT3a) receptor 
• GABA receptor a-1 subunit 
• Glutamate (NMDA) receptor subunit zeta 
1 
• P2X purinoceptor 1 
• P2X purinoceptor 2 
• P2X purinoceptor 3 
• P2X purinoceptor 4 
• P2X purinoceptor 5 
• Acetylcholine receptor protein a chain 
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• P2X purinoceptor 6 
• P2X purinoceptor 7 
• Serotonin 3a (5-HT3a) receptor 
Membrane receptor 
None • s opioid receptor 
• Translocator protein 
None 
Nuclear receptor 
• Androgen Receptor 
• Glucocorticoid receptor 
• Androgen Receptor 
• Glucocorticoid receptor 






• Monoamine oxidase A 
• Cyclooxygenase-2 
• Monoamine oxidase A 
None 
Phosphodiesterase 
• Phosphodiesterase 3A 
• Phosphodiesterase 4D 
• Phosphodiesterase 3A None 
Primary active 
transporter 
None • Sodium/potassium-transporting ATPase 
a-1 chain 
None 
Protease None • Angiotensin-converting enzyme None 





• Sodium channel protein type V asubunit 
• Voltage-gated L-type calcium channel a-
1C subunit 
• Voltage-gated potassium channel subunit 
Kv7.1 (+ Voltage-gated potassium channel 
b subunit Mink) 
• Potassium channel, inwardly rectifying, 
subfamily J, member 11 
• Small conductance calcium-activated 
potassium channel protein 1 
• Small conductance calcium-activated 
potassium channel protein 2 
• Small conductance calcium-activated 
potassium channel protein 3 
• Sodium channel protein type V a subunit 
• Voltage-gated L-type calcium channel a-
1C subunit 
• hERG 
• Potassium channel, inwardly rectifying, 
subfamily J, member 11 
• Sodium channel protein type V a-subunit 






Screening compounds at a single fixed concentration, such as 10 µM, and observing the percentage 
inhibition is more cost-effective than determining the full dose-response curve to determine the 
IC50, so this is often used in safety target screening (19, 22, 62, 65). Often only target binding is 
established, rather than the agonist or antagonist mode, for instance using radioligand binding 
assays (19, 20, 22, 62). Such binding assays primarily detect antagonists, and while in practice most 
drugs with binding affinity are antagonists, there are some exceptions such as 5-HT2B agonism (22, 
62, 66). When using binding assays, target interaction and dose-response can subsequently be 
investigated in more detail (22, 60, 62, 65). Other safety target panels do include agonist and 
antagonist modes, or consist of a combination of functional and binding assays (60). 
1.4.1.3 Remaining questions around target selection and interpretation 
In early drug discovery, secondary pharmacology screening is widely used to flag potential adverse 
effects in large sets of compounds and to rank and (de)select compounds for further study (19, 
62). Later on, the results are used to design further preclinical and clinical studies (19, 62, 69). 
However, despite their widespread use, there are remaining questions regarding a range of aspects 
of the current secondary pharmacology screening panels. 
 
Firstly, the rationale for the selection of individuals targets is not consistently included on 
published panels, as illustrated by only two of the published panels including full references to 
supporting evidence on which target inclusion is based (Table 1.3). From the overlap between 
different panels it is also clear that companies have made different choices regarding targets to be 
screened (Table 1.4) (22). For example, the panel by Lynch et al. includes one melatonin receptor, 
whereas Bowes et al. and Bendels et al. specifically did not include any melatonin receptors due to 
lack of evidence of adverse effects (19, 65). Even in regulatory submissions, authors from the US 
FDA stated that “the panels of targets that are employed vary widely and are often selected without 
justification or a description of their relevance to human safety” (70). In the panel reported by 
Bendels et al. (65), most targets were included despite not having established evidence of safety 
implications while other targets were specifically excluded from the list of Bioprint targets on 
which the panel was based, due to lack of clinical relevance (65). Other differences in target 
selection may be due to different experiences within organisations, therapeutic areas, and primary 




Secondly, there is a lack of information on how to interpret secondary pharmacology screening 
results and use the findings in subsequent decision-making. Comprehensive qualitative and 
quantitative annotations are considered important for interpretation and decision-making (22, 62, 
66). Off-target activities may give an early idea of potential susceptibilities to AEs e.g. in certain 
patient groups (47), and therefore the results influence in vivo safety assessment and endpoints to 
monitor during clinical trials (19, 66). For example, inhibition of phosphodiesterase 3 (PDE3) is 
linked to an increase in cardiac contractility that may have a negative impact in congestive heart 
failure (47, 62). Thus, if this is relevant to the intended therapeutic area of the molecule or 
candidate, secondary screening results for this target can aid the compound selection (47). 
However, only few of the published panels include full annotations of the in vivo biological effects, 
phenotypes, or associated ADRs (Table 1.3) (22, 62, 66). Krejsa et al. reported that while secondary 
pharmacology screening results are used to design subsequent studies “the interpretation of off-
target binding results is usually based on the personal experience of the development research 
team” (69). Thus, additional, more widely available information of target-associated effects to 
support decision-making based on safety pharmacology would be valuable. 
 
A third limitation of secondary pharmacology panels includes the lack of quantification of the 
correspondence between in vitro secondary pharmacology activities and in vivo effects. In early 
screening, the most important question is how likely an adverse effect is given an observed in vitro 
potency (71). Therefore, Pollard et al. point to the Positive Predictive Value (PPV) and Negative 
Predictive Value (NPV) as the relevant measures for (de)selecting compounds; these measures 
identify the fraction true positives in terms of in vivo effects among all compounds active in vitro, 
and the fraction of true negatives among all inactive compounds, respectively (71). Depending on 
the bioactivity threshold (0.3, 1, 3, 10, 30, 100, 300, and 1000 µM) for in vitro hERG inhibition, 
Pollard et al. report PPVs ranging from 1.00-0.29 and NPVs between 0.94 and 0.78 with respect 
to QT interval prolongation in humans (71). To use this information for decision-making, Pollard 
et al. suggested that based on the low risk of in vivo effects for compounds with low-potency at 
hERG, compounds can be progressed at early stages (71). Similarly, Krejsa et al. studied the 
usefulness of in vitro potencies at different safety targets for predicting clinical adverse effects, 
reporting the PPVs for different in vitro potency ranges (69). For example, 80% of drugs with an 
IC50 under 0.1 µM at the muscarinic receptor M1 listed tachycardia on the drug label (69). Similarly, 
the PPVs for the other IC50 bins were as follows (approximate values): 50% for 0.1-1 µM, 45% 
for 1-10 µM, 39% between 10-50 µM, and 25% for drugs with an IC50 > 50 µM (69). Similar 
concentration-response relationship were reported for the relationships between histamine H1 and 
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somnolence, and between dopamine D1 and tremor or extrapyramidal symptoms (69). Krejsa et 
al. suggested that analyses such as these can help to identify those targets with the strongest 
statistical links to ADRs, supporting the quantitative interpretation of in vitro pharmacological 
activities as well as the selection of targets for in vitro screening and computational model 
development (69). However, beyond these two articles reporting on only few target-AE 
combinations, there is a lack of publicly available information on the predictive values of secondary 
pharmacology activities, with none of the published panels listed in Table 1.3 including any 
quantitative measures of association. Without quantitative information on the likelihood of in vivo 
effects, there is a risk that too many candidates are flagged if assays have high false positive rates, 
and potentially safe compounds are not taken forward, which would hamper the discovery process 
(52, 66). A similar lack of information on the predictive value of other nonclinical safety 
assessments, and quantitative knowledge to inform decision-making, such as safety margins, and 
has also been identified (19, 22, 24). Overall, there is a need for greater understanding of the 
translation of in vitro activities to in vivo effects and quantitative information on this relationship 
(19, 66).  
1.4.1.4 Additional uses of secondary pharmacology screening results  
Apart from ranking and (de)selecting candidates for progression, one of the other main purposes 
of safety target screening is to inform structure-activity relationships that can be used in attempts 
to eliminate the off-target activities using medicinal chemistry (19, 22, 66, 72). Therefore, structure-
activity relationships may be built using the results (22). The results of secondary pharmacology 
screens also feed into the development of in silico models for target activity that may become 
alternatives to in vitro profiling (19, 60, 72).  
 
In the lead optimisation phase, predictions for the therapeutic plasma concentration can be made, 
which allows teams to focus on achieving the widest safety margins (19). A safety margin is the 
ratio of the AC50 in an in vitro assay and the (predicted) free plasma concentration (19, 22). It is 
emphasized that activity on safety target panels does not necessarily mean that an ADR will be 
observed, since as described in the earlier, the ultimate effects of drugs also depend on the 
pharmacokinetics (20, 66). Thus, integration with the free plasma concentration is considered 
useful and important for the interpretation of off-target activities and the translation to adverse 
effects in humans (19, 20, 22, 57, 66, 69, 73). It is also recommended to focus on this kind of 
quantitative, integrated risk assessment in regulatory submissions (19, 70). 
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Another use of secondary pharmacology screening is to rationalise species differences observed in 
preclinical toxicity studies or discrepancies between the effects observed in animal studies and 
clinical trials (22, 66). This also highlights one of the potential advantages of in vitro 
pharmacological profiling, which is that it focuses on human targets, since some adverse effects 
may be difficult to examine in animals, e.g. suicidal intent or hallucinations (15, 67, 74). Muller et 
al. identified 10 protein targets associated with suicidal intent and behaviour, showing that in vitro 
target activities can be associated with complex AEs (75). 
1.4.1.5 Compound promiscuity 
Compound promiscuity has been found to correlate with toxicity, e.g. studies found that 
promiscuity is correlated with in vitro cytotoxicity (76) and in vivo toxicity findings in animal studies 
(76–78). Similarly, another study found that candidates that were terminated are more often 
promiscuous than marketed drugs (79). The knowledge that compound promiscuity is linked to 
several physicochemical properties such as lipophilicity and basicity is being used in drug discovery 
to reduce undesired promiscuity (19, 45, 76, 78). Another trend is the use of small in vitro 
pharmacology panels in early drug discovery, similar to the safety target panels introduced earlier, 
but these promiscuity panels are run separately and include a much smaller set of targets. For 
example, Sameshima et al. described a panel of 8 targets from diverse target families which 
correlated well with promiscuity measured in larger panels (76). Such small-scale promiscuity 
panels can be used early on to filter out promiscuous compounds (76) and is considered separately 
from multi-target activity in larger in vitro pharmacology screens (78). The former establishes 
promiscuity for a compound while not having knowledge of the precise targets and potential 
consequences, whereas the latter focuses on identifying secondary targets and their potential 
consequences for specific ADRs (78). 
1.4.2 Preclinical phase 
In the preclinical phase, the pharmacokinetics and toxicity of drug candidates are investigated in 
animals, such as during repeat-dose studies over several weeks or months (55). A range of doses 
is included and generally the number of animals per dose group is usually 20 or fewer (55). Aspects 
investigated include body weight, electrocardiography, haematology, clinical chemistry, 
histopathology of the organs, as well as carcinogenicity and reproductive toxicology studies (55). 
The doses used are generally higher than the intended therapeutic dose (55). Separately, safety 
pharmacology studies investigate pharmacologically-mediated effects on important physiological 
functions - cardiovascular, respiratory and central nervous systems - often after a single dose in 
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the therapeutic range or above (15, 55). Both toxicology and safety pharmacology studies follow 
strict sets of guidelines and regulatory requirements with respect to study design and endpoints 
assessed (55). 
 
A number of studies performed statistical analyses of large datasets to study the concordance 
between preclinical and clinical AEs. Toxicities in animals predict a reasonable fraction of clinical 
adverse effects, but they remain imperfect, especially in their negative predictive value, that is the 
absence of animal toxicity predicting the absence of ADRs in humans (74, 80, 81). The predictive 
value of animal studies also varies by organ system (74, 80, 81). 
1.4.3 Clinical phase 
During clinical trials, drug candidates are tested in humans for therapeutic efficacy and safety. The 
process usually takes place according to the following four phases (54). In phase I clinical trials, 
the drug is tested in around 25-100 healthy volunteers for tolerability, pharmacokinetics, and safety 
(54). The efficacy and safety are investigated in phase II trials and phase III trials, including 
hundreds to thousands of subjects with the relevant condition (54, 55). Phase IV refers to post-
marketing surveillance, often based on over 10,000 subjects with the condition in the population 
(see section 1.4.4 below) (54, 55). Clinical trial phases I-III usually include one or more control 
groups who are given a placebo or an active comparator drug (54, 82). Blinded, controlled trials 
help to control bias and confounding factors and are the gold standard for evaluating new drugs 
(54, 82, 82).  
 
The safety aspects studied during clinical trials include AEs, physical examinations, laboratory 
tests, vital signs, electrocardiography, and hospitalisations (82). The extent of safety monitoring 
generally decreases with these phases, for example phase I subjects are monitored in the clinic but 
phase III patients would only have regular visits to their clinician (55). Significant differences in 
the incidence and severity of AEs between the control and treatment groups are identified (54, 
82). AEs observed during clinical trials are commonly recorded in the MedDRA vocabulary (56, 
82).  
 
Clinical trials have limitations in terms of their duration, diversity of patients included, and sample 
size (14, 83). If the duration of clinical trials does not reflect the chronic use of the medication, 
clinical trial data can underestimate the true level of adverse drug effects (82). The diversity of 
patients included is also limited, for example elderly patients and those with co-morbidities are 
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typically excluded or underrepresented in clinical trials (54, 82). Moreover, some AEs are rare, e.g. 
occur in less than 1 in 1000 patients, and the sample size of clinical trials may not detect such 
events (3, 82).  
 
In addition to inherent limitations to clinical trials, there are also concerns about their reporting. 
Although it is required by US law that clinical trial results, including serious AEs, are reported on 
e.g. ClinicalTrials.gov, a recent study found that results for 35% of registered trials have not been 
reported (84), and even when results are reported, inconsistencies in the serious AEs reported for 
the same study in peer-reviewed literature versus on ClinicalTrials.gov were found to occur in 35% 
of cases, in one survey (85). Once drugs are marketed, information on adverse effects is included 
in the patient information leaflet, as well as on the prescribing information for health professionals 
(56, 86). This latter information has been subject to text-mining to create datasets for research (87), 
as will be discussed in more detail later. 
1.4.4 Post-marketing phase 
Monitoring of AEs continues beyond marketing authorisation (3). Most commonly, this occurs in 
the form of spontaneous reporting, i.e. healthcare providers and consumers can voluntarily report 
case reports of AEs and suspected ADRs to regulatory authorities or directly to pharmaceutical 
companies (56, 88–90). Data from post-marketing surveillance are of interest because they reflect 
the more realistic and diverse real-world population, and are based on the exposure of a greater 
number of subjects. The individual reports and databases containing collections of reports are then 
analysed for signals (3, 88).  
 
A signal has been defined by the World Health Organisation (WHO) as “reported information on 
a possible causal relationship between an AE and a drug, the relationship being unknown or 
incompletely documented previously” (3). Both detailed clinical reviews of individual submitted 
reports and large-scale statistical data mining are used to evaluate potential signals (88, 89). Health 
authorities can act upon safety concerns with regulatory actions such as requiring changes the drug 
label with respect to warnings or contraindications, implementing restrictions on drug use, 
informing the public of possible risks, or withdrawing the drug from the market (3, 56, 89). 
 
One of the largest spontaneous reporting databases is the US FDA Adverse Event Reporting 
System (FAERS) database, and other large databases are VigiBase, maintained by the WHO, and 
EudraVigilance, maintained by the European Medicines Agency (EMA) (91–93). Pharmaceutical 
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companies also maintain their own databases of AEs (88).  Most pharmacovigilance organisations 
use disproportionality analyses for signal detection (88, 94). These types of analyses determine 
whether the rate of the AE reporting with a drug of interest is higher than would be expected 
based on the background rate of AE reporting across all other drugs in the database (94).  
1.4.4.1 Biases in spontaneous reporting data 
Since spontaneous reporting data are based on voluntary reporting, the sampling structure is 
uncertain; the numbers of patients who have taken the medicine cannot be derived from 
spontaneous reporting data (3, 90). Therefore, spontaneous reporting systems cannot be used to 
estimate incidence rates of AEs, and the term ‘reporting rates’ are used instead (90).  
 
In randomised controlled studies, randomisation should reduce systematic differences between 
the treatment groups, but this is not the case for drug prescriptions in the general population from 
which spontaneous reporting data is derived (95, 96). In routine clinical care, drug prescription is 
based on the patient’s underlying conditions, resulting in differences between patients prescribed 
certain drugs and other patients (97). As a result, spontaneous reporting data suffers from potential 
biases (90, 96). One source of bias is sampling variance, which is the variation in reporting rates of 
AEs across e.g. time, drugs, and the type of AE (98, 99). Examples of such variation are the greater 
reporting of AEs considered more important or serious by health care professionals and increased 
reporting for drugs covered in news reports (9, 73). Another type of bias, reporting bias, results 
from the underreporting of AEs, which is thought to be widespread, with one meta-analysis 
finding rates of underreporting between 82-94% (9, 100). 
 
Another type of bias, sampling bias, can result from the existence of confounding factors. A 
confounding factor is a covariate such as a co-medication, co-morbidity or indication that is 
associated with exposure to the drug of interest (101, 102). For example, if two drugs are frequently 
co-prescribed, but only one of them causes a particular side effect, statistically both drugs will be 
associated with the side effect (101).  
 
One of the main confounding factors in FAERS is drug indication, since treatment choices in the 
population are based on the conditions affecting the patients, and this can result in indication bias 
(97). In such cases, it can be difficult to determine whether observed AEs are related to exposure 
to the drug, or underlying factors such as the disease or age (97). In studies of FAERS it has been 
observed that drugs tend to be statistically associated with AEs related to the disease that the drugs 
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intend to treat. For example, it happens that drugs against type-2 diabetes are associated with high 
blood glucose (73, 98). However, rather than this being a consequence of drug use, it is likely a 
consequence of the disease (98). One study estimated that up to 5% of all reports in FAERS list 
the drug indication as an AE (73). Perhaps the report submitters confuse the disease indication 
and the AE (73), however, indication-related AEs are frequently due to the underlying disease and 
its symptoms. For example, a case studies of different drugs used for hypertension showed that 
around double the rate of cardiac and vascular disorders were reported in post-marketing data 
compared to clinical trials, which can be attributed to the disease being treated rather than the drug 
(47). 
 
Statistical methods have been developed to reduce potential biases in observational data such as 
post-marketing databases, and a further section below (1.7.2) is devoted to these in more detail. 
1.5 The study of target-adverse event relationships using data 
analysis 
 
The introduction so far has outlined the drug discovery process and the various types of studies 
performed at each stage. Advancing through each stage in drug development, more information 
of the in vivo drug effects becomes available. Knowledge of target-AE relationships is useful at 
different stages, but especially in early drug screening and lead optimisation, when safety target 
panels can be screened and computational models for off-targets can be used (19, 66). 
 
The analysis of marketed drugs has been important in the discovery and annotation of currently 
known safety-related targets, as illustrated by the previously mentioned examples of 5-HT2B and 
hERG (66, 67). However, there are remaining questions around secondary pharmacology 
screening and there is a need for further studies to address the lack of quantitative annotations and 
knowledge of the predictive values of targets on screening panels. One way to study target-AE 
relationships is through the analysis of empirical datasets, such as measured in vitro bioactivities 
and AEs observed in humans, and this is the focus of the current work.  
 
The main types of data needed for such analyses are links between drugs and their pharmacological 
activity at protein targets - drug-target links – and links between drugs and AEs – drug-AE links. 
This is illustrated conceptually in Figure 1.10. The next sections will introduce sources of such 
data and applicable methods, and discuss previous literature of target-AE associations.  
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Figure 1.10 Associations between targets and adverse drug effects can be derived based on 
datasets of drug-AE links and drug-target links. 
In addition to data analysis of in vitro pharmacological activities, other methods to discover targets 
that mediate adverse effects include knock-out studies and studies of phenotypes associated with 
genetic variation in humans (64, 67, 103). These methods have also been used to inform the 
selection of proteins for safety target panels (64, 67). For example, a recent study by Deaton et al. 
investigated correspondence between pharmacological modulation of targets and human genetic 
information of the target, and used this to inform targets to be included on a panel of 70 targets 
intended for pharmaceutical development (64). The study revealed that the highest 
correspondence between pharmacological effects and genetic phenotypes occurs for AEs in the 
categories blood platelet disorders, seizures and coronary artery disease (64). Another recent study 
by Nguyen et al. found a correlation between the effects of genetic variation in proteins that are 
drug targets and ADRs observed in clinical trials of drugs targeting these same proteins (103). 
However, the discussion of data sources and previous literature below will focus on 
pharmacological and bioactivity data, given these are directly relevant to the current work. 
1.6 Data sources for studying relationships between drugs, 
bioactivities, and adverse events  
1.6.1 Large-scale measured and predicted bioactivities 
Several databases provide large-scale measured bioactivity data. Among the largest publicly 
available ones is the ChEMBL database (104). It provides in vitro bioactivity data that was manually 
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extracted from medicinal chemistry scientific literature, with additional curation of compound 
structures and information on approved drugs (105). The ChEMBL database version 24 published 
in 2018 contains over 1.8 million unique compounds with measured bioactivity against 3,569 
unique human proteins (106). The activity types include IC50, Kd, Ki, and percentage inhibition 
(105). Except for a few subsets of the data, the majority of data is not a full matrix and is sparsely 
populated (107). Negative data is underrepresented since this is often not included in scientific 
publications, thus ChEMBL contains a relatively high proportion of active compounds (105, 106). 
ChEMBL also incorporates a selection of data from PubChem (making up ~40% of ChEMBL 
data), another large publicly available bioactivity database (104, 105). PubChem focuses on storing 
results from high-throughput screening initiatives, and thus contains more full-matrix and negative 
data (104, 105). Only the datapoints derived from dose-response assays in PubChem are 
incorporated in ChEMBL (105). The ExCAPE-DB integrates datapoints from ChEMBL and 
PubChem and standardised the compound structures in a common way for use in chemogenomics 
studies (108). Similarly, the Search Tool for Interacting Chemicals (STITCH) also collates a range 
data sources, including databases such as ChEMBL and DrugBank and datasets curated from 
scientific literature, into one integrated dataset (109). DrugBank is a manually curated dataset of 
drug-target interaction data, as well as other data about approved drugs and clinical candidates 
(110). However, numeric affinities and potencies are not readily available from DrugBank, since 
drug targets are provided as a list.  
 
A relevant commercial source of bioactivity data is the Bioprint database developed by Cerep (now 
Eurofins) (69). The database is a nearly full matrix of measured in vitro bioactivities of drugs and 
drug-like compounds against targets specifically related to safety (45). In 2012, the database 
contained 2,413 compounds and 141 targets (45).  
 
Another effort to generate publicly available in vitro bioactivity data is the ToxCast and Tox21 
initiative resulting from a collaboration between different US federal agencies (111). The 
programme screened over 10,000 compounds, including drugs, in a range of assays focused on 
nuclear receptor interaction and higher-level cellular responses such as activation of stress-
response pathways (111). 
 
It is acknowledged that public availability of measured bioactivity data, even for marketed drugs, 
is not comprehensive, with many missing datapoints (63, 107). The availability of the above-
described databases, amongst others, has facilitated the development of in silico ligand-based target 
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prediction models (22, 107, 112). Such models generally use numeric descriptors of the compounds 
and machine learning models to predict the potency of a query compound or a probability of 
activity based on classification models (112). The numeric descriptors are computed from the 
compound’s two-dimensional structure and predictions are based on underlying similarity between 
the compound of interest and known ligands for the target of interest (63, 113).  
 
The target prediction tool ‘Prediction IncluDinG Inactivity’ (PIDGIN), which is used in this work, 
uses Random Forest models to predict the probability of activity based on RDKit Morgan 
fingerprints (114). Morgan fingerprints are type of circular fingerprint that iteratively consider the 
atom environments in a given radius around atoms in a molecule (115) (Figure 1.11). Chemical 
substructures are condensed by a hashing function into features, the presence or absence of which 
can then be represented as a bit vector of a defined length describing a molecule (115).  
 
 
Figure 1.11 Circular fingerprints consider atom environments around a central atom. Reprinted 
with permission from D. Rogers, M. Hahn, Extended-Connectivity Fingerprints. J. Chem. Inf. 
Model. 50, 742-754 (2010) Copyright 2010 American Chemical Association. 
PIDGINv3 is a collection of classification models that are trained on a dataset of known active 
molecules and a combination of measured inactive and putative inactive molecules from ChEMBL 
and PubChem (116). A classification threshold, e.g. 10 µM, is typically used to define active and 
inactive molecules for each protein (114). PIDGINv3 supports multiple classification thresholds 
per protein, namely 0.1, 1, 10 and 100 µM, with a separate model for each threshold (116). Morgan 
fingerprints of 2,048 bits are calculated for the active and inactive molecules using a radius of 2 
(114). The Random Forest algorithm is used to train models that aim to relate chemical features 
from the fingerprints to compounds’ biological activities (117). The applicability domain of the 
PIDGINv3 models is defined using the reliability-density neighbourhood method, which 




Other target prediction methods use different molecular fingerprints or machine learning methods. 
For example, the Similarity Ensemble Approach (SEA) uses the Daylight chemical fingerprints 
computed from the two-dimensional compound structure, to compare query compounds and 
known ligands of a target (113). The method then uses a chemical similarity model to calculate the 
significance over similarities expected at random (63, 113). Another target prediction workflow by 
Lampa et al. uses the signature molecular descriptors in a Support Vector Machine (112). Similar 
to PIDGIN, Bosc et al. used the RDKit Morgan fingerprints in combination with Random Forest 
models and conformal prediction (107).  
1.6.2 Side Effect Resource (SIDER) 
The Side Effect Resource (SIDER) is primarily derived from ADRs observed in clinical trials. The 
dataset contains a list of ADRs for 1,556 marketed drugs. These have been extracted via text-
mining from the drug prescribing information, which are the documents prepared by drug 
manufacturers listing information about the approved drug for use by professionals (18, 87, 119). 
The most abundant information in SIDER is the listing of adverse effects in combination with a 
drug without further quantification. For around 40% of datapoints, the frequency of the ADR in 
patients is available as a percentage of patients affected or description of the frequency. Only for 
20% of datapoints with a frequency, the corresponding frequency in the placebo group is available 
for comparison (87, 119). A few examples of datapoints from SIDER are shown in Table 1.5. 
Although SIDER also provides MedDRA LLTs in most instances, the PT is recommended for 
analysis (47, 120). 
Table 1.5 Example datapoints from SIDER version 4 for levocarnitine (STITCH identifier 
CID000010917) and bupropion (CID000000444), showing the listing of MedDRA PTs for drugs, 
different percentages of patients affected in different studies of the same drug (levocarnitine), and 
occasionally a frequency for the placebo group. In most cases, frequency information is not 
available, such as in the case levocarnitine-gastritis. 
Data from the SIDER version 4 download files (120).  
Drug Adverse event (MedDRA PT) Frequency (%) or description 
of frequency 
LEVOCARNITINE Anaemia 12 
LEVOCARNITINE Anaemia 3 
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LEVOCARNITINE Anaemia 5 
LEVOCARNITINE Anaemia 6 
LEVOCARNITINE Anaemia Placebo: 3 
LEVOCARNITINE Gastritis Not available 
LEVOCARNITINE Convulsion Not available 
BUPROPION Amnesia Rare 
BUPROPION Oedema Frequent 
1.6.3 FDA Adverse Event Reporting System (FAERS) 
Of the different post-marketing databases maintained by health authorities and other 
organisations, FAERS is the only one publicly available as a complete database download, making 
it suitable for large-scale informatics research (91–93).  
 
FAERS is a collection of individual case reports submitted to the FDA by health care 
professionals, consumers, and drug product manufacturers (89). Overall, around half of all reports 
are submitted by health care professionals, a further 40% by consumers, 3% by lawyers, and 9% 
are unspecified (73).  
 
An overview of the tables included in the FAERS database and the main types of information they 




Figure 1.12 Overview of the main tables and content in FAERS, adapted from the documentation 
provided with the FDA quarterly release files from 2019 and related documentation 
References: (89, 91). 
A typical report includes patient characteristics (demographics table), the drugs the patient was 
prescribed (drugs table), the indications/diagnoses for which the drugs were prescribed 
(indications table), AEs/reactions experienced (reactions table) and a categorical outcome 
(outcomes table). However, the level of completeness of the various fields in the database varies, 
e.g. not all reports list the patient demographics or dose (17). For example, in a recent quarterly 
release of FAERS (faers_ascii_2019Q3), less than half of the reports include the patient age and 
weight (91). 
 
Drugs may also be classified as primary suspect, secondary suspect, concomitant, or interacting 
(121). An example of the information of one report is shown in Table 1.6, listing the drugs and 
AEs, and one drug annotated as primary suspect for the AEs.  
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Table 1.6 The drugs used, indications, and AEs experienced listed on one case report in FAERS. 
Data extracted from FAERS Adverse Event Open Learning through Universal Standardisation 
(AEOLUS) (121) 


















Sometimes it happens that several versions of the same report exist in the database, for example 
because an updated report on the same case is submitted (121, 122). Deduplication of such reports 
is not performed by the FDA, since it publishes the raw data without processing or analysis applied 
(91). Although AEs and drug indications in FAERS are recorded in the MedDRA vocabulary, the 
drugs names are not standardised or mapped to external sources. The need for extensive pre-
processing of FAERS has resulted in the publication of curated versions of FAERS which have 
duplicate case reports removed and drug names standardised (121, 123, 124). This is important 
because such aspects can influence statistical analyses performed on FAERS (73).  
1.7 Statistical methods 
1.7.1 Signal detection in spontaneous reporting data 
Disproportionality methods are applied on databases such as FAERS to identify overrepresented 
combinations of drugs and AEs which may be signals (97). Therefore, observed-to-expected ratios 
are determined for drug-AE combinations based on a contingency table as shown for an example 






Table 1.7 Example of the contingency table used for calculating the disproportionality of the 
reporting of the AE ‘injection site pain’ with the use of etanercept. The background used is all 
other reports, i.e. reporting on drugs other than etanercept, in the database. 
Example from Banda et al. (121). 
 Reports with Injection site pain Reports without Injection site 
pain 
Total 
Reports with etanercept 30,793 (") 647,134  ($) " + $ 
All other reports 140,853 (&) 61,815,244  (') & + ' 
 
Different measures of disproportionality include the Proportional Reporting Ratio (PRR), 
Reporting Odds Ratio (ROR), Information Component (IC) and Empirical Bayes Geometric 
Mean (EBGM) (88). For example, the PRR for injection site pain with etanercept according to the 




(( + 2) 3
(3 + 4)
5 = 19.98 (1.7.1) 
 
The PRR compares the rate of AE reporting among the reports listing a drug of interest, 
corresponding to (/(( + 2), with the rate of AE reporting in background reports, which is 
3/(3 + 4) (97). Similarly, the ROR is also based on the concept of disproportionality but is a ratio 
of odds: the odds of the number of reports of a given AE with the drug of interest to the number 
of reports for the same AE with other drugs, i.e. (/3, over the odds of the number of reports with 
other AEs with the drug of interest to those without the drug of interest, i.e. 2/4 (126). Therefore, 
the ROR is calculated as follows (125, 126):  





 The IC is derived using a Bayesian framework by taking the logarithm (base 2) of the observed-
to-expected ratio, resulting in a value similar to the )#-!!++ (97, 99, 125, 127): 
C'D#"E(%&#'	F#E$#','%	(CF) = )#-!G( (( + 2)(( + 3)
(( + 2 + 4 + 4)
H I
= )#-!
((( + 2 + 3 + 4)
(( + 2)(( + 3) 																																																																																		(1.7.3) 
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This incorporates the expected count K that is based on assuming no association between the drug 
and the AE (99, 125): 
K = (( + 2)(( + 3)(( + 2 + 3 + 4) (1.7.4) 
 
Hence, the IC represents the observed-to-expected ratio. The expected count is based on the 
number of reports of a specific drug in the database and the number of reports of a specific ADR 
in the database. In a Bayesian framework, the expected count represents the prior estimate of the 
probabilities (127). This is compared to the probability of the ADR being listed on a report given 
a drug is listed on a case report, i.e. the posterior probability, which is based on the number of 
times a specific drug-ADR combination occurs in the database (127). The basis of one method, 
the Bayesian Confidence Propagation Neural Network (BCPNN) is that as new reports are added 
to the database, previously calculated posterior probabilities are used as prior estimates, resulting 
in constantly updated estimates of the IC (127). In addition, a confidence interval is calculated for 
the IC which helps to define the signals (127). The EBGM is a similar measure of 
disproportionality also derived by Bayesian inference, and while it is also based on the observed-
to-expected ratio, it adjusts the ratio towards 1, which is the null value, i.e. no association between 
the drug and the AE (97). The advantage of this ‘shrinkage’, which is also already incorporated in 
the IC (128), is that the resulting values are less extreme when the number of reports are very small 
(97, 129). These adjustments prevent large numbers of positive signals and thus give more weight 
to associations with greater support in terms of the number of reports (97, 129). In contrast, the 
PRR and ROR are less reliable when the number of reports is small (97). Another approach to 
avoid false positive associations is to require a minimum number of reports for the drug-AE 
combination, such as at least three or five reports (88). Examples of signal detection thresholds 
for disproportionality measures used by pharmacovigilance organisations are shown in Table 1.8, 
some of which incorporate a minimum number of reports. 
Table 1.8 Examples of signal detection methods used by various organisations. n=number of 
reports. 
Adapted from Candore et al. (88). 
Method Thresholds Organisations using threshold 
PRR PRR ³ 2 and c2 ³ 4 and n ³ 3 Bayer; AstraZeneca until 2009 
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PRR ³ 3 and c2 ³ 4 and n ³ 3 Historic use at Medicines and Healthcare 
products Regulatory Agency (MHRA) 
ROR ROR lower bound 95% CI > 2 
and n ³ 5 
Medicines Evaluation Board  
IC IC lower bound of the 95% CI 
> 0 
Uppsala Monitoring Centre  
EBGM EB05 ³ 1.8 and n ³ 3 and 
EBGM ³ 2.5 
MHRA 
 
Some measures of disproportionality have advantages in certain situations, such as the ROR 
performing best for early detection of AEs (130). However, all these methods converge to the 
same result given enough drug-AE reports, e.g. most methods give similar results if the number 
of reports is greater than 3 (97), and it has been suggested that the choice of algorithm can be 
based on the convenience of implementation (88, 94).  
 
Pharmacovigilance organisation have specialised data management systems for storing and 
running signal detection algorithms, and this software is not available to most academic researchers 
(131). To improve the situation for researchers, Banda et al. (121) published a standardised version 
of FAERS named FAERS AEOLUS. In addition to standardised and mapped drug names and 
case report deduplication, FAERS AEOLUS includes precalculated PRRs and RORs (121). While 
this provides an easily accessible source of drug-AE associations, potential biases have not been 
addressed in this dataset, which will be discussed in the next section. 
1.7.2 Addressing potential biases in post-marketing reporting data 
As introduced in section 1.4.4.1, observational data suffers from a range of biases due to sampling 
variance and confounding factors.  
 
With respect to sampling variance, the methods described above incorporating shrinkage already 
address the issue of possible spurious associations arising when there are only few reports for a 
given drug or AEs, which makes reporting ratios more sensitive to sampling variance (129, 132, 
133).  To counteract varying reporting rates due to media attention, Maciejewski et al. calculated 
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reporting rates in FAERS on a monthly basis and correlated this with reports in the media (73). 
Observing whether the monthly reporting rates are still elevated outside of periods of media 
attention can help distinguish between true signals and signals due to stimulated reporting (73). 
 
With respect to confounding factors, disproportionality methods by themselves do not control for 
confounding factors (94), but these factors can lead to the masking of true associations or the 
detection of false associations when using disproportionality methods (132). Methods to reduce 
confounding factors include stratification, subgroup analysis, regression, and propensity scores.  
1.7.2.1 Stratification and subgroup analysis 
Stratification is a procedure in which the data is divided into groups, or strata, each with the same 
or a restricted range of the confounding factor (134).  The expected counts are then calculated for 
each of the strata and pooled to give an overall weighed expected count that is compared to the 
observed rate according to the Mantel-Haenszel procedure (99, 134): 
 
M4NO=%,4	#2=,"P,4-%#-,Q$,3%,4	"(%&# = 	 ((" + (!)
R ((" + 2")((" + 3")((" + 2" + 3" + 4") +
((! + 2!)((! + 3!)
((! + 2! + 3! + 4!)S
(1.7.5) 
 
where the values (, 2, 3,	and 4 correspond to those in Table 1.7, and the subscripts 1 and 2 might 
be male and female, for example, or another variable to be stratified on (99). 
 
In the related subgroup analysis, the disproportionality statistic is calculated for each of the strata 
separately and it is considered a signal if the statistic of any of the strata is significant (134). Both 
stratification and subgroup analysis are effective in reducing the effects of confounding factors but 
subgroup analysis performed better for large databases when evaluated against a reference of 
known ADRs (134). A limitation of both methods is that only a limited number of co-variates can 
be taken into account and it would not be feasible to include large numbers of co-medications at 
the same time, which occurs in FAERS (94, 128). 
1.7.2.2 Regression 
Regression models can take into account multiple variables at the same time and can be used to 
adjust for confounding factors. For example, logistic regression can be used to model the odds of 
an ADR V being listed on a given AE report as the binary dependent variable: 
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)#- R $1 − $S = X# +	X"Q" +⋯+ X$Q$ (1.7.6) 
 
where $ is the probability of a report listing the ADR V, Pr(V = 1), and the explanatory variables 
Q" to Q$ are different other drugs listed on the report or other potential confounding factors, such 
as drug indications (128, 135). The inclusion of confounding factors allows for their adjustment. 
For example, one study used logistic regression to investigate contrast agent-induced nephropathy, 
and considered the co-prescription of 200 nephrotoxic drugs in the regression, as well as including 
the patient age, patient sex and the year of the report (135). The regression coefficients were 
converted to estimated Odds Ratios to identify which specific contrast agents were associated with 
nephropathy (135). In another study, logistic regression models were used for all possible reported 
AEs, separately, as a means of signal detection in the database (128). Therefore, identifying drugs 
with positive X coefficients for given ADRs enabled the listing of drug-AE combinations as 
signals, while confounding due to co-prescriptions was controlled (128). Regression models can 
unmask associations that would remain undiscovered with other methods and prevent false 
associations that may be caused by confounding factors (128, 135). 
1.7.2.3 Propensity scores 
Propensity scores are another method used to reduce biases in observational studies (136) and are 
used in this thesis. A propensity score is defined as “the conditional probability that a person will 
be in a treatment group, given his or her specific characteristics” (136). True propensity scores are 
unknown in observational research, but may be estimated using available data (137). The most 
common way to do so is by modelling the treatment status Z of a patient, where the patient is 
either treated (Z=1) or not treated (Z=0) with a particular drug, as dependent on the baseline 
patient characteristics Q" to Q$ in logistic regression (137, 138): 
 
)#- R $1 − $S = X# +	X"Q" +⋯+ X$Q$	 (1.7.7) 
 
where $ is the probability of a patient being prescribed a drug, Pr(] = 1), based on their baseline 
characteristics (137). In contrast to the previous logistic regression (1.7.6), in which the ADR being 
reported is the dependent variable, now the dependent variable represents an intermediate step, 
i.e. the predicted probability of a patient being prescribed a drug of interest. The propensity score, 
ranging between 0 and 1, is used for balancing treated and untreated patients, based on the 
principle that for groups of individuals with the same propensity score, the distribution of baseline 
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covariates is the same (137). The aim is then to compare an outcome of interest, such as an AE, 
in the groups of treated and untreated patients while taking into account propensity scores.  
 
Therefore, there are four common ways in which propensity scores are used to reduce bias: as a 
basis of stratification, as a covariate to be adjusted, for weighting study subjects/patients 
differently, or for matching patients (95, 136, 137, 139). The first two relate to the previously 
discussed methods, so the propensity score can be used to derive strata for stratification, e.g. using 
the quintiles of the propensity scores as cut-offs for the strata, or the propensity scores can directly 
be included as a covariate in a  regression instead of multiple covariates being included separately 
(95). In using propensity scores for weighting study subjects, a synthetic sample of patients is 
created in which each patient is weighed according to the inverse of the propensity scores, which 
is then used to analyse the outcome of interest (138). In Propensity Score Matching (PSM), groups 
of treated and untreated patients with similar values of their propensity scores are identified, and 
the outcome of interest can then be directly compared between the matched groups of patients 
(137). The matching can be one-to-one, with one matched untreated subject for each treated 
subject, or many-to-one, with multiple untreated subjects per treated subject, which may in turn 
be selected as the most similar untreated patients from a larger group of untreated subjects (95, 
137). Figure 1.13 represents the concept of propensity score matching in observational studies 
involving drug treatments. 
 
 
Figure 1.13 Conceptual representation of propensity scores used for matching in an observational 
study. The outcome of interest is compared in the matched groups of treated and untreated 
patients 
Adapted from (139). 
Propensity score  
No treatment with drug X  
Treatment with drug X  






In the context of post-marketing surveillance, propensity scores are the estimated probability that 
a patient is prescribed a drug based on the patient demographics and pre-existing conditions, i.e. 
the patient’s diagnoses (98, 138). Tatonetti et al. used PSM on the FAERS database to find 
comparable group of patient reports, of which one group was exposed to the drug of interest and 
the other was not, before calculating disproportionality statistics using the matched groups of 
reports (98). The variables included in the propensity score model were co-medications and 
indications correlated with a drug of interest, and the authors showed that the method reduced 
false positive associations due to these confounding factors (98). The method also reduced 
differences in age and sex between the groups used for comparison, even though these variables 
were not included in the model, which the authors attribute to concomitant drugs and indications 
being correlated with other patient characteristics for which they are able to serve as a proxy (98). 
This result is encouraging because these correlated variables may be unmeasured and unknown 
confounders. The drug-AE dataset from this publication was released as the OFFSIDES dataset 
(98). However, case-deduplication and standardisation of drug names were not performed in this 
dataset (98). 
 
An advantage of propensity score methods compared to e.g. stratification is that they can include 
large numbers of covariates. For example, one study investigated the gastrointestinal (GI) side 
effects of cyclooxygenase inhibitors in electronic health records, considering between 200 and 500 
empirically identified covariates (140). The study showed that the analysis using propensity scores 
produced results comparable to those of randomised controlled trials of the same effect (140). 
1.7.3 The contingency table and related metrics 
Once drug-AE and drug-target relationships are identified, the next step towards identifying target-
AE relationships is to infer relationships between targets and AEs. Therefore, a measure is needed 
to study the concordance between these two variables. The relationship between two dichotomous 
variables can be investigated using a contingency table, also known as a confusion matrix, which 







Table 1.9 Example of a contingency table with two categories 
  True category 
  Positive Negative 
Test result or predicted 
category 
Positive True positive (TP) False positive (FP) 
Negative False negative (FN) True negative (TN) 
 
Confusion matrices are frequently applied to evaluate the usefulness of diagnostic tests in medicine 
(141) and the performance of predictive classification models (142). Using the numbers from Table 
1.9, the sensitivity and specificity of a test or predictive model can be calculated as follows (141). 
 
^,'=&%&P&%V = 	 _!_! + `a	 (1.7.8) 
 
^$,3&D&3&%V = 	 _a`! + _a (1.7.9) 
 
The sensitivity, or true positive rate, indicates the fraction of true cases that have a positive test 
result or predicted class, whereas the specificity indicates the fraction of true negative cases that 
have a negative test result or predicted class (141, 142). The sensitivity and specificity represent the 
accuracy for the true positive and true negative classes respectively (142), but they do not directly 
indicate the chances that a new sample belongs to the positive or negative class given the test 
result, which is often a relevant question in practice (141, 143, 144). When applying models to new 
samples, or doing in vitro testing such as in secondary pharmacology screening, the true categories 
are unknown and only the prediction or test result is available (142). Therefore, predictive values 
have been suggested as relevant metrics for decision-making in practice (71, 142, 144). The PPV 
is the proportion of true cases among all positive test results and the negative predictive value is 
the proportion of true negative cases among all negative test results, and they are calculated as 
follows (141, 143).  
 
!#=&%&P,	$",4&3%&P,	P()O, = _!_! + `! (1.7.10) 
 
a,-(%&P,	$",4&3%&P,	P()O, = _a`a + _a (1.7.11) 
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The studies by Pollard et al. and Krejsa et al. (69, 71) discussed earlier in section 1.4.1.3 used PPVs 
to characterise target-AE relationships, using different thresholds for the IC50.  
 
Predictive values are influenced by the prevalence, i.e. the fraction of individuals in the population 
with the disease in case of a diagnostic test (141). Higher PPVs are observed with increasing 
prevalence, and lower PPVs with decreasing prevalence, all else staying the same, because the 
number of false positive test results increases when testing a population with low disease 
prevalence (141, 143). On the one hand, the fact that predictive values take into account the 
prevalence can be useful because it allows the PPV to indicate the probability of a new sample 
belonging to the positive or negative category (142). On the other hand, it can be a drawback when 
wishing to compare the predictive values of tests for outcomes with different prevalence, such as 
different preclinical toxicity findings in animal studies (81), when some events are more common 
than others. One way to alleviate this is by calculating the value-added PPV, which is the PPV 
minus the expected prevalence (141). This is related to the idea that an initial estimate of the 
probability of disease before testing can be set as the prevalence, which is then updated to the PPV 
after testing (143). Thus, the value-added PPV indicates the additional usefulness of the test in 
addition to the prevalence as initial estimate, and is calculated as follows (141, 143): 
 
c()O,-(44,4	!!c = 	!!c − _! + `a_! + `! + `a + _a (1.7.12) 
 
Another metric that is independent of the prevalence is the Likelihood Ratio (LR), indicating the 
likelihood of a certain test result in diseased individuals compared to unaffected individuals, in 
other words, how many more times likely a positive result is in diseased individuals than in healthy 
individuals (141, 145). For the likelihood of a positive test result, the LR is calculated as follows 
(141, 145).  
d++	= 	 =,'=&%&P&%V(1 − =$,3&D&3&%V) =
(_! (_! + `a))⁄
(`! (`! + _a))⁄ (1.7.13) 
 
The LR+ is equivalent to the percentage of positive test results in the positive group over the 
percentage of positive test results in the negative group (145). For the likelihood of a negative test 
results, the LR- is calculated as: 
d+−=	 (1 − =,'=&%&P&%V)=$,3&D&3&%V = 	
`a (_! + `a)⁄
_a (`! + _a)⁄ (1.7.13) 
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The LR can take on values between 0 and infinity, with high LR+ values occurring when a positive 
test result is much more frequent among individuals with the disease than unaffected individuals, 
and the test is considered useful (145–147). Conversely, LR- values close to 0 mean that a negative 
test result provides evidence for the negative class, and values of LR+ or LR- close to 1 mean that 
the test does not provide useful information for decision-making, (145, 146). Clark et al. used LRs 
to study the concordance between preclinical and clinical AEs, using the AE observed in animals 
as a predictor for the clinical AE (74, 81). In this thesis, the metrics introduced here will be used 
to evaluate the relationship between the in vitro activity and in vivo AEs, using the in vitro activity as 
the predictor of the AE. Therefore, continuous data such as IC50 values for bioactivity and PRR 
values for AE associations will be binarized using a threshold to define the positive and negative 
categories for the contingency table. 
1.8 Literature review of studies deriving target-adverse event 
relationships  
 
Having reviewed relevant data sources and statistical methods, this section will review previous 
literature that used data analysis of drug-target and drug-AE datasets to derive target-AE 
relationships. 
 
The study by Krejsa et al., discussed before in section 1.4.1.3, derived associations between 
compounds’ in vitro potency at safety targets and ADRs reported on drug labels, as compiled in 
the Bioprint database (69). Only three examples of such relationships for previously reported 
target-AE associations were presented: muscarinic receptor M1 and tachycardia; histamine H1 and 
somnolence; and dopamine D1 receptor and tremor/extrapyramidal symptoms (69). While these 
associations were already known at the time, Krejsa et al. provided the quantification in terms of 
PPVs by binning the in vitro potencies and reporting the percentage of drugs listing the ADR in 
each potency bin (Table 1.10) (69). These results show a concentration-response relationship 







Table 1.10 Approximate PPVs (%), corresponding to the percentage of classified active 
compounds reported in each potency bin that listed the side effect on the drug label 
From the study by Krejsa et al. (69). 










> 50 µM 25 42 21 
10 – 50 µM 39 40 40 
1 – 10 µM 42 65 41 
0.1 – 1.0 µM 52 80 42 
< 0.1  µM 80 90 90 
 
Pollard et al. calculated the sensitivity, specificity, area under the receiver-operator curve 
(AUROC), and predictive values of in vitro hERG inhibition for clinical QT interval prolongation 
(71). They studied different bioactivity cut-offs (1, 3, 10, 30, 100, 300, and 1000 µM) for activity at 
hERG, and also considered exposure margins with respect to the unbound Cmax (3, 10, 30, 100, 
300, and 1000-fold), reporting the PPV and NPVs with respect to QT interval prolongation for 
each of these. The absolute hERG IC50 had an AUROC of 0.78 whereas considering the margin 
between the hERG IC50 and the unbound clinical peak plasma concentration resulted in an 
AUROC of 0.80 (71). The PPVs observed in the study are shown in Table 1.11, showing that the 
PPV is highest (1.00) when the safety margin between the hERG IC50 and clinical Cmax  is less than 
10-fold. However, the authors comment that in early drug discovery the clinical Cmax is not known, 
so that the PPV of 0.63 is applicable, meaning that drugs with an in vitro IC50 below 10 µM have a 
63% chance of causing clinical QT prolongation (71). While this study is detailed in the 





Table 1.11 PPVs for clinical QT prolongation measured in Thorough QT/QTc Studies, when 
considering two types of thresholds: the absolute hERG IC50 or alternatively the safety margin 
between the hERG IC50 and the clinical free plasma concentration. A prevalence of 0.22 was used 
in the study for the fraction of drugs with QT prolonging effects. 
From the study by Pollard et al. (71) 
Thresholds <1 <3 <10 <30 <100 <300 <1000 
As absolute hERG IC50 (µM) 1.00 0.54 0.63 0.42 0.37 0.27 0.29 
As safety margin between hERG IC50 and clinical 
free Cmax (exposure multiple) 
-  1.00 1.00 0.68 0.54 0.28 0.27 
 
Instead of focusing on the relationships between with single targets and ADRs, Fliri et al. studied 
the full bioactivity profiles of 872 approved drugs by clustering their in vitro bioactivity fingerprints 
comprised of activity against 92 proteins (148). ADRs from drug labels, derived from both 
placebo-controlled trials and post-marketing reports, were extracted from the Bioprint database 
(69, 148). Binary fingerprints of 240 different ADRs were constructed and also clustered (148). 
Next, the authors compared whether drugs with similar in vitro bioactivity profiles also had similar 
ADR profiles (148). A positive correlation was found between the in vitro bioactivity similarities 
and in vivo ADR profiles across different pharmacological drug classes, suggesting that full in vitro 
pharmacological profiles can be used to predict clinical ADRs (148). The authors suggest that in 
vitro biological fingerprints can be used to guide drug discovery towards candidates with fewer 
ADRs (148). 
 
To investigate the predictive ability of pharmacological fingerprints more explicitly, Bender et al. 
built multi-class Bayesian models for target prediction using ECFP_4 chemical fingerprints to 
predict the likelihood of activity at 70 targets on the safety panel at Novartis (149). Using the full 
predicted bioactivity fingerprint of drugs, the authors then built another set of multi-class models 
to predict ADRs for drugs, which had been extracted from the World Drug Index (149). Using 
examples of marketed and withdrawn drugs, the authors showed that the models picked up known 
target-related ADRs and that the target-ADR relationships ranked highly by the model were 
supported by literature (149). In a case study of arrhythmia, the authors further showed how 
extracting underlying features from the ECFP_4 fingerprints can identify features of chemical 
structures associated with ADRs, i.e. toxicophores (149). Both such toxicophores as well as in silico 
ADR predictions may support virtual screening of drug candidates in drug development (149).  
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Lounkine et al. also used target predictions but additionally were able to validate some of the 
predictions in vitro (63). They first used the Similarity Ensemble Approach (SEA) to predict the in 
vitro bioactivity of 656 marketed drugs for a set of 73 proteins included on the Novartis safety 
pharmacology panel (63). They then tested novel predicted activities in vitro and filtered the in vitro 
bioactivities for in vivo relevance by comparing to the Cmax of the drugs (63). Using ADRs from the 
World Drug Index, Enrichment Factors with c2 test q-values were calculated to identify 
overrepresented target-ADR pairs (63). Based on this, the authors identified novel target-ADR 
associations and proposed mechanisms behind known drug-ADR pairs (63). One of the main 
findings was that abdominal pain reported with the use of the synthetic oestrogen chlorotrianisene 
could be explained by the drug’s predicted activity on cyclooxygenase 1 (COX-1), which is known 
to mediate GI ulceration, as illustrated in Figure 1.14 (63).  
 
 
Figure 1.14 Results from the study by Lounkine et al. in which COX-1 was a predicted target of 
chlorotrianisene. Based on enrichment analysis of multiple drugs, this target was related to 
abdominal pain, whereas the known target of chlorotrianisene, the oestrogen receptor, was not 
related to this ADR, leading the authors to suggested the involvement of COX-1 as mechanism 
behind the abdominal pain. 
Reprinted by permission from Springer Nature: Springer Nature, Large-scale prediction and 
testing of drug activity on side-effect targets. E. Lounkine, M. J. Keiser, S. Whitebread, D. 
Mikhailov, J. Hamon, J. L. Jenkins, P. Lavan, E. Weber, A. K. Doak, S. Côté, B. K. Shoichet, L. 
Urban, Nature 486, 361–367 (2012), Ó 2012 (63). 
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In the study by Lounkine et al., when multiple targets were associated with the same ADR and 
drugs were active at these multiple targets, the target with the highest Enrichment Factor was used 
to suggest a plausible mechanism behind the ADR, thus providing a way to prioritise the numerous 
associations arising from drug promiscuity (63). 
 
Using experimental instead of predicted target interactions, Kuhn et al. performed a systematic 
analysis of ADRs for 996 drugs from the SIDER (version 2) database and measured in vitro drug-
target data for 841 drugs from STITCH3 (150). For 732 out of the 1,428 AEs (51%) analysed, the 
authors were able to identify overrepresented targets that were statistically linked to the AE based 
on the Fisher’s exact test (150). A total of 262 distinct protein targets were overrepresented, and 
they provided a plausible causal explanation for the ADR in 70% of the drug-ADR pairs, based 
on supporting literature evidence (150). Supporting literature included both pharmacological 
effects as well as effects from mouse knock-out studies. A significant fraction of target-ADR 
associations could be correlated with identical or related phenotypes observed in mouse knock-
out studies of the same target, showing how genetic data can be used to support target-ADR 
relationships (150). The results from the study included the novel significant association between 
activation of the serotonin 7 (5-HT7) receptor and hyperesthesia, which is increased pain 
sensitivity (150). The authors confirmed this effect in mice using a 5-HT7 agonist and antagonist 
(150). In the methodology used by Kuhn et al., when multiple targets were statistically associated 
to an AE of which one had been previously reported, the latter target was annotated as the causal 
explanation and other targets for that event were disregarded (150). While this reduces possible 
coincidental associations due to compound promiscuity, the method could also limit the possibility 
of discovering novel targets. A further limitation of the study is that quantifications such as 
predictive values that can be of value for interpreting secondary pharmacology screening (71) were 
not provided. 
 
Another study by Duran-Frigola and Aloy (151) used a similar approach as the studies discussed 
above but included a greater range of other data types in addition to target interactions. They 
considered 1,626 ADRs of 992 drugs from SIDER (version 2), relating these to 88 distinct 
therapeutic drug targets from DrugBank (151). Using the Fisher’s exact test, the authors identified 
79 overrepresented targets that were statistically associated to at least one of 674 ADRs (151). This 
means that 41% of ADRs included in the study were significantly associated to one or more protein 
targets. The study also considered other biological features including protein interactors, biological 
pathways, and Gene Ontology terms (151). In total 67% of ADRs could be related to a therapeutic 
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target or another biological feature. Comparing to previous literature, 16% of these biological 
overrepresented features were found to be previously reported (151). Next, in order to gain an 
estimate of the comprehensiveness of current molecular information, the authors tried to predict 
ADRs based on the overrepresented biological features as well as chemical features including small 
fragments, scaffolds, and ChEBI chemical ontology terms (151). Therefore, the authors built 
decision tree classifiers allowing multiple features to be used in combination (151). Models for 164 
ADRs (14% out of the total 1,162 ADRs with overrepresented features) had an F1 score above 
0.5 (151). Out of these, models for 24 ADRs included annotated therapeutic targets as features 
(151). The authors found that the models relied more often on biological features only (38% of 
models) versus chemical features only (6%), showing that currently known biological features are 
important in explaining ADRs (151). A limitation of the study is that only therapeutic drug targets 
were included as opposed to secondary targets, although protein interactors were included (151). 
In addition, the associations were not quantified beyond their p-values and non-significant 
associations were not published, possibly limiting our knowledge of associations that were 
included in the study but not statistically significant. 
 
Only few studies have investigated targets related to post-marketing AEs and these tend to report 
on a limited number of associations rather than a large-scale analysis. For example, Maciejewski 
and co-workers presented three detailed case studies based on FAERS, in which they showed how 
integrating FAERS data with drug pharmacokinetics can be crucial to discovering the underlying 
targets and mechanisms behind ADRs (73). In the first case study, the association between 19 
drugs targeting the vascular endothelial growth factor receptor (VEGFR) and the ADR 
hypertension was studied (73). The authors showed that the exposure margin, calculated by taking 
the ratio of the biochemical IC50 over the drug Cmax, can separate VEGRF inhibitors that are versus 
those that are not associated with hypertension (73). An exposure margin of 10 nearly perfectly 
separated the drugs (73). In the second case study, the atypical antipsychotic aripiprazole was 
compared to risperidone, a drug used in attention deficit hyperactivity disorder (73). Risperidone 
is associated with the ADRs gynaecomastia and hyperprolactinaemia, whereas aripiprazole is much 
less so, based on the number of reports in FAERS (73). Although both drugs have similar in vitro 
potencies against the dopamine D2 receptor, the exposure margin for risperidone is narrow (<1) 
compared to a margin of over 10 for aripiprazole, which can explain the difference in ADR reports 
(73). This shows how integration with pharmacokinetic data can be important for the 
interpretation of FAERS data (73). In a similar study of the kinase inhibitor sunitinib, also targeting 
VEGFR, four targets could be related to the drug’s AEs of thrombotic angiopathy and related 
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effects, based on the drug’s bioactivities (47). The target list was narrowed down to one off-target, 
platelet-derived growth factor, (PDGFR) in addition to the on-target VEGFR (KDR) based on 
the clinical Cmax of sunitinib, as shown in  Figure 1.15 (47). While these studies demonstrated the 
approach and potential usefulness of integrating in vitro safety pharmacology with pharmacokinetic 
parameters, this integration was not performed on a systematic scale across all drugs. 
 
 
Figure 1.15 Relating targets to reported AEs of sunitinib while taking into account the Cmax 
(represented by the dotted orange line). While four targets of sunitinib have known relationships 
to coagulopathies and platelet disorders, only the potency of sunitinib at VEGFR/KDR and 
PDGFR is high enough compared to the plasma concentration, to be plausibly related to the 
ADRs. 
Reproduced from (47) with permission from John Wiley and Sons Ó 2015. 
Studying the Cmax of drugs in relation to AEs in greater depth, Redfern et al. identified a link 
between the safety margin between the in vitro IC50 at hERG and the unbound drug plasma 
concentration of drugs, and the risk of TdP. In the study, 100 drugs were classified in different 
categories according to existing evidence of associated TdP, based on drug withdrawals and the 
number of AE reports, and it was observed that for almost all drugs without reports of TdP in 
humans, there was at least a 30-fold separation between the in vitro hERG IC50 and the unbound 
effective therapeutic plasma concentration, and this was recommended as a safety margin for drug 
development (152). This was in contrast to smaller margins for other drugs, such as those 
withdrawn for TdP, which had a margin between 0.31 and 13 (152). 
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A different type of study by Sipes et al. also applied the Cmax-IC50 ratio but now on a larger scale 
(153). Although the study did not specifically focus on ADRs, it highlights the use of above ratio 
at compound screening stages. The authors used large-scale data from the Tox21 screening 
initiative, which screened 10,000 environmental, pharmaceutical, consumer and industrial 
chemicals for activity in biological stress-response assays (153). They estimated the likelihood of 
the in vitro activities being relevant to in vivo effects by using predicted Cmax values, and using the 
Cmax-AC50 ratio obtained to classify these likelihoods, as illustrated in Table 1.12.  
Table 1.12 Boundaries for the likelihood of human in vivo interaction in the study by Sipes et al., 
which used the ratio of the predicted Cmax and the in vitro half-maximal effective concentration 
AC50 





Possible 1	 > !!"#"!$%
≥ 0.1 
Possible with 10x factor 0.1	 > !!"#"!$%
≥ 0.01 
 
Other studies that used post-marketing data to derive target-AE relationships have mostly been 
restricted in scope, such as the study by Svensson et al. (154), which focused on structural 
cardiotoxicity. Using a version of FAERS with standardised drug names by Wang et al. (155), the 
analysis tried to identify whether drugs with reports of structural cardiotoxicity, identified using a 
list of relevant clinical conditions (e.g. mitral valve incompetence, left ventricular dysfunction) 
could be derived from in vitro bioactivities in ToxCast (154). Safety signals in FAERS were defined 
as ROR ³ 2 and Fisher’s exact test p-value £ 10-4. The authors ranked associations based on the 
Mutual Information metric for information dependence, and then investigated the highest-ranking 
in vitro assays against previous literature (154). Based on this, the authors suggested two putative 
adverse outcome pathways for structural cardiotoxicity involving proteins measured in vitro assays: 
one involving modulation of the translocation protein (TSPO), and another involving reduced 
expression of Tissue Factor (154). Limitations of the study are that potential confounding factors 
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were only addressed with a simple filter that excluded any case reports of patients with 
cardiovascular indications, and only one specific disease area was investigated (154).  
 
Two other studies specifically studied reports of serotonin syndrome in post-marketing data in 
relation to in vitro bioactivities. Serotonin syndrome is a potentially life-threatening ADR presenting 
clinically as changes in mental status and abnormalities in the neuromuscular and autonomous 
nervous system, with symptoms including tachycardia, tremor, hyperthermia, and agitation (14, 
156). The syndrome is a consequence of excess serotonin in the central and peripheral nervous 
system resulting from exposure to serotonergic drugs (156). Culbertson et al. used ligand-based 
target prediction to predict the probability of 71 drugs interacting with different serotonin 
receptors, the serotonin transporter, the norepinephrine transporter, and muscarinic receptors M1 
to M5 (157). Target prediction was used due to lack of a sufficiently complete measured bioactivity 
matrix (157). The authors then classified the drugs into 7 different categories based on their 
predicted pharmacology profile and calculated the mean PRR for serotonin syndrome for each of 
the drug categories using an in-house version of FAERS (157). Serotonin syndrome was defined 
in the study based on the presence of up to 10 symptoms that together identify the syndrome 
according to established criteria (157). The drug category with the highest PRR (PRR=1.54 and 
PRR=1.72 depending on the definition of serotonin syndrome used) contained drugs with 
simultaneous predicted bioactivities across three target (groups): the serotonin transporter, the 
norepinephrine transporter, and muscarinic receptors M1 through M5 (157). Since the PRR in this 
triple-activity group was higher than for drugs acting on the serotonin and norepinephrine 
transporters only, the authors suggested the potential contribution of muscarinic receptors in the 
origin of serotonin syndrome (157). Limitations of this study are that the version of FAERS used 
is not publicly accessible and confounding factors were not addressed. 
 
The other study on serotonin syndrome, by Racz et al., analysed post-marketing data to suggest 
mechanistic hypotheses for the way second-generation antipsychotics can increase the risk of 
serotonin syndrome (158). Analysing FAERS through the commercial Molecular Health EFFECT 
platform and using targets reported for the respective drugs in DrugBank, they calculated the PRR 
for groups of drugs active at different targets, e.g. drugs active at the sodium-dependent serotonin 
transporter had a PRR of 8.67 for serotonin syndrome (158). In this case serotonin syndrome 
reports were used if they directly reported serotonin syndrome. Similarly, they analysed enriched 
targets among second-generation antipsychotics, and further investigated the overlapping 11 
mostly highly ranked targets. Next, the PRR was calculated separately for drugs acting as agonists 
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and antagonists at each of these targets, which resulted in the greatest signals observed for 5-HT1A 
receptor agonism, 5-HT1A receptor antagonism, 5-HT1B receptor agonism, 5-HT2A receptor 
antagonism, 5-HT2C receptor agonism, and a-2A adrenergic receptor antagonism (158). Literature 
support was found for 5-HT1A agonism and 5-HT2A antagonism as mechanisms potentially leading 
to serotonin syndrome (158). To investigate confounding factors and potential drug-drug 
interactions, PRRs were calculated separately for reports listing second-generation antipsychotics 
in combination with or without serotonin reuptake inhibitors, and this showed that combined use 
is associated with a disproportionately increased risk of serotonin syndrome, although both classes 
also had increased risk individually compared to background reports (158). Limitations of the study 
are that only serotonin syndrome was investigated and a commercial platform was used for the 
FAERS analysis, but strengths are that care was taken to include functional effects – agonism and 
antagonism – and confounding factors. 
 
To the best knowledge of the author only one study investigated post-marketing target-AE 
associations on a systematic scale. The recent study by Ietswaart et al. retrieved AE reports from 
FAERS and trained Random Forest models to predict these AEs based on the in vitro 
pharmacological profiles of 2,134 marketed drugs against 218 assays measured at Cerep (159). AEs 
were mapped to 321 HLGTs, which were the dependent variable for the models, and the features 
were the in vitro activities discretised in 3 ranges: highly active (0-3 µM), active (3-30 µM), and 
inactive (> 30 µM) (159), with inactivity assumed for unmeasured drug-target combinations (159). 
They mitigated potential biases in FAERS by using the Empirical-Bayes Regression-adjusted 
Arithmetic Mean, which adjusts for age, sex and reporting year, and by only selecting reports that 
were submitted by physicians and on which the drug was listed as the primary suspect (159). To 
discover significant relationships between targets and AEs, the authors inspected the Gini 
coefficients and identified the target activities with the greatest importance to the models, 
identifying significant relationships between 51 targets and 221 AEs (MedDRA HLGTs) (159). 
The results identified previously known relationships such as hERG with various cardiac disorders, 
but also identified potentially novel AEs for familiar targets, for instance they found that 
cyclooxygenase-2, hERG, and phosphodiesterase 3 were associated with different kidney 
disorders, some of which were not previously reported and are suggestions for further study (159). 
The study considered functional effects for some assays, but did not take into account any 
pharmacokinetic data (159). 
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To summarise the studies that focus on target-ADR relationships discussed in this literature 
review, Table 1.13 shows the main details of the datasets used as well as the number of significant 
targets reported.  It can be seen that no study to date has considered pharmacokinetic data on a 
global scale using post-marketing data. 
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Krejsa et al. 
(2003) (69) 
Drug labels Bioprint PPV per in vitro 
IC50 bin 
Reported on 3 targets only Reported on 3 AEs 
only 
 










73 targets of Novartis safety 
panel 
317 AEs with 
significantly 
associated targets 
Ö, reported for 
examples only 





















Not specified Exposure margins 
(IC50/Cmax) 
Case study of VEGFR inhibitor 
sunitinib (1 target associated) 
Thrombotic 
angiopathy 
Ö, case study only 
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Not specified Exposure margins 
(IC50/Cmax) 
Case studies of drugs active at 
VEGFR and dopamine D2 




Ö, case studies only 
Redfern et al. 
(2003) (152) 
100 drugs with 
varying levels of 
evidence/reports 
of TdP versus 










hERG TdP Ö, unbound 
therapeutic plasma 
concentrations 
Svensson et al. 
(2018) (154) 
FAERS version 




16 significant protein targets and 





Culbertson et al. 







PRR per category 
of drugs with 
similar bioactivity 
profiles 
21 protein targets studied only Serotonin syndrome 










DrugBank PRR per group of 
drugs active at the 
same single target 
Considered 20 proteins most 
associated, of which 11 studied 
by agonism/antagonism 
Serotonin syndrome 














models for AEs 
51 targets were significantly 
related to AEs, out of 218 assays 
considered  
Global analysis of 






1.9 Aims of the thesis 
The aim of this work is to identify and quantify associations between targets and AEs 
systematically using statistical data analysis of available datasets, while taking into account 
pharmacokinetics and controlling potential biases in post-marketing data.  
 
Most previous studies using post-marketing data have focused on specific ADRs or have only 
presented few examples from systematic analyses in their publications, and currently few studies 
using FAERS data to identify targets associated with AEs have attempted to control potential 
biases, which are known to substantially affect post-marketing data. Thus, the current work aims 
to systematically analyse target-AE associations while incorporating existing techniques to control 
biases in post-marketing data. Therefore, chapter 2, which focuses on the identification of drug-
AE associations in FAERS, applies the PSM technique to reduce the effect of confounding factors. 
The effects of the technique on indication bias are explored using an independent dataset. The 
resulting dataset of drug-AE relationships is then compared to those derived from clinical trials 
using the SIDER dataset. Thus, chapter 2 provides datasets of drug-AE relationships for further 
analysis of associated targets in subsequent chapters.  
 
Although it is widely recommended to take into account pharmacokinetic parameters such as Cmax 
in the analysis and interpretation of in vitro safety pharmacology results, such integration has only 
been presented in existing literature as case studies and examples, thus the current work aims to 
integrate exposure data systematically and explore the impact of doing so. Therefore, chapter 3 is 
concerned with drug-target links from bioactivity data, providing the other crucial dataset for 
analysis. In this chapter, measured and predicted in vitro bioactivities are integrated with drug 
plasma concentrations compiled from scientific literature, and it is investigated to what extent this 
influences the in vitro drug-target activity calls. 
 
Given the lack of systematic annotations of safety targets and knowledge of their relevance to drug 
safety in humans, which are crucial to the interpretation of safety pharmacology screening results, 
this work aims to contribute to knowledge of target-ADR associations by providing information 
on in vitro-in vivo concordance. Therefore, building on the preparatory work form chapters 2 and 
3, chapter 4 comprehensively identifies and quantifies associations between in vitro bioactivity at 
human targets, adjusted for drug plasma concentrations, and AEs from human data, focusing on 
their predictive values and LRs. This contributes to filling the current gap in knowledge about 
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targets related to post-marketing AEs, and the identification of potentially novel associations, 
especially since the amount of post-marketing data is continuously increasing and provides an 
opportunity to look for emerging associations between targets and AEs. An additional aim is to 
compare target-ADR associations from clinical trials with those from post-marketing data as this 
has not been addressed in previous studies. 
 
The results of this work can be used in drug discovery for the interpretation of secondary 
pharmacology screening results in terms of the human relevance of in vitro target activities, as well 
as for the selection of targets to be used in screening. In addition, knowledge of targets involved 
in ADRs can improve our mechanistic understanding of adverse drug effects and provide 
suggestions for the development of predictive computational models.  
 
Figure 1.16 shows the chapter structure of the thesis in support of the above aims. 
 
 











This chapter will compile two sets of drug-AE relationships, based on FAERS and SIDER, which 
will be used for further analysis in subsequent chapters. Given the many potential biases that affect 
post-marketing data, this chapter applies the PSM technique as reported by Tatonetti et al. (98) 
with the aim of reducing confounding factors and improving the reliability of the data. The aim of 
the PSM procedure is to select a subset of background patients for disproportionality statistics that 
is as representative as possible of the patients using the drug of interest. Results of implementing 
this technique on the FAERS AEOLUS dataset, which is larger than the version Tatonetti et al. 
used (98), are presented.  
 
The curation performed in FAERS AEOLUS consists of (1) deduplication of case reports, (2) 
standardisation of drug names, and (3) incorporation of FAERS legacy data (121). Duplication of 
case reports can happen when multiple health professionals submit a report on the same case or 
when a follow-up report about a patient is submitted (121, 160). Drug names in the original FAERS 
are recorded as free text and therefore many names for the same drug may be used (73, 121). Both 
the duplication of reports and the variety of drug names have the potential to affect further 
statistical analysis on FAERS (73, 121, 160). The legacy data included is FAERS data from the 
years 2004 – 2012, which follows a different database structure than the current schema, which 
was introduced in 2012 (121). Thus, the inclusion of the legacy data results in coverage of the years 
2004 – 2015. 
 
Because the PSM method is implemented here independently of Tatonetti’s code, and on a 
different database, this chapter starts by reproducing some of the case studies from Tatonetti’s 
work, to generally verify that the implementation works as intended.  
 
Next, the effect of the method on indication bias is investigated using an independent dataset. 
Tatonetti et al. investigated the effect of PSM on indication bias using a manually constructed 
dataset of AEs that are caused by the drug indication, but this dataset was not included in the 
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publication (98). Since drug indications are available from other sources, the effect of PSM on a 
set of drug indications from the National Library of Medicine is examined in this chapter (161). 
Indication bias may be more easily observed than other types of bias, and therefore serves as a 
useful example for verifying the results of implementing the PSM method in this work. The 
rationale for using an independent dataset is that this provides a reliable, comprehensive source of 
drug-indication relationships in comparison to the user-submitted drug indications present in 
FAERS. 
 
Both clinical trials and post-marketing surveillance have limitations, and neither is expected to 
provide a full profile of possible ADRs. Thus, to complement the post-marketing AEs from 
FAERS, this chapter also selects ADRs derived from clinical trials from SIDER. Since these 
datasets will form the basis of most of the analyses in subsequent chapters, this chapter will 






















2.2 Materials and methods 
2.2.1 Food and Drug Administration Adverse Event Reporting System (FAERS) 
The FAERS AEOLUS database was installed as a MySQL database using the scripts provided by 
the authors (121). The AEOLUS database contains close to five million unique case reports, 17,710 
unique AE terms, 14,063 unique indications, and 3,526 drugs mapped to the RxNorm drug 
vocabulary (121).  
 
Not all tables from the original FAERS database are included in FAERS AEOLUS. Notably the 
tables containing the patient age, sex, and reporting country are not included. Thus, these 
characteristics cannot be analysed using AEOLUS unless linking back to the original FAERS. An 
overview of the tables in the original FAERS and the information they contain is shown in Figure 
2.1, showing which information is retained in FAERS AEOLUS and focused on in the current 




Figure 2.1. Overview of tables in the FDA Adverse Event Reporting System and the main types 
of information reported in each of the tables. The curated FAERS AEOLUS version only 
OUT (outcome)
• Patient outcome, one of:
• Life-Threatening
• Hospitalization – Initial or prolonged
• Disability
• Congenital Anomaly
































• Drug start date
• Drug end date
INDI (indications)
• Indications, i.e. diagnoses 
(MedDRA-coded) for reported 
drugs
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includes data from the tables highlighted in red. The fields marked in bold are the main fields 
used in the current work. 
2.2.2 Propensity Score Matching (PSM) 
The current work closely follows the reported PSM method by Tatonetti et al. (98) and all work 
was done in Python. A separate logistic regression model was implemented per RxNorm drug in 
AEOLUS using the scikit-klearn (0.21.3) linear_model.LogisticRegression function, to estimate 
the propensity scores. The model tries to estimate the probability of a patient report listing the 
drug of interest, i.e. dependent variable, using the independent variables which in this study are 
dummy variables for the presence of co-reported drugs and indications on the report. Patient 
reports were identified by the ‘primaryid’ or ‘isr’ report identifiers in AEOLUS. To increase the 
possibility for data-driven discovery, all co-reported drugs were included, regardless of whether 
they were listed as primary suspect drugs. As discussed in the original publication (98), the number 
of features in the model must be restricted to prevent a model with thousands of features, thus 
only drugs and indications associated with the drug of interest were included. The 200 most highly 
ranked positively associated (Fisher’s Odds Ratio > 1) statistically significant (corrected p-value 
<0.05) co-reported drugs and indications, sorted by their corrected p-values, were identified using 
the two-sided Fisher’s exact test (fishers_exact function) from the SciPy (1.3.2) stats package (162) 
and Benjamini-Hochberg multiple testing correction using the Statsmodels (0.9.0) multipletests 
function (163). Separate multiple testing correction was performed on the drugs and indications.  
 
Using the propensity score model for each drug, propensity scores were calculated for all patient 
reports listing a drug of interest, referred to as exposed reports, and up to 100,000 (to limit 
computational cost) non-exposed background reports sampled randomly from all reports listing 
at least one of the associated drugs or indications. Next, the range of scores for the exposed reports 
was divided into twenty equally spaced bins, and for each bin containing reports, up to ten times 
as many ‘control’ reports with propensity scores in the same range were selected from the 
background reports. If the number of control subjects in a certain bin was fewer than the number 
of exposed reports, the control reports were sampled with replacement. When there were no 
control reports available, the bin was excluded. At the end of these procedures, a set of reports 
with the drug of interest and matched background reports was available per RxNorm drug in 
AEOLUS.  
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2.2.3 Detection of drug-adverse event associations in FAERS 
To be able to investigate the effect of using PSM, drug-AE associations from FAERS were 
calculated both while using PSM, as described above, and without using PSM as a baseline 
scenario. In the latter baseline scenario, the two-by-two table for calculation of the PRR compared 
the AE among all reports listing a drug of interest to all other non-exposed background reports in 
the database. In contrast, when using PSM, the matched exposed and non-exposed reports were 
used in the two-by-two table. Thus, instead of using all background reports, a set of reports 
matched on propensity scores is used as background in case of PSM.  
 
The PRR was calculated as described in section 1.7.1 according to van Puijenbroek et al. (125), on 
the MedDRA PT in the standard standard_case_outcome table in FAERS AEOLUS, counting 
unique report identifiers in each cell of the two-by-two table. The corresponding c2 statistic was 
calculated using the SciPy (1.3.2) chi2_contingency function, while setting a minimum expected 
count of five reports in each cell of the contingency table (163). Significant drug-AE pairs were 
identified using a previously reported signal detection threshold used in pharmacovigilance of PRR 
> 2 and c2 > 4 (88). The PRR was only calculated if there was at least one report of the AE in 
combination with the drug of interest and one among the background reports.  
2.2.4 Drug indications 
For the drugs from FAERS, corresponding drug indications were retrieved from the independent 
RxClass API (RxNorm vocabulary version 02-Dec-2019) using the RxNorm drug identifiers 
provided in FAERS AEOLUS. Encoded by the relationships ‘may_prevent’ and ‘may_treat’, the 
RxClass API provides drug indications as Medical Subject Heading (MeSH) terms from the 
Medication Reference Terminology (MEDRT) source, which is in turn provided by the Veterans 
Health Administration (161). Next, to map these MeSH terms to MedDRA terms, the 
MRCONSO.RRF mapping file provided by RxNorm (RxNorm_full_03092019) was used, which 
provides MedDRA PT and HLTs (164). Thus, where available, this resulted in a set of drug 
indications in the MedDRA vocabulary per RxNorm identifier. At least one drug indication was 
available for 85% of the drugs from FAERS. Reported AEs associated with drugs in FAERS based 
on the PRR analysis were considered to be a drug indication if they had the same HLT as the 
retrieved drug indications from RxClass for that drug. 
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2.2.5 Side Effect Resource (SIDER) 
The SIDER version 4.1 dataset was obtained from the download files (87). The meddra_all_se file 
lists side effects for 1,556 drugs, when counting identifiers that include stereochemistry where 
applicable (“STITCH stereo compound id column”), connected to 4,251 unique side effects 
(MedDRA PTs, “side effect name” column). The meddra_freq_file lists side effects marked as 
post-marketing for 624 drugs and additionally, for around 30% of all drug-side effect pairs from 
the meddra_all_se file, contains information on the occurrence of side effects in clinical studies. 
A few records from meddra_freq_file that were listed as being incorrect in the SIDER code 
repository were removed (165). To select the clinical effects only, first all drug-AE combinations 
from the meddra_all_se file for 928 out of 1,556 drugs were retained because these drugs did not 
have any post-marketing annotations in the meddra_freq file. Next, for drugs present in both files, 
drug-AE combinations listed as post-marketing in the meddra_freq file were excluded unless a 
frequency was available for that same effect, since frequencies can generally only be derived from 
clinical trials (90). While these steps create the largest possible set of effects from SIDER 
originating from clinical trials, it is possible that the above filter of post-marketing effects removes 
some genuine clinical trial effects. This is because some effects could have been observed in both 
clinical and post-marketing sections, such as nausea for doxorubicin, but it is not currently possible 
to distinguish these based on the download files from SIDER. 
2.2.6 Drug mapping 
The drugs in the FAERS and SIDER datasets have different drug identifiers, thus mapping to a 
common identifier was needed for comparison. Since a crucial part of the subsequent work 
described in chapter 3 involves retrieving bioactivities from the ChEMBL database, the ChEMBL 
molregno was used as the common drug identifier. The molregno is suitable because it is stable, 
unique, and links directly to a unique chemical structure described by its InChI and a connection 
table in ChEMBL. Furthermore, relationships between salt forms and parent forms of drugs are 
provided as relationships between molregno and parent_molregnos in ChEMBL. In this work, the 
aim was to link AEs with the parent drug, thereby grouping different salt forms of the same active 
ingredient, based on the assumption that drugs exert their main pharmacological action via the 
active ingredient.  
 
For the drugs from SIDER, the STITCH identifiers (“STITCH stereo compound id column”) 
were taken from the download files and converted to their PubChem identifier by removing the 
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extra zeros. Unichem is an online service that provides mappings of compound identifiers in 
different databases based on the molecule InChI Keys (166). Thus, the PubChem identifiers were 
submitted to UniChem to retrieve ChEMBL molregnos for version 24.1. This step excludes any 
drugs without an InChI Key such as biological drugs (166). To group different salt forms of the 
same drug, the parent_molregno was retrieved from a local MySQL installation of ChEMBL 
version 24.1 (167). 
 
There is no direct link from the drugs in FAERS AEOLUS, which are mapped to the RxNorm 
vocabulary, to the molecular structure. The only mapping with a link to molecular structures is 
between RxNorm and Drugbank provided by RxNorm. After retrieving the most up-to-date 
RxNorm identifiers from the RxNorm API (version: 03-Dec-2018), the RXNCONSO.RRF file 
provided by RxNorm (RxNorm_full_12032018) was used to find Drugbank identifiers for the 
RxNorm concepts (164). UniChem, then containing Drugbank version 5.1.1, was used to map to 
the DrugBank identifiers to molregnos in ChEMBL version 24. As with the SIDER data, salt 
forms were grouped according to their parent_molregno from the local MySQL version of 
ChEMBL 24.1. Further queries were also done on the local ChEMBL database; in case the 
retrieved Drugbank-to-ChEMBL mapping was to an unapproved drug (ChEMBL max_phase < 
4), a direct match of the RxNorm compound name to ChEMBL pref_name, compound_name or 
synonyms (excluding trade name) of an approved drug was preferred, as it is expected to be more 
accurate due to manual curation in ChEMBL. For any remaining unmapped drugs, the RxNorm 
compound name, RxNorm synonyms (excluding NDFRT, SNOMED_US, and CVX, taken from 
the RXNCONSO.RRF file from RxNorm_full_12032018 (164)) were checked for direct matches 
against the ChEMBL pref_name, ChEMBL compound_name, and ChEMBL synonyms. 
Mappings from this last step were included based on manual inspection of the matches.  
2.3 Results 
2.3.1 FAERS drug mapping 
Out of the 4,245 RxNorm drugs in the FAERS AEOLUS database, 2,764 drugs could be mapped 
to a ChEMBL identifier. Concepts that could not be mapped include vaccines and substances such 
as herbal products or chemicals that are not drugs and could not be mapped to a molecular 
structure or drug identifier in ChEMBL. Out of the 2,764 mapped drugs, the vast majority 
(n=2,108) are approved drugs in ChEMBL. The non-approved compounds include herbal 
products and supplements, e.g. menthol, activated charcoal etc., compounds from clinical trials, 
 80 
e.g. trimebutine, which is annotated as having reached phase 3 in ChEMBL, and other molecules 
that are not drugs e.g. oxyquinoline and propylene glycol. 
2.3.2 Detection of adverse events in FAERS 
Using the PRR, drug-AE relationships could be calculated for 1,345 unique RxNorm drug concept 
identifiers corresponding to 1,323 ChEMBL drugs when not using PSM. When using PSM, this 
was 1,414 RxNorm drugs corresponding to 1,388 ChEMBL drugs. While the PRR was calculated 
for each RxNorm drug separately, the results are integrated at the level of parent drugs when 
preparing the final dataset of drug-AE associations for further analysis (section 2.3.5). The slightly 
higher number of drugs with PRR calculations in the PSM scenario could be explained by the 
oversampling of background reports, due to sampling with replacement (see 2.2.2) leading to the 
minimum expected count of 5 reports in each cell of the 2-by-2 table for the c2 test being reached 
more often (see section 2.2.3). 
2.3.3 Propensity Score Matching reduces differences in patient groups to be 
compared 
The PSM procedure should result in matched groups of patients that are more similar in baseline 
characteristics than the exposed group is to the group of all non-exposed reports. As an example, 
Figure 2.2 shows such results of the PSM procedure for the drug prochlorperazine, a drug used to 
control nausea and to treat schizophrenia (168), where this has worked well. The figure compares 
the listing of the most strongly correlated drugs with prochlorperazine, which could be potential 
confounding factors, between the exposed and non-exposed reports. For example, among the 
reports listing prochlorperazine, 26% also list ondansetron, which is also used against nausea (169), 
but among all non-exposed background reports in the database less than 1% of reports also list 
ondansetron, resulting in a 25% difference in the use of ondansetron between the groups of 
reports when not using PSM (Figure 2.2). After using PSM, 28% of the selected exposed reports 
list ondansetron and similarly 30% of the matched non-exposed reports (Figure 2.2). Thus, 
differences in concomitant drugs between the groups of reports to be compared have successfully 
been reduced, providing a better base for subsequently comparing AEs associated with 
prochlorperazine between the two groups of reports. In this example, PSM is expected to reduce 
the chance of associating prochlorperazine with AEs that are actually due to ondansetron.  
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Figure 2.2 Differences in the percentage of exposed versus non-exposed background reports 
that list one of the 15 most strongly correlated concomitant drugs reported with 
prochlorperazine in the baseline scenario compared to using PSM. After applying PSM, 
differences in the listing of concomitant drugs between exposed and non-exposed reports are 
reduced, providing a better basis for comparing AE reporting rates in the two groups. 
Similarly, Figure 2.3 shows the changes for the most strongly correlated drug indications on reports 
listing prochlorperazine, with particularly the difference in the percentage of reports listing 
vomiting and nausea being reduced after using PSM. Since both prochlorperazine and ondansetron 
are used to control nausea (168, 169), the correlated drug indications are consistent with this, and 
PSM appropriately selected background reports of patients that are more similar to the patients 
using prochlorperazine in the database. 
 
Figure 2.3 Differences in the percentage of exposed versus non-exposed background reports 
that list one of the 15 most strongly correlated indications reported with prochlorperazine in the 
baseline scenario compared to using PSM. After applying PSM, differences in the listing of drug 
indications between exposed and non-exposed reports are reduced. 
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While the results of prochlorperazine are just one example, similar results were generally observed 
for other drugs and these cases are representative of the general pattern observed. In some cases, 
PSM made little difference due to the groups already being fairly balanced, such as for valproate, 
for which the percentage of exposed and non-exposed reports listing co-reported drug indications 
differed by less than 1% (Figure 2.4). Occasionally, reducing differences in some attributes comes 
at the cost of worsening differences in other individual attributes, such as for concomitant drugs 
with dexfenfluramine (Figure 2.5). Across all the plots discussed, it is also clear that PSM reduces 
but does not eliminate differences between groups. 
 
 
Figure 2.4 Differences in the percentage of exposed versus non-exposed background reports 
that list one of the 15 most strongly correlated indications reported with valproate in the baseline 
scenario compared to using PSM. Since the differences are smaller than 1%, in practice PSM 
makes little difference. 
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Figure 2.5 Differences in the percentage of exposed versus non-exposed background reports 
that list one of the 15 most strongly correlated concomitant drugs reported with dexfenfluramine 
in the baseline scenario compared to using PSM. After applying PSM, most differences in the 
listing of concomitant drugs are reduced, but some differences have increased, such as for 
diethylpropion. 
While these results are based on visual inspection and only a few representative examples are 
presented here, the results provide a first indication of PSM having the desired effect. The next 
question is whether PSM actually reduces false associations with AEs that are actually drug 
indications, which the next section will consider more systematically.  
2.3.4 Propensity Score Matching reduces false associations to drug indications 
To examine whether PSM reduces false associations to drug indications, the AEs associated with 
drugs in the PSM versus the baseline scenario were overlapped with the list of independently 
retrieved drug indications from RxClass for the corresponding drug. For 1,171 out of 1,388 drugs 
from the PSM results, drug indications were available, allowing comparison of the PRRs for drug 
indications in both scenarios. Figure 2.6 shows that PSM preferentially reduces the PRRs of AEs 
which are in fact drug indications, from a median PRR of 2.5 to 1.2. The PRRs of other AEs, i.e. 
those not being listed as drug indications in RxClass, are reduced from a median PRR of 1.4 to 
1.0. In addition to the reduction in the median, the whole distribution of PRRs is reduced to a 
greater extent in the case of drug indications (Figure 2.6), e.g. the 75th percentile is reduced from 
4.5 to 1.7 for drug indications compared to a change from 2.2 to 1.4 for non-indications. This 
shows that PSM, as expected, reduces the PRR of confirmed false associations to a greater extent 
than other associations. These other associations, i.e. non-indications, of which the PRRs are 
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reduced from a median 1.4 to 1.0 are expected to represent (1) true associations to AEs, but also 
(2) additional false associations to indications or related symptoms that were not listed in RxClass, 
and (3) potentially false positive associations to AEs due to confounding factors. It would be 
difficult to distinguish the three cases in an automated way. It would not be desirable for the PRR 
of true associations to AEs - the first of the above three cases – to be reduced, but PSM is intended 
to reduce the PRR in the last two cases. Therefore, the slight reduction in the PRR for non-
indications is consistent with a beneficial effect of PSM. Overall, it is concluded that PSM 
specifically reduces the PRR of confirmed false associations to drug indications. 
 
 
Figure 2.6. Comparison of the PRR of drug-AE associations in the PSM versus No-PSM 
scenario, split by whether the AE is actually a drug indication. It can be seen that PSM 
specifically reduces the PRR of drug indications, showing that the procedure reduces indication 
bias. Boxplot whiskers extend to 1.5 times the interquartile range (IQR). 
For cases where a PRR is available for the exact same AE in both the PSM and No-PSM scenario, 
the change in the PRR is plotted in Figure 2.7. This again shows that for the majority of drug-AE 
pairs, PSM preferentially reduces the PRRs of drug indications, with the median reduction in the 
PRR of indications being 1.4, and the median reduction being 0.4 in the case of AEs (Figure 2.7). 
This supports the conclusion that the PRRs for drug indications are reduced more strongly by the 
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PSM procedure than PRRs for AEs that are not listed as drug indications in the independent 
dataset. 
 
Figure 2.7. Change in PRR of drug-AE associations by PSM across 1,117 drugs. PSM 
preferentially reduces the PRR of drug-AE associations in which the AE is actually a drug 
indication. Boxplot whiskers extend to 1.5 times the IQR. 
An intuitive example of false associations between drugs and their indications is the association 
between cholesterol-lowering drugs and hypercholesterolaemia. Hypercholesterolaemia does not 
represent an AE but an underlying characteristic of the patient population that is prescribed 
cholesterol-lowering drugs. Tatonetti et al. used this example in a case study (98), which is reprinted 
in Figure 2.8. Using the same drugs where possible, Figure 2.9 shows that the overall ranges of the 
PRRs for the same associations are similar in the current study, although the exact numbers differ 
due to different databases being used. Thus, PSM reduces the PRR of these false associations in 
the current study with similar magnitude of the effect as in the study of Tatonetti et al. (98). 
Therefore, it can be concluded that the current implementation of PSM has similar effects as in 
the original publication of the method in this case study. The implications of the effect by PSM 
are that the dataset of drug-AE associations derived from using PSM is expected to be more 







Figure 2.8 Reduction in the PRR for hypercholesterolaemia associated with cholesterol-lowering 
drugs in the study by Tatonetti et al. Figure from N. P. Tatonetti, P. P. Ye, R. Daneshjou, R. B. 
Altman, Data-driven prediction of drug effects and interactions, Science Translational Medicine 
4, 125ra31-125ra31 (2012). Reprinted with permission from AAAS. 
 
Figure 2.9. Change in PRR for hypercholesterolaemia for the same cholesterol-lowering drugs as 
in the original case study by PSM in the current study. PSM reduces the PRR of these false 
associations. 
In their other case studies, Tatonetti et al. showed the effects of PSM for specific drugs indicated 
for diabetes, arrhythmia, and hypercholesterolaemia (98). Now using all the drugs indicated for 
these diseases in the current dataset of drug indications, Figure 2.10 shows that the implementation 
of PSM in this work reproduces the desired effects of reducing the PRR for these indications, 
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often to a PRR below 2, which is a commonly used threshold for the PRR in pharmacovigilance 
(88). Thus, it can be concluded that the current implementation of PSM has a similar desired effect 
as the original publication of the method (98). In addition to these cases studies, the previous 
Figure 2.6 and Figure 2.7 have shown that the effect is observed in the whole dataset, which 
includes a range of drug indications, and thus is not limited to these case studies. 
 
 
Figure 2.10. PRRs of drug indications in the PSM and No-PSM scenarios, for the drug 
indications of Tatonetti et al.’s original case studies but using the drugs from the current 
independent dataset of indications. PSM generally reduces the PRR of false associations to drug 
indication. The dotted line indicates a threshold of PRR=2. 
To investigate in more detail whether PSM behaves differently across different types of drug 
indications, Figure 2.11 shows the change in PRR per MedDRA SOC of the associated AE. While 
the magnitude of the effect varies between SOCs, PSM generally changes the PRR in the right 
direction across SOCs, except for the class ‘congenital, familial and genetic disorders’, shown by 
the median of the boxplot for the indications being greater than zero. This suggests that PSM is 
effective at reducing indication bias across a wide range of drug indications. However, the whiskers 
of the boxplots extend to changes in PRRs greater than zero, which indicates an increase in the 
PRR of drug indications falsely associated with some drugs. Thus, it appears that for a minority of 






Figure 2.11. Change in PRR of drug-AE associations by PSM per primary MedDRA SOC of the 
AE (or falsely the drug indication). PSM generally reduces the PRR of drug indications across all 
SOCs except ‘Congenital, familial and genetic disorders’, showing that PSM works for a wide 
range of drug indications. Boxplot whiskers extend to 1.5 times the IQR. 
A PRR ³ 2 and c2 ³ 4 is a common significance threshold in pharmacovigilance (88), and Figure 
2.6 already showed that for over 75% of drug indications in the PSM scenario, the PRR is below 
2. It would be expected that PSM would reduce the overall fraction of statistically significant drug-
AE associations that are in fact drug indications. While the median percentage of drug-indication 
pairs among the significant drug-AE pairs per drug is only slightly reduced from 0.9 to 0.7% 
(Figure 2.12), the total percentage of drug-indication pairs when adding all drugs together remained 
the same at 2.3%. Perhaps this is related to the increase in PRR for some drug-indication pairs in 
the PSM scenario noted from the distributions in Figure 2.11. Figure 2.12 shows that for a minority 
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of drugs the percentage of drug-indication-pairs among all drug-AE pairs per drug is indeed higher 
in the PSM scenario. Thus, while PSM appears to have the desired effect overall, there are cases 
where it is not effective or counterproductive, potentially contributing to masking an effect on the 
total share of indications among the associated AEs. The fact that PSM also seems to reduce the 
PRR of non-indications to below the significance threshold could also be compensating for the 
reduction in associations to indications, resulting in the overall percentage staying the same. 
 
 
Figure 2.12. Percentage of drug-indication pairs among the significant drug-AE associations per 
drug for 1,046 drugs (PRR > 2 and c2 >4). While the median percentage of indications is 
reduced, a minority of drugs has a higher percentage of indications in the PSM scenario. Boxplot 
whiskers extend to 1.5 times the IQR. 
2.3.5 Size of drug-adverse event datasets for further analysis 
Based on the previous results, the drug-AE associations derived from FAERS using PSM are taken 
forward for further analysis. Requiring a minimum of 5 drugs per AE results in a dataset of 1,263 
ChEMBL parent drugs significantly associated with one or more of 3,365 unique AEs (PTs), 
comprising a total of 72,200 significant drug-AE associations. This will be referred to as the 
FAERS dataset of drug-AE associations. 
 
For the SIDER dataset, a total of 1,219 drugs were mapped to molecular structures in ChEMBL. 
After making the selection of effects derived from clinical trials as described in the methods and 
excluding side effects with fewer than 5 associated drugs, the clinical trial-focused dataset contains 
1,027 ChEMBL parent drugs, which in total are linked to 1,131 unique side effects (PTs). The total 
number of drug-AE links is 47,324. This will be referred to as the SIDER dataset of drug-AE 
associations. 
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The drugs of both datasets will be used to retrieve corresponding bioactivities in chapter 3, and 
the drug-AE associations which be used to derive target-AE relationships in chapter 4. Therefore, 
the remainder of this chapter will consider the overall differences between these datasets in terms 
of drug classes and AE classifications. 
2.3.6 Comparison of significant drug-adverse event associations in the FAERS and 
SIDER datasets 
2.3.6.1 Number of significantly associated adverse events per drug 
Figure 2.13 shows the distributions of the number of significantly associated AEs per drug in the 
FAERS and SIDER datasets. The median number of associated AEs is 26 for FAERS and 29 for 
SIDER, whereas the maximum number of associated events is 896 and 388 respectively. Thus, the 
FAERS dataset contains a small number of drugs with a high number of significantly associated 
events. Overall, the distributions of the number of significantly associated AEs per drug are similar 
between FAERS and SIDER. However, there are large differences between drugs, i.e. some drugs 
are associated with many AEs at the same time, and others with only few AEs. The 75th percentile 
of both distributions is just over 60 AEs. Thus, in the majority of cases, drugs are associated with 
fewer than 60 AEs. The exponential shape of the distribution is in line with another study of 
FAERS that observed a similar distribution, commenting that 90% of ADRs were related to 40% 
of the drugs (73). Overall, it can be concluded that the number of associated AEs varies but is 




Figure 2.13. Distribution of the number of significantly associated AEs per drug in the FAERS 
(PRR > 2 and c2 > 4) and SIDER datasets 
2.3.6.2 Distribution of drugs across Anatomical Therapeutic Chemical Classes 
To assess whether any of the datasets is biased towards any therapeutic area, Figure 2.14 shows 
the Anatomical Therapeutic Chemical (ATC) classes of the drugs in the FAERS and SIDER 
datasets compared to those of all approved small molecule drugs in ChEMBL 25. The drugs’ 
distribution across ATC classes is largely similar to the set of all small molecule drugs in ChEMBL 
(Figure 2.14). However, there are some differences, for example, the percentage of drugs used for 
nervous system indications is 17% higher in the FAERS and SIDER datasets than in the set of all 
marketed small molecules (Figure 2.14). Nevertheless, both datasets represent all ATC classes of 
marketed drugs, thus providing a fair representation of therapeutic classes and it can be concluded 




Figure 2.14 Distribution of drugs with significant associations to AEs in the FAERS and SIDER 
datasets across ATC classes compared to approved small molecule drugs in ChEMBL 25. 
Multiple ATC labels per drug were included where this occurred. Both datasets appear to be 
representative of small molecule therapeutic classes. 
2.3.6.3 Overlap in drugs and adverse events between datasets 
A total of 696 drugs are shared between the FAERS and SIDER datasets, which is ~44% of the 
union of unique drugs. A remaining ~36% of drugs are only present in the FAERS dataset and a 
further ~21% of drugs occur in SIDER (Figure 2.15). Thus, both datasets contribute a 
considerable fraction of drugs not contained in the other.  
 
Regarding the AE terms in the two datasets, ~29% of the unique PTs occur in both datasets, with 
a remaining 68% and 3% of AEs terms only occurring in FAERS and SIDER respectively (Figure 
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2.15). This shows that FAERS contains a greater diversity and number of unique AE terms, as the 
above percentages correspond to 2,349 PTs only occurring in FAERS and 115 only in SIDER.  
 
Comparing the AEs at the HLT level reconciles the discrepancy to some extent, with ~52% of 
unique HLT terms occurring in both datasets, compared to ~29% of PTs (Figure 2.15). 
Nevertheless, ~46% of HLTs only occur in the FAERS dataset, versus only ~2% of HLTs that 
are unique to SIDER (Figure 2.15). Thus, while the FAERS dataset contains more drugs in total, 
it contains a disproportionately higher number of unique AEs, suggesting a greater diversity of 
AEs in FAERS. This could be related to the more diverse population from which FAERS reports 
are derived compared to clinical trials and the focus of post-marketing surveillance on unexpected, 
rare events.  
 
Figure 2.15. Unique drugs and AEs shared between the FAERS and SIDER datasets. The 
datasets appear complementary because many AEs only occur in either dataset. The FAERS 
dataset has a large number of AEs not shared with SIDER.  
2.3.6.4 Drugs are associated with different adverse events in FAERS and SIDER  
To investigate to what extent AEs associated with the same drug are different between FAERS 
and SIDER, only the AEs associated with the 696 drugs that occur in both datasets were examined. 
Figure 2.16 shows that for most of these drugs less than 10% (median 1.5%) of all unique AEs 
listed are shared between the datasets. Therefore, generally, AEs are associated with a given drug 
only in one of the datasets as opposed to in both, showing that the datasets provide different 
information.  
 
Furthermore, Figure 2.16 shows FAERS and SIDER contribute a roughly equal share of unique 
AEs, with the median percentage of AEs being unique to FAERS being 55% and 40% for SIDER. 
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This means that in most cases, FAERS and SIDER both contribute around half of the unique 
events per drug. Occasionally, either FAERS or SIDER provides the majority of unique AEs for 
a given drug, which is indicated by the whiskers of the ‘FAERS only’ and ‘SIDER only’ boxplots 
(Figure 2.16). Both distributions span nearly the entire range, indicating that both FAERS and 
SIDER occasionally provide nearly all of the unique AEs. Therefore, both datasets provide distinct 
information for different individual drugs. Overall, these results suggest that FAERS and SIDER 
provide complementary information. 
 
 
Figure 2.16. Percentage of all unique AEs associated with the a given drug overlapping between 
the FAERS and SIDER datasets or being unique to either dataset. AEs for the same drug rarely 
overlap between FAERS and SIDER, with only a median 1.5% of unique AEs overlapping 
between the datasets. Boxplots show the median with whiskers extending to 1.5 times the IQR. 
2.3.6.5 FAERS and SIDER show a different diversity of adverse events across System Organ Classes  
Considering the diversity of AEs in the FAERS and SIDER datasets across SOCs, Figure 2.17 
shows the distribution of unique AE terms occurring in the datasets, now considering the full 
dataset again as opposed to overlapping drugs only. ‘Investigations’ form the largest group of AEs 
in FAERS, which is a highly diverse SOC that includes events such as electrocardiogram 
observations and changes in blood pressure, whereas nervous system disorders are the largest 




Figure 2.17. Diversity of reported unique AEs across SOC by dataset. Each distinct AE is 
counted once per dataset, even if associated with multiple drugs. Investigations are the largest 
group of AEs in FAERS, whereas nervous system disorders are the largest class in SIDER. The 
largest differences between FAERS and SIDER are seen for ‘injury, poisoning and procedural 
complications’, being enriched in FAERS, and eye disorders being enriched in SIDER. 
The largest difference between the two datasets is seen for the SOC ‘Investigations’, which 
comprises over 9% of unique AEs in FAERS but less than 6% for SIDER (Figure 2.17). Similarly, 
over 6.5% of AEs in FAERS belong to the SOC ‘injury, poisoning and procedural complications’, 
compared to less than 2% of AEs in SIDER. These differences could reflect the fact that FAERS 
contains reports of accidental and intentional overdoses, medication errors, and product problems 
(7). The SOC ‘surgical and medical procedures’ is similarly enriched in FAERS, comprising 3% of 
unique AEs in FAERS but less than 0.5% in SIDER, which is perhaps also related to the nature 
of FAERS reporting in terms of accidents and emergencies (Figure 2.17). Another enriched SOC 
among the FAERS AEs is ‘neoplasms benign, malignant and unspecified (incl. cysts and polyps)’. 
Neoplasms generally take long to develop, thus perhaps this could be related to the longer time 
scale of drug use for reports submitted to FAERS (83, 94). Lastly, FAERS contains more AEs in 
‘pregnancy, puerperium and perinatal conditions’, which could reflect the longer time frame and 
 96 
diversity of exposures in the wider population compared to clinical trials (83, 94), e.g. pregnant 
women are frequently excluded from clinical trials (170, 171). The SOCs mostly highly enriched in 
SIDER are ‘eye disorders’, and ‘skin and subcutaneous tissue disorders’, suggesting that events in 
these categories are more typically reported during clinical trials than pharmacovigilance reporting. 
One reason for such differences can be that once drug effects are listed on the drug label, they are 
less likely to be reported to pharmacovigilance systems (21). Overall, it can be concluded that the 
AEs in FAERS and SIDER have a different distribution of unique AEs across SOCs, perhaps 
reflecting their distinct origin.  
2.4 Discussion and conclusions 
This chapter began with applying PSM on a larger version of FAERS than previously reported and 
reproducing case studies from the original publication of the method. Using an independent 
dataset of drug indications, the desired effect of PSM on reducing the statistical association to drug 
indications was verified, although in a minority of cases PSM appears to increase false associations 
to drug indications. While indication bias is only one of the potential biases affecting FAERS, it 
serves as an example for verifying the effects of PSM, and it is expected that other confounding 
factors are also reduced by the procedure. Previously, Tatonetti et al. showed that when only taking 
into account drug indications and concomitant drugs in PSM, differences in sex and age were also 
reduced (98). The result from this chapter not only confirm that the implementation of PSM is 
working as expected with respect to drug indications, they also strengthen the validation of PSM 
further to the work of Tatonetti et al. by using an independent dataset of drug indications. 
 
One of the limitations of implementing the PSM procedure in a high-throughput, automated way, 
is that models are not implemented and evaluated as extensively as would be possible when only 
studying one drug-AE combination. For example, more sophisticated methods exist for variable 
selection for propensity score models (102, 172) and model evaluation (173, 174) than used in this 
work. These might have the potential to identify cases where PSM is less successful at balancing 
relevant covariates and reducing the effect of confounding factors, but would require a 
considerable amount of further work to be implemented on a large scale, so this was beyond the 
scope of the current work.  
 
An additional limitation is that the PSM method samples non-exposed reports with replacement, 
meaning that the same non-exposed report can be counted more than once. While this does help 
to retain as many drugs as possible when suitable background reports are scarce, it might introduce 
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or amplify imbalances unintendedly. This might be one of the reasons why for a minority of drugs, 
PSM increased the association to drug indications. Future work could consider whether using one-
to-one matching is more reliable. Nevertheless, it is useful that even in the automated way that 
PSM is implemented here, biases such as indication bias are reduced. These results are in line with 
another study showing benefits of an automated implementation of a propensity score model 
(140). Meanwhile, it remains a limitation that propensity score methods do not eliminate biases, 
but only reduce them. 
 
There are also limitations to the drug-AE relationships compiled from FAERS and SIDER. 
FAERS is affected by the lack of causal evidence behind AE reports (7), underreporting of AEs, 
and remaining confounding factors in FAERS, whereas text-mining errors may have affected the 
SIDER data (87). As a result, some of the drug-AE relationships derived may prove to be incorrect 
in the future, and at the same time some true drug-AE associations may be missing from the 
datasets compiled. Nevertheless, this chapter has shown that PSM reduces potential biases in post-
marketing data and has helped to create more reliable dataset of drug-AE associations based on 
FAERS for further study. 
 
Lastly, this chapter compared the drug-AE associations from FAERS to those recorded in SIDER. 
While the drugs of both datasets represent all therapeutic classes measured by ATC codes, both 
datasets contain drugs not contained in the other. Moreover, shared drugs are associated with 
different AEs in the two datasets. The datasets also differ in their distribution of unique AEs 
across SOCs, with FAERS showing a greater diversity of AEs and potentially reflecting more long-
term effects as well as diverse populations. From these results it can be concluded that FAERS 
and SIDER are complementary, each providing unique AE relationships. The distributions of the 
datasets presented provide a background against which to interpret the target-AE relationships 
which will be derived in chapter 4. 
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3 Adjusting activity calls for 
measured and predicted in vitro 





Having prepared the FAERS and SIDER datasets containing drug-AEs links in the previous 
chapter, the next step towards linking AEs to underlying protein activities is to identify bioactivity 
data for the drugs from the AE datasets. Therefore, this chapter will use the drugs from the 
datasets compiled in chapter 2 and introduce their corresponding in vitro bioactivities and ligand-
based target predictions, and integrate them with drug plasma concentrations. As outlined in the 
thesis Introduction, it is generally recommended to consider the free drug plasma concentrations 
alongside in vitro drug potencies and affinities to determine the in vivo relevance of in vitro 
bioactivities, and this is common practice in later stages of drug development and risk assessment 
(19, 20, 57, 66, 69, 73). However, existing studies of target-AE associations that use drug plasma 
concentrations have only reported on a limited number of examples, with no existing study 
reporting results of a large-scale integration of drug plasma concentrations. On the one hand, 
analysis of in vitro bioactivity data without plasma concentrations represents the early stages of drug 
discovery (71), since plasma concentrations are determined later in the drug development process. 
On the other hand, to discover the true relevance of secondary pharmacology target activities for 
in vivo events, the pharmacokinetics must be considered. One likely reason for the lack of 
systematic studies using drug plasma concentrations is that they are not as easily available in the 
public domain as in vitro bioactivity data. For example, Table 3.1 contrasts the number of drugs 
that have bioactivity data versus those with Cmax data in ChEMBL, showing that plasma 
concentrations are only available for a limited set of drugs. The Cmax is generally the most abundant 
parameter to characterise effective drug plasma concentrations in literature, compared to e.g. 
steady-state concentrations or effective concentration ranges (36). 
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Table 3.1. Number of parent compounds with bioactivity and Cmax data in ChEMBL version 24.1 
by clinical phase. In vitro bioactivities are more abundant than peak plasma concentrations. 
Maximum clinical phase 
of drug 
At least one bioactivity 
against a human target (n 
parent compounds) 
Human Cmax data (n parent 
compounds) 
0 735,344 139 
1 129 4 
2 323 15 
3 318 20 
4 (approved drugs) 1,578 183 
 
While data availability is limited, no current study has reported to what extent active and inactive 
labels for drug-target pairs differ when solely based on in vitro potency compared to considering 
both the in vitro potency and the drug plasma concentrations. Therefore, in this chapter a set of 
drug plasma concentrations and plasma protein binding data is compiled from scientific literature 
and the ChEMBL database. These drug plasma concentrations will be considered alongside the in 
vitro potency or affinity by means of their ratio, similar to the approach introduced in Table 1.12 
in the Introduction, to derive an ‘adjusted’ activity call for drug-target pairs. Thus, this chapter 
provides intermediate results in terms of the bioactivity datasets, and the way classified active and 
inactive datapoints are affected by the additional consideration of plasma concentrations. This data 
provides further background to chapter 4, which will analyse how using the adjusted activity calls 







3.2 Materials and methods 
3.2.1 Extraction of in vitro bioactivity data 
For the drugs from the FAERS and SIDER datasets mapped to ChEMBL parent compounds, 
ChEMBL version 25 was queried using a local MySQL installation. Bioactivities against any human 
single protein or protein complex were retrieved, regardless of these being primary or secondary 
drug targets. In the case of protein complexes, bioactivities at each of the constituent single 
proteins listed in the target_components table were listed. The activity types included were 'IC50', 
'EC50', 'XC50', 'AC50', 'Ki', 'Kd' and 'Potency' for assay types ‘B’ (binding) and ‘F’ (functional) 
with standard_flag=1. Using the confidence scores of 7 (protein complexes) and 9 (single proteins) 
ensures the highest level of confidence in target assignment (107). Inactive data was retrieved by 
extracting records containing any of the following in the activity_comment: ‘Not active’, ‘inactive’, 
‘No inhibition’ and allowing standard_flag=0 for these records. The median reported pXC50 was 
computed per parent drug for further analysis and in the case of conflicting active and inactive 
assignments for the same drug, the active assignment was taken forward. 
3.2.2 Protein target prediction 
To supplement the measured bioactivity data, the probability of in vitro activity at single human 
proteins was predicted using the ligand-based target prediction tool PIDGIN version 3 (114, 116) 
as follows: compounds were standardised using the e-Tox compound standardiser (175), and the 
separate classification models available in PIDGIN were used to obtain predictions for the activity 
below the thresholds of 0.1, 1, 10 and 100 µM (116). The applicability domain threshold was set 
at a minimum of 0.7 and only models with a minimum Precision-Recall Area Under the Curve of 
0.7 during time-series split cross-validation were included (116). Overall, experimental bioactivity 
values were used where available, with predictions obtained using the settings described above 
being added to the compound-target bioactivity matrix, but only if at least one measured bioactivity 
was available for the target, to ensure that subsequent analyses are based on a combination of 
measured data with supplemented predictions instead of solely on predictions, which would be 
associated with greater error. 
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3.2.3 Drug plasma concentrations 
Plasma concentration data were compiled from a variety of sources. The upper therapeutic plasma 
concentrations listed in the supplementary data of the publication by Schulz et al. (176) were 
extracted. In addition, human plasma concentrations (Cmax) were retrieved from ChEMBL 24.1, 
allowing the tissues plasma, blood and serum in case the assay_tissue field was filled, and 
additionally accepting records where the assay_tissue field was empty, thus assuming these are 
plasma/blood measurements. Furthermore, the standard_flag=1 was used and records with 
unusual values (data_validity_comment= ‘Outside typical range’) were excluded, which in case of 
plasma concentrations enforces a normal range between 1 nM and 10 mM or alternatively between 
0.5 ng/ml and 5 mg/ml according to the activity_stds_lookup table in ChEMBL. Values referring 
to metabolites in either of these sources were excluded based on the mentioning of ‘metabolite’ or 
similar in the assay description. Molar concentrations were calculated using the molecular weight 
of the parent drug recorded in ChEMBL. Where multiple plasma concentrations were available 
for the same drug and the standard deviation of the pMolar concentration exceeded 1, values were 
checked against the original publication and corrected where necessary. These corrections affected 
8 datapoints from the ChEMBL database. Data for the fu and PPB of drugs was retrieved from 
ChEMBL 24.1 and from several publications (59, 152, 177, 178). Where a range was provided, the 
average of the two values was calculated. For the fu and PPB extracted from publications, drugs 
were mapped using the InChI Key and alternatively drug names provided in the publication via 
direct matching to the pref_name, synonyms, or compound_name in ChEMBL. The median fu 
was calculated using the fu and PPB data, and then multiplied by the total plasma concentrations 
to derive the unbound plasma concentration. The median total or calculated unbound plasma 
concentrations were calculated for further analysis. 
3.2.4 Activity calls using a constant bioactivity cut-off 
To be able to study the effect of integrating bioactivities with plasma concentrations, a baseline 
dataset was created using a constant cut-off on the pChEMBL value without consideration of the 
plasma concentrations. Therefore, drugs were assigned as active if the pChEMBL value for the 
drug-target pair was ³ 6 (XC50 £ 1 µM), else the drug was assigned inactive. This constitutes the 
activity call using the constant bioactivity cut-off. This threshold was chosen because it is a 
commonly used in vitro bioactivity threshold (40, 65, 67). This dataset will be referred to as the 
‘constant cut-off dataset’. 
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3.2.5 Integration of bioactivities and drug plasma concentrations to derive adjusted 
activity calls 
3.2.5.1 Measured bioactivities 
The bioactivity measurements and the plasma concentrations were compared to assign an active 
or inactive label to the drug-target pair, which is the ‘adjusted’ activity call for that drug-target pair. 
Therefore, drugs were assigned as active on a given target if the drug plasma concentration 
exceeded the in vitro bioactivity concentration, or was up to 10 times lower (1 log unit) than the in 
vitro concentration. The leeway of 1 log unit is aimed at maximising the potential signal given 
experimental variability of bioactivity measurements, which may be around half a log unit (44, 
179), and considerable inter-individual variability in pharmacokinetics (176). If the plasma 
concentration was more than 10-fold lower than the measured in vitro concentration, the drug-
target pair was classified as inactive. Additionally, inactive calls were made based on the 
activity_comment conveying inactivity as described in section 3.2.1 above. The conditions for the 
adjusted activity calls are summarised in Table 3.2. Assuming that plasma concentrations 
correspond to concentrations in target tissues, the adjusted activity calls provide an approximation 
of whether a target will be modulated sufficiently to obtain an effect.  
Table 3.2 Defining the adjusted activity call based on the integration of the in vitro bioactivity and 





Drug plasma concentration exceeds measured 




Drug plasma concentration is up to 10-fold 




Drug plasma concentration is more than 10-




Measured in vitro bioactivity annotated as 
inactive 
‘Not active’, ‘inactive’, ‘No 




3.2.5.2 Predicted bioactivities 
Depending on whether drugs were in the applicability domain of the target prediction models, 
probabilities between 0 and 1 were available at all or some of the activity thresholds (0.1, 1, 10 and 
100 µM) for each drug-target pair. When predictions were available, a probability below 0.4 was 
considered inactive and above 0.6 active for each threshold. The lowest predicted active threshold 
was compared to the plasma concentration, in the same way as for the measured bioactivity data, 
to derive adjusted activity calls. This is shown for potential scenarios in Table 3.3. For a low 
percentage of drug-target pairs (<0.01%), the available predictions followed a counterintuitive 
concentration-response curve, which arises from the models at different thresholds being built on 
different training sets, and these records were excluded. If all available predictions were inactive, 
the datapoint was included as inactive if the plasma concentration was lower than 10 times (1 log 
unit) the highest predicted inactive threshold otherwise the data point was not used (Table 3.3). 
However, if a compound was in the applicability domain of the models for each threshold, and 
consistently predicted to be inactive, the datapoint was included as inactive, because the negative 
predictions span a wide range of concentrations (Table 3.3). 
Table 3.3 Target predictions were integrated with plasma concentrations depending on the pattern 
of active and inactive predictions across the four activity thresholds, as illustrated with potential 
scenarios. 
Activity threshold (µM) Description Decision/Adjusted 
activity call 
0.1 1 10 100 




Inactive Active Active Active Both active and 
inactive predictions 
Active if plasma 
concentration exceeds 
the lowest predicted 
active concentration (1 
µM in example), or is up 
to 10 times lower (1 log 








Active Active All active 
predictions 
Active if plasma 
concentration exceeds 
the lowest predicted 
active concentration (10 
µM), or is up to 10 times 
lower (1 log unit). Else 
excluded (not enough 
data). 




Inactive if plasma 
concentration is lower 
than 10 times (1 log unit) 
the highest predicted 
inactive threshold (10 
µM). Else excluded (not 
enough data). 




for all thresholds 




inactive at wide range of 
thresholds) 
3.2.6 Filter for minimum number of actives 
Previous studies (150, 151) filtered bioactivity data to have at least 5 drugs classified as active at a 
given protein, to prevent any further analysis being based on very limited data. Thus, this filter is 
also applied on the data here after deriving the baseline and adjusted activity calls. 
3.3 Results  
3.3.1 Origin and size of retrieved bioactivity datasets 
The initial dataset of measured in vitro bioactivity data for human targets, using the drugs from the 
AE datasets, was extracted from ChEMBL and contained 113,710 datapoints. Table 3.4 lists the 
original sources of this data as listed in ChEMBL, showing that DrugMatrix, scientific literature 
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and PubChem are the main original sources of measured bioactivity data. This is encouraging 
because data from DrugMatrix and PubChem are derived from screening and thus are full matrices 
(105, 107). Furthermore, it is clear that DrugMatrix is a larger source of bioactivity data for 





Table 3.4 Sources of ChEMBL bioactivity data for the drugs from the AE datasets. DrugMatrix is 
the largest source of measured bioactivity datapoints for drugs in this study. 
Source of ChEMBL bioactivity data Datapoints (%) 
DrugMatrix 82.16 
Scientific Literature 10.42 
PubChem BioAssays 7.022 
TP-search Transporter Database 0.291 
BindingDB Database 0.062 
Patent Bioactivity Data 0.041 
K4DD Project 0.004 
Deposited Supplementary Bioactivity Data 0.001 
 
To examine the number of drugs and targets present in the dataset, Table 3.5 shows that the 
experimental bioactivities include 1,147 unique parent drugs and span 1,044 unique targets. 
However, only 4.8% of the full matrix is filled with datapoints with the rest of the cells being 
empty, i.e. no data available (Table 3.5). After inserting the predictions into the matrix of measured 
datapoints, the matrix density of filled datapoints increases to 26.6% of the full matrix. Overall, 
predicted datapoints comprise 86.2% of all datapoints after combining experimental and predicted 
data (Table 3.5). This shows that using ligand-based target predictions increases the number of 
datapoints for further analysis considerably. 
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In terms of the percentage of active versus inactive datapoints, based on the constant cut-off of 
pChEMBL value ³ 6, a total of 6.7% of experimental datapoints are classified as active (Table 3.5). 
Among predicted datapoints, a lower total of 0.4% of datapoints is predicted active at any of the 
prediction thresholds, resulting in an overall percentage of 1.3% of datapoints classified as active 
(pChEMBL value ³  6 or predicted active) in the combined matrix of experimental and predicted 
bioactivities (Table 3.5). Thus, it can be concluded that target predictions primarily add negative 
(inactive) datapoints when using the absolute cut-off. Furthermore, it is concluded that predictions 
comprise the majority (86.2%) of all drug-target datapoints, and that in the overall dataset of 
combined experimental and predicted values, 1.3% of datapoints is classified as active. The active 
labels counted here are used to give an idea of the share of active versus inactive datapoints, in the 
next sections the activity calls will be adjusted with the plasma concentrations. 
Table 3.5 Size of bioactivity datasets for drugs from the AE datasets, contrasting the set of 
measured data with the set of measured plus predicted data. Predicted active is defined as the 
predicted probability of activity > 0.6 for any of the predicted concentrations (100,10,1 and 0.1 
µM) for the purpose of this dataset count. A pChEMBL value of 6 corresponds to a concentration 
of 1 µM.  
 Measured bioactivity 
dataset  
Measured + predicted 
bioactivity dataset 
Number of unique parent drugs 1,147 1,491 
Number of unique targets 1,044 1,044 
Matrix cells with data (%) 4.8 26.6 
Drug-target pairs with data (n) 56,909 413,840 
Datapoints derived from 
predictions (%)  
- 86.2 
Datapoints “active” 
(pchembl_value ≥ 6) (%) 
 6.7 1.3 
3.3.2 Distribution of compiled plasma concentrations 
Plasma concentrations were extracted from publications and ChEMBL, and unbound drug 
concentrations were calculated where possible. Total and unbound concentrations were available 
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for 625 and 466 drugs respectively. As expected, the unbound concentrations are lower than the 
total concentrations (Figure 3.1). The median total plasma concentration is 5.8 (pMolar) with a 
standard deviation of 1.3, whereas the median unbound concentration is 6.6 (pMolar) and the 
standard deviation is 1.5 (Figure 3.1). Some of the highest values on the distribution are those 
around pMolar concentrations of 3 and 4, corresponding to plasma concentrations of 1 mM and 
100 µM respectively. As described in the Methods, the drugs with multiple plasma concentration 
measurements of which the standard deviation was greater than 1 log unit were inspected against 
original data. This check revealed 8 errors in ChEMBL data, mostly related to unit transcription 
errors, which were corrected, and while it would not be feasible to check every data point when 
using data from other sources, this illustrates that one of the limitations of using data from 
previous compilations and databases is potential transcription errors. Another limitation of this 
data is that different routes of administration are all included but respective plasma concentrations 
may differ (36, 176). Lastly, the unbound plasma concentrations are based on the fu and PPB, which 
are mostly measured in vitro (36) and may not reflect in vivo values perfectly. 
 
 
Figure 3.1 Distributions of the total and calculated unbound plasma concentrations available for 
the drugs from the AE datasets prepared in chapter 2. In case of multiple measurements for the 
same drug, the median was taken. 
Looking at the difference between the total and unbound concentrations, Figure 3.2 shows the 
distribution of the difference between the total and unbound concentrations per drug. For the 
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majority of drugs, the difference is less than 1 log unit but there are cases of over 3 log units 
difference, which seems considerable and would be expected to impact further analysis.  
 
 
Figure 3.2. Distribution of the difference between the total and unbound plasma concentrations 
per drug 
3.3.3 Integration of bioactivity data and plasma concentrations 
3.3.3.1 Effect of using plasma concentrations on the size of the dataset 
Plasma concentrations were only available for a subset of all drugs, therefore reducing the size of 
the dataset for further analysis. To quantify this effect on the size of the dataset, Table 3.6 shows 
the number of datapoints when using the plasma concentrations as a percentage of the dataset 
using the constant cut-off. As expected, requiring plasma concentrations in the analysis reduces 
the size of the dataset. Overall, 63% and 51% of the drug-target pairs are retained when using the 
total and unbound plasma concentrations respectively. While the number of unique drugs is 
reduced by up to 7%, the number of unique targets when using the total and unbound 
concentrations is reduced to 83% and 63% of the dataset respectively. Furthermore, requiring 
unbound concentrations restricts the dataset more than requiring total concentrations due to 
limited data availability. Overall, it is concluded that requiring drug plasma concentrations reduces 
the available drug-target bioactivity datapoints by around 40-50%. The rest of the results in this 
chapter focus on the activity calls adjusted with the unbound plasma concentrations. 
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Table 3.6. The percentage of drug-target pairs, unique drugs and unique targets retained when 
using the drug plasma concentrations compared to using the dataset with pChEMBL value ³ 6 
cut-off. All datasets compared include target predictions. 
 Total plasma concentration Unbound plasma concentration 
Drug-target pairs (%) 63 51 
Unique drugs (%) 95 93 
Unique targets (%) 83 63 
3.3.3.2 Effect of using unbound plasma concentrations on the target class distribution 
To examine the effect of using unbound plasma concentrations on the overall distribution of 
bioactivity datapoints across target classes, Figure 3.3 compares the target class distribution of all 
bioactivity datapoints to those with unbound plasma concentrations available. Although the 
percentage of kinase datapoints is slightly reduced and the percentage of Family A G protein-
coupled receptor datapoints is increased, the distributions are similar (Figure 3.3). Thus, it appears 
that the subset of the dataset with unbound concentrations available is roughly representative of 
the complete bioactivity dataset and no large bias has been introduced at this stage.  
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Figure 3.3. Distribution of all bioactivity datapoints across target classes, compared to the 
datapoints with unbound plasma concentrations available. The distributions are similar, so the 
subset with unbound plasma concentrations seems to be a representative sample in terms of 
target classes. The target class shown is the second level of the ChEMBL target hierarchy if 
available (e.g. lyase), otherwise only the first level is shown (e.g. enzyme). Only target classes 
containing more than 1% of datapoints are shown. 
3.3.3.3 Effect of using unbound plasma concentrations on activity calls 
Using the plasma concentrations to derive adjusted activity calls results in 1.0% of all datapoints 
being classified as active, which is similar to the 1.3% in the dataset based on using the constant 
bioactivity threshold. Also similar is that the percentage of adjusted activity calls classified as active 
is higher among the experimental (3.6%) than predicted datapoints (0.1%), upholding the 
observation that the predicted datapoints primarily add datapoints classified as inactive. 
 
Considering the drug-target pairs that are present among both the baseline and adjusted activity 
calls, only 0.6% of all datapoints is different, i.e. the activity call is reversed by consideration of the 
unbound plasma concentration. Of these changes, 68% are in the direction of inactive to active,  
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resulting in drug-target pairs newly labelled as active, which would not be classified as active when 
using the constant cut-off. In addition, the changes in the direction of active to inactive affect 19% 
of active labels among the baseline activity calls. Figure 3.4 contrasts the active drug-target pairs 
among the baseline and adjusted activity calls, showing the 19% (n=298 drug-target pairs) of active 
pairs in the constant cut-off dataset are not shared with the active adjusted activity calls. A total of 
647 pairs are only assigned active when using the unbound concentrations. This means that 34% 
(647 out of (1250 + 647)) of active labels among the adjusted activity calls are unique to this 
scenario, and would be classified as inactive with the constant cut-off. Thus, even though the 
majority of active labels stays the same after adjustment with the unbound plasma concentrations 
(1250), the set of active drugs changes considerably when using the unbound plasma 
concentrations compared to the absolute cut-off. To what extent the adjusted activity calls are 
more accurate and relevant to in vivo AEs will be investigated in the next chapter, which will 
consider how the targets selected by the different activity calls relate to AEs. At this stage, it can 
be concluded that the set of active labels is considerably different after integration the with 
unbound plasma concentrations and this warrants further investigation.  
 
Figure 3.4. Overlap in drug-target pairs classified as active when using the constant cut-off of 
pChEMBL value ³ 6 compared to using the ratio of the unbound plasma concentration and the 
pChEMBL value (adjusted activity calls) as described in the Methods. 19% of the active calls 
(n=298) when using the constant cut-off are changed to inactive by considering the unbound 
plasma integration, while a further 647 pairs are changed from inactive to active by the integration, 
meaning they are unique active calls to the dataset based on using unbound drug plasma 
concentrations. 
3.3.3.4 Effect of using plasma concentrations on activity calls by target class 
To investigate how the integration with unbound plasma concentrations affects the activity calls 
in different target classes, Figure 3.5 shows the distribution of datapoints across target classes. The 
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top bar for each target class indicates the percentage of all drug-target pairs that fall within that 
class, whereas the lower bar indicates the percentage of all datapoints changed by the integration 
that fall within the class (Figure 3.5). For example, bioactivities at kinases comprise around 19% 
of all datapoints with unbound concentrations available, but only 4% of the activity calls changed 
by unbound plasma concentrations concern kinase datapoints. Thus, activity calls for kinases are 
proportionately less affected by plasma concentrations, meaning their baseline and adjusted 
activity calls are generally the same. The lower bar for each target class in Figure 3.5 furthermore 
show the direction of change for the datapoints that are affected by plasma concentrations, e.g. 
for kinase datapoints that are changed, 79% is in the direction inactive to active. 
 
 
Figure 3.5. Distribution of all bioactivity datapoints by target class for which the unbound drug 
plasma concentration was available, compared to the activity calls that are changed by the 
integration of the unbound plasma concentration, with the underlying activity calls shown. The 
target class is the second level of the ChEMBL target hierarchy if available (e.g. lyase), otherwise 
only the first level is shown (e.g. enzyme). Activity calls that are changed by the plasma 
concentrations most often change from inactive to active, except for the family A GPCRs and 
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cytochrome P450s, for which most of the changes are from active to inactive. Only target classes 
containing more than 1% of datapoints are shown.  
In contrast to kinases, datapoints for enzymes, unclassified proteins, voltage-gated ion channels, 
lyases, and electrochemical transporters are proportionately more affected by the integration. For 
example, 17% of datapoints changed by the plasma concentrations are enzyme datapoints, whereas 
<8% of all datapoints fall within this class (Figure 3.5). Thus, these classes appear more sensitive 
to the integration with unbound plasma concentrations. 
 
Furthermore, looking at the direction of changes in the lower bar of each class, it can be seen that 
for the majority of datapoints, adjustments by plasma concentrations occur in the direction from 
inactive to active (Figure 3.5). In fact, for lyases, proteases and writers, all changes are in the 
direction from inactive to active (Figure 3.5). Exceptions to this observation are the family A 
GPCRs and cytochrome P450s, for which the majority (63%) of changes are from active to inactive 
(Figure 3.5). 
 
In conclusion, the integration with unbound plasma concentrations does not affect activity calls 
equally in each of the target classes, with enzyme, unclassified protein, and electrochemical 
transporter datapoints being more frequently changed, whereas kinase datapoints more often stay 
the same. When datapoints are changed, these are most frequently in the direction from inactive 
to active, except for family A GPCRs, for which most of the adjustments result in a new inactive 
label. The next chapter will investigate the relevance of the novel activity calls for relationships to 
AEs, but if the activity calls using plasma concentrations are more accurate, as would be expected, 
these results suggest that using a constant bioactivity cut-off results in more false negative activity 
calls overall, except for family A GPCRs, for which it would result in more false positive calls. This 
suggests that consideration of unbound plasma concentrations may be able to reduce the rate of 
false negative activity calls based for most target classes and reduce the rate of false positive activity 
calls for GPCRs.  
3.3.4 Effect of minimum support (³5 actives) filter 
The final step in preparing the drug-target datasets for further analysis is filtering the data for a 
minimum of 5 actives per target in line with previous studies. However, it was observed that this 
final step affects the distribution of data across target classes, as shown in Figure 3.6. While the 
distribution is similar for the SIDER and FAERS datasets, the fraction of kinase datapoints drops 
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from ~22% in the constant cut-off dataset to less than 5% in the adjusted dataset. Previously, the 
subset of data with plasma concentrations was shown to only have slightly fewer kinase datapoints 
(Figure 3.3) than the complete dataset, thus this change is due to the filter for a minimum number 
of actives, not due to the use of plasma concentrations in general.  
 
To further investigate how the number of active compounds varies by target class, Figure 3.7 
inspects the number of active datapoints per unique target across target classes, showing that 
kinases have a low median number of actives per target, in other words, there are few different 
compounds available for the same kinase. Looking at the underlying datasets, this is related to the 
low number of kinases in the DrugMatrix dataset, from which a large part of the measured 
bioactivity data in this work originates, but which only includes 9 unique kinase targets. The 
originally downloaded bioactivity data for the drugs from the AE datasets - not restricted to those 
with plasma concentrations includes 341 unique kinases, but for only 22 out of those there are 5 
or more unique drugs measured against them. Contrast this with the Family A GPCRs, for which 
106 targets are included in the original bioactivity dataset but of which 59 have at least 5 measured 
drugs and 48 are included in DrugMatrix.  
 
Thus, the underrepresentation of kinases in DrugMatrix means that the rest of the measured kinase 
data is derived from scientific literature, which provides measurements for a large variety of distinct 
kinases (>300) but not sufficient data for different approved drugs measured against the same 
kinase (Figure 3.7). This shows the value of initiatives such as DrugMatrix which screen a full 
matrix consistently, compared to literature-derived data. The reason why kinases are most affected 
may be due to the fact that pXC50 datapoints were used for the analysis in this work, which are 
more rare in ChEMBL for kinases, since kinases are often screened on a large scale using a single 
concentration, yielding percentage inhibition datapoints instead, e.g. (180).  
 
Due to above reasons, the kinases are disproportionately affected by the minimum support filter 
of 5 datapoints per target when the available data is halved due to requiring plasma concentrations 
(Figure 3.7). It can be concluded that being restricted to a smaller dataset of drug-target datapoints 
with available plasma concentrations results in the underrepresentation of kinases, and therefore 
associations of AEs with kinases removed from the dataset will not be discoverable in the next 
stages. One possible way of remedying the loss of kinases would be to include percentage 




Figure 3.6 Distribution of drug-target datapoints for drugs in the AE datasets across target 
classes after applying a filter of minimum 5 actives per target on the constant cut-off dataset (left 
panel) and the dataset using the adjusted activity calls based on unbound plasma concentrations 
(right panel). The largest change is in the share of kinase datapoints, which is smaller in the latter 
case. 
 
Figure 3.7 Number of active calls per target where activity is defined by the ratio of the unbound 
plasma concentration and the in vitro pXC50. Kinases have a very low median number of actives 
per target, thus are affected by the minimum support filter of 5 actives per target, highlighted by 
the vertical line. The number of unique proteins in each target class is shown in parentheses. 
Boxplots show the median and 1.5 times the IQR.  
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3.3.5 Number of bioactivity datapoints for further analysis of FAERS and SIDER 
datasets 
For the final datasets that will be taken forward to the next chapter, Table 3.7 shows the number 
of datapoints in the baseline dataset and the adjusted dataset for FAERS and SIDER. In both 
cases, the adjusted dataset is around half the size or smaller than the baseline dataset. The number 
of bioactivity datapoints and unique drugs in the FAERS datasets is higher than that in the SIDER 
datasets, while the number of targets is the same (Table 3.7). The total number of unique drugs in 
the final datasets, now combining FAERS and SIDER, for the constant cut-off and adjusted cut-
off scenarios are reported in Table 3.8, showing that drugs are included based on the presence of 
numeric measurements and plasma concentrations, inactive ‘activity_comments’, or consistent 
negative predictions. In conclusion, the dataset using unbound plasma concentrations is around 
half the size of the constant cut-off dataset in terms of drug-target pairs and the number of drugs 
with bioactivity data is slightly higher for FAERS than SIDER.  
Table 3.7. Number of datapoints in the baseline bioactivity dataset compared to the adjusted 
dataset based on the integration of in vitro bioactivities and unbound plasma concentrations, both 
of which include predictions, split by the two AE datasets FAERS and SIDER. 
 
pChEMBL cut-off 
(pChEMBL value ³ 6) 
Unbound plasma concentrations 
 FAERS SIDER FAERS SIDER 
Drug-target pairs (n) 85,155 70,953 34,247 27,063 
Unique drugs (n) 1,173 1,001 1,019 873 
Unique targets 234 234 104 104 
Table 3.8 Number of unique drugs in the datasets, showing they are included based on numeric 
data, based on inactive ‘activity_comments’ in ChEMBL or based on inactive predictions 
 
pChEMBL cut-off (n drugs) 
Unbound plasma 
concentrations (n drugs) 
Numeric bioactivity 
measurement 
1044 Integrated with plasma 
concentration: 466 
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Included based on ‘inactive’ 
activity_comment only 
98 448 
Included based on consistent 
negative prediction at each 
PIDGINv3 threshold 
344 357 
Total unique drugs 1,486 1,271 
 
3.4  Discussion and conclusions 
The main contribution of this chapter is the assessment of the impact of integrating unbound drug 
plasma concentrations with bioactivities on resulting bioactivity calls, which has not previously 
been reported on a large scale. It was found that requiring unbound plasma concentrations to 
derive activity calls reduces the size of the drug-target dataset by about 50%.  Furthermore, most 
of the adjustments resulting from consideration of the plasma concentrations occur in the 
direction inactive to active, thus creating novel active labels, except for the family A GPCRs, for 
which most changes are from active to inactive. The comparison of active labels among the 
baseline and adjusted activity calls shows that around 20% of the active calls made using the 
constant cut-off are changed by consideration of the unbound plasma concentration, and 34% of 
active-labelled adjusted activity calls are unique to this scenario. At this stage, it can be concluded 
that the number of changes to active labels as a result of integrating unbound plasma 
concentrations is not negligible. The next more important question is to what extent this matters 
for selecting targets relevant to AEs, and this will be investigated in the next chapter. The 
distribution of datapoints across target classes provides a background against which to interpret 
these further results, such as the expected absence of AE associations with kinases due to a low 
number of datapoints, and the prominence of GPCRs, being the largest class of bioactivity 
datapoints.  
 
Based on the findings in this chapter, it can be concluded that target predictions make a large 
contribution to the overall bioactivity dataset, comprising around 85% of all datapoints and 
increasing the density of the drug-target matrix to over 26% instead of 5% with measured 
datapoints only. It is inevitable that there are more uncertainties in predicted than experimental 
datapoints, and some of the predictions may be incorrect. This was mitigated as much as possible 
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by choosing relatively high thresholds for the target prediction applicability domain and model 
performance in cross-validations. 
 
Limitations of the bioactivity data used include that it is sparse and incomplete (107), and lacks 
complete information on functional effects (19, 107), which therefore were not taken into account 
in the current work. Limitations of the drug plasma concentration data derived from literature 
include that they are a mixture of ‘normal’ therapeutic concentrations, some of which are actually 
minimal effective concentrations (176), and Cmax. Furthermore, the plasma concentrations are not 
patient-specific because plasma concentrations are not generally included on reports in FAERS. 
However, it is known that there is inter-individual variation in plasma concentrations (14, 36, 176), 
which may play a role in ADRs but could not be taken into account in this work. In addition, only 
one plasma concentration was used per drug, not distinguishing between different drug indications 
for the same drug that may require different doses. Moreover, the focus on therapeutic drug 
plasma levels excludes effects due to higher concentrations as a result of drug interactions or 
overdose. Overall, the aim of using plasma concentrations is to refine the activity calls based on a 
constant cut-off for in vitro potency, acknowledging above limitations of the pharmacokinetic data 




4 Identification of protein 




This chapter will build on the drug-AE datasets prepared in chapter 2 and the drug-target dataset 
prepared in chapter 3 to compute target-AE relationships, which is the ultimate aim of this work. 
The workflow from the previous chapters and how these feed into the current chapter is 
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Baseline activity calls using constant 
cut-off (1 µM) and adjusted activity 
calls using Cmax/XC50 ratio 
 
Constant cut-off: 1,486 drugs 
Adjusted cut-off: 1,271 drugs  
Constant cut-off: 1,486 unique drugs (1,173 for FAERS; 1,001 for SIDER) 
Adjusted (unbound) cut-off: 1,270 unique drugs (1,019 for FAERS; 869 for SIDER) 
 
Current chapter: Identify target-AE associations 
(Positive Predictive Value, Likelihood Ratio, Fisher’s exact test) 
 
2,764 drugs mapped 
to ChEMBL ID 
FAERS 
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Figure 4.1 Workflow summary. The work from the previous chapters now forms the basis of 
this chapter with the final aim of identifying target-AE associations. 
Deriving target-AE relationships may help to identify targets that are responsible for causing AEs 
and therefore guide the design of future safety pharmacology screens to anticipate AEs in drug 
discovery. There is a lack of publicly available systematic annotations of target-AE relationships, 
which will be addressed in this chapter by using the statistical metrics introduced in the 
Introduction to identify and quantify overrepresented target-AE combinations. Knowledge of 
quantified associations, such as predictive values, may be able to help the interpretation of secondary 
pharmacology screening results in terms of the likelihood of in vivo effects upon observing in vitro 
activities. 
 
While previous studies have considered drug plasma concentrations alongside secondary 
pharmacology results in case studies of a handful of target-AE combinations, no study to date has 
systematically compared the impact of using drug plasma concentrations on derived target-AE 
relationships, thus this chapter will begin by examining this. Next, the distribution of association 
metrics and predictive values across all target-AE relationships is presented, and explored across 
target classes and SOCs. This provides a large-scale overview of target-AE associations. 
 
Then, the strongest individual associations will be considered in the context of previous literature, 
before comparing the target-AE associations derived in this work to those specifically reported on 
published safety pharmacology panels. However, focusing on individual target-AE associations 
has the limitation of not considering cases in which an AE may be caused independently by 
multiple targets. Thus, this chapter will also explore the value of considering combinations of 
targets associated with the same AE.  
 
The final analyses in this chapter will assess the distribution of individual derived target-AE 
associations across SOCs in order to reveal which types of AEs may be predictable from secondary 
pharmacology screens, and which types of AEs are rarely related to in vitro bioactivities, 
highlighting potential areas with more apparent versus limited translation between in vitro and in 
vivo effects. Lastly, the target-AE associations based on SIDER and FAERS will be compared, 







4.2 Materials and methods 
4.2.1 Identification of significantly associated target-AE combinations 
Building on the datasets prepared in chapters 2 and 3, for each target, the drugs from the AE 
datasets with available measured or predicted bioactivity data were identified and counted in a 
contingency table as illustrated in Table 4.1. Association with the AE is based on the PRR for 
FAERS or the presence of the AE in SIDER, as described in chapter 2. Activity at the target is 
based on either the constant bioactivity cut-off (baseline activity calls) or the Cmax/XC50 ratio 
(adjusted activity calls), as described in chapter 3 (Table 4.1). Only measured and predicted 
bioactivity data is used, and inactivity at targets is explicitly not assumed, resulting in a different 
total number of drugs counted in the contingency table for each drug-target combination. 
Table 4.1 Contingency table for the association between measured and predicted bioactivities of 
drugs and their associations to AEs. Each cell contains the count of the number of drugs in that 
category. 
  Activity at target (Using Cmax/XC50 ratio or a constant cut-off 




Associated (PRR > 2 
and c2 > 4) 
True positives (TP) False negatives (FN) 
Not associated False positives (FP) True negatives (TN) 
 
 
The Scikit-learn version 0.21.3 confusion_matrix function (162, 181) was used to obtain the 
number of true negatives (TN), false positives (FP), false negatives (FN) and true positives (TP). 




The LR+ was calculated as LR=sensitivity/(1 – specificity) (141, 145). For all pairs with a LR > 1, 
indicating a positive association between the AE and activity at the target, the Fisher’s exact p-
values were corrected for multiple testing with the Benjamini-Hochberg method using the 
Statsmodels 0.9.0 multipletests function (182). Associations were considered statistically significant 
if they have a corrected p-value £ 0.05. 
 
The PPV was obtained by dividing the number of drugs that were active and associated with the 
AE by the total number of drugs active at the target (141, 143).  
 
The value-added PPV was calculated by subtracting the prevalence, i.e. the fraction of drugs 
measured at a given target that is also associated with a given AE, from the PPV (141). 
4.2.2 Compilation of previously reported safety targets and their associated adverse 
events 
The target-AE associations reported for three published secondary pharmacology panels (19, 20, 
62), which were presented in Table 1.4 in the Introduction, were compiled by manually extracting 
protein names and adverse effect descriptions. The protein names were manually mapped to 
Uniprot protein identifiers in ChEMBL based on name. Arrows and terms used in the original AE 
description, such as ‘enhances’, ‘induces’, ‘facilitates’, ‘exacerbates’ etc. were reformatted to 
‘increased’ and terms such as ‘inhibits’, ‘reduces’, ‘impairs’ etc. to ‘decreased’. The terms were then 
submitted to the National Center for Biomedical Ontology Bioportal, specifically the ‘Annotate’ 
functionality, for annotation with MedDRA terms (183). All results were manually inspected and 
selected. Additionally, mappings for terms that did not yield any results in this way were identified 
by manually querying the terms in the MedDRA web-based browser and selecting appropriate PTs 
or HLTs (25). The HLTs and SOCs from MedDRA versions 21.1 and 22.1 were obtained using 
the Hierarchy Analysis function in the MedDRA web-based browser (25). To calculate the recall, 
associations from FAERS and SIDER in the current study were considered previously reported if 
the HLT matched the HLT of a previously reported association for the same target, considering 
the “Primary SOC” obtained from the MedDRA web-based browser (25). 
4.2.3 Assessing combinations of targets 
To assess combinations of targets in cases where multiple targets were each individually associated 
with a given AE, all possible sets of the associated targets were listed. Next, drugs that were 
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measured at all these targets were identified, if any. Using this set of drugs and the logical ‘or’ to 
consider bioactivity at any of the constituent targets, the PPV and fraction of AE-associated drugs 
identified was calculated for the combination overall. 
4.3 Results and discussion 
4.3.1 Impact of using plasma concentrations on target-AE associations 
To assess the impact of using plasma concentrations compared to using a constant bioactivity cut-
off on target-AE associations, the number of target-AE pairs that could be studied in either case 
is first compared. After overlapping the bioactivity data prepared in chapter 3 with the AE data 
from chapter 2, the number of target-AE pairs that could be considered is shown in Table 4.2. 
The FAERS dataset contains about four times as many target-AE pairs as the SIDER dataset, both 
when using a constant bioactivity cut-off and when using the adjusted activity calls. This is 
consistent with the higher number of unique PTs present in the drug-AE dataset based on FAERS, 
which was observed in chapter 2. Since there are more unique PTs, this results in a greater number 
of target-AE combinations, given that the number of targets in the bioactivity datasets was the 
same for FAERS and SIDER (chapter 3). 
 
Similar to the reductions in available bioactivity data for analysis when using unbound plasma 
concentrations described in chapter 3, the dataset using the adjusted activity calls also contains 
around 40-50% fewer target-AE pairs compared to using the baseline activity calls (Table 4.2). 
Thus, using unbound plasma concentrations limits the number of target-AE combinations that 
can be evaluated in the study. 
Table 4.2. The number of target-AE pairs that were considered in the study 
 pChEMBL cut-off (baseline 
activity calls) 
Unbound plasma concentrations 
(adjusted activity calls) 




313,661 89,105 197,236 42,652 
Unique targets (n) 182 167 100 79 
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Unique adverse events 
(n MedDRA PTs) 
3340 1119 3278 982 
 
Of the numbers in Table 4.2, a total of 1,092 (FAERS) and 2,155 (SIDER) target-AE associations 
were statistically significant based on the constant cut-off and 224 (FAERS) and 315 (SIDER) in 
the case of the unbound plasma concentrations. Thus, even though more combinations were 
considered in the FAERS dataset, SIDER yields more significant target-AE combinations, which 
may be related to the noisier nature of FAERS, as well as to the high number of distinct AEs in 
FAERS, for which there may not be sufficient reports to result in statistical significance.  
 
Comparing the significant target-AE associations shows that 21% (SIDER) and 66% (FAERS) of 
target-AE associations found when using unbound concentrations are not significant when using 
the constant cut-off. Thus, the significant target-AE associations found when using plasma 
concentrations are not a direct subset of the dataset using a constant cut-off, showing that using 
plasma concentrations results in a different set of significant target-AE associations. 
 
With regards to the accuracy of the associations, the lack of a gold standard for target-AE 
associations makes it difficult to evaluate both outcomes (70). Therefore the target-AE associations 
from the two datasets were evaluated by comparing them to previously reported associations from 
three reported safety target panels (19, 20, 62). The overall retrieval of these previously reported 
associations as statistically significant in this study, at the level of HLTs, is 6% using the unbound 
concentrations and 12% when using the constant cut-off. Thus, using the unbound concentrations 
results in a lower recall of previously reported associations. This could be related to the fact that 
plasma concentrations were only available for a subset of the data, resulting in fewer datapoints 
for analysis (Table 4.2), since this likely reduced the power of this study.  
 
The low recall generally, being only 12% when using the constant cut-off, could be related to 
differences in the way AEs are recorded, for example, the review by Bowes et al. focuses on 
biological effects such as “increase in blood pressure” (19). In patients, such effects may not be 
immediately noticed but could ultimately result in a stroke, which could end up being the reported 
AE in pharmacovigilance activities. As a result, the exact AE terms, even at the HLT, would not 
match despite the effects being biologically related. This would result in lack of recall. Similarly, 
the effects described in Lynch et al. (62) focus on pathological effects from animal studies, of 
which some, such as organ histopathology, are unlikely to be observed in humans. Alternatively, 
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effects may only be observed at high doses that may be used in animal studies but are not used 
clinically, further contributing to low recall of previously reported effects in this work. 
 
However, inspecting the distribution of the measures of association for those target-AE pairs that 
are retrieved shows that those from the dataset based on unbound plasma concentrations have 
larger LRs, indicating that adjusted in vitro target activities are more useful for identifying AEs than 
bioactivities based on the constant cut-off (Figure 4.2). Similarly, the PPVs and value-added PPVs 
of the associations that are retrieved are higher when using unbound plasma concentrations 
(Figure 4.2). This indicates that using plasma concentration results in fewer false positive signals 
compared to using the constant cut-off, and is overall more precise. However, the fraction of drugs 
associated with the AE per target, which would be the ‘detection’ rate of AE-associated drugs if 
the target is used as a predictor of AEs, is lower for the target-AE associations based on the 
adjusted activity calls (Figure 4.2). This indicates that the higher LRs and greater precision when 
using plasma concentrations comes at the cost of lower recall.  
One interpretation of these results is that using plasma concentrations retrieves known signals 
more strongly and precisely, but that recall could be limited by the amount of data available. 
Despite the lower overall recall, some familiar associations, such as hERG-torsade de pointes and 
5-HT2B-cardiotoxicity in the FAERS dataset, as well as dopamine D2-galactorrhoea in both the 
FAERS and SIDER datasets, were only significant when using plasma concentrations and not 
when using the constant cut-off. Since the plasma concentrations are a novel aspect of the current 
study and the results show that they retrieve known signals with greater LRs and PPVs, the 




Figure 4.2 Quantification of target-AE associations reported in previous studies that were retrieved 
as significant in the current work when using a constant bioactivity threshold (pChEMBL ³ 6) to 
define active drug-target pairs, versus using the ratio of the unbound plasma concentrations over 
the in vitro bioactivity to do so. Using the unbound plasma concentrations retrieves known 
associations with greater strength of association (median LR) and the associations are more precise 
(median PPV). However, this comes at the cost of a lower recall, as only 33 versus 80 previously 
reported target-AE associations are retrieved, and a lower detection rate of AE-associated drugs 
(fraction of AE-associated drugs that are active). Boxplots show the IQR including the median 
and whiskers extend to 1.5 times the IQR. 
4.3.2 Quantification of associations between the activity of drugs on proteins and 
AE reporting 
Activity calls adjusted using the unbound plasma concentrations were evaluated as predictors of 
AEs by analysing to what extent statistically significant target-AE associations provide information 
about the AE. The median LR for target-AE associations from FAERs is 11.8 and for those from 
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SIDER the median LR is 16.4 (Figure 4.3). LRs higher than 1 indicate that in vitro activities at the 
target are observed more frequently among AE-associated drugs than other drugs, thus the median 
LRs being above 10 indicate that being active at these increases the probability of the in vivo AE 
(Figure 4.3) (147). Next, the results focus on the PPV, the fraction of active drugs that are 
associated with the AE, because this relates the presence of bioactivity to the presence AEs. The 
median PPV for significant target-AE associations from SIDER is 0.38 with a standard deviation 
of 0.2, while FAERS associations have a median PPV of 0.23 (standard deviation=0.1), meaning 
that across significant target-AE associations ~23-38% of drugs active at the target are associated 
with an in vivo AE (Figure 4.3). The observation that PPVs are lower for FAERS compared to 
SIDER means that bioactivities have higher false positive rates for AEs in FAERS. Thus, although 
the fraction of drug associated with the AE, i.e. the detection rate of AE-associated drugs, or 
sensitivity, is higher for FAERS, this is at the cost of lower precision (PPVs). The lower LRs and 
PPVs for FAERS compared to SIDER could be due to FAERS being noisier as a result of the 
way the way AEs are reported, making it more difficult to identify target-AE associations in the 
dataset.  
 
The value-added PPV indicates the additional information provided by the protein target activity 
over the prevalence to predict AEs. This is because higher PPVs are generally seen with higher 
prevalence, referring in this study to the fraction of drugs with bioactivity data that are associated 
with a certain AE (184). The value-added PPVs follow a similar distribution to the PPVs, except 
for associations with high PPVs, such as 1.0, which are reduced. (Figure 4.3). This shows that the 
bioactivities provide additional information and that the PPVs are not primarily driven by the 
prevalence itself. The prevalence (fraction of drugs associated with AE) is plotted for reference, 





Figure 4.3 Quantification of statistically significant target-AE associations using the LR, PPV and 
value-added PPV. Associations in SIDER have higher LRs, with a median of 16.4 compared to 
11.8 for FAERS. Similarly, the PPVs are higher in SIDER, with a median of 0.38 compared to 
0.23 for FAERS. Boxplots show the IQR including the median and whiskers extend to 1.5 times 
the IQR. 
4.3.2.1 Positive Predictive Values by target class 
To investigate how PPVs differ by target class, Figure 4.4 shows the distribution of PPVs of 
significant target-AE associations by target class, now combining the FAERS and SIDER data. 
The highest PPVs (up to 1.0) are observed in the lyase and family A GPCRs, which are the target 
classes containing the highest number of associations. Oxidoreductases and electrochemical 
transporters generally have lower PPVs (up to ~0.6-0.8), and there are also fewer target-AEs 
associations in these classes (Figure 4.4). In addition, a small number of membrane receptors – 
those not further classified in the ChEMBL hierarchy – also have lower PPVs (up to 0.38) (Figure 
4.4). The target-AE pairs that were reported on published safety target panels (19, 20, 62) and 
retrieved in the current study are also shown in Figure 4.4, showing that some previously reported 
associations have low PPVs, such as the relationship between the muscarinic M3 receptor (a family 
A GPCR) and miosis, which has a PPV of 0.25 (Figure 4.4). This shows that some target-AE 
associations that have been previously reported were retrieved as significant in this study but have 
low PPVs, possibly due to AEs being known but not often reported. In other cases, the mapping 
categories used for annotating associations as previously reported, i.e. the MedDRA HLTs, are 
very broad such as ‘neurological signs and symptoms’ which results in precision being lost. At the 
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same time, the results show that the current study identifies many novel target-AE associations 




Figure 4.4 PPVs of significant target-AE associations by protein class of the target, for classes with 
more than 4 target-AE associations. Classes correspond to the second level of the ChEMBL target 
hierarchy except ‘membrane receptors’, which is the highest level since those targets are not further 
classified. The highest PPVs occur in the lyase and family A GPCR classes, which also contain the 
highest number of target-AE associations. Boxplots show the IQR including the median and 
whiskers extend to 1.5 times the IQR. 
 
4.3.2.2 Positive Predictive Values by System Organ Class (SOC) 
The distribution of PPVs for target-AE associations across MedDRA SOCs of the AE is examined 
in Figure 4.5. The range of PPVs within most SOCs is wide, with the highest median PPV of 0.56 
occurring for ‘blood and lymphatic system disorders’, and the lowest median PPV of 0.21 for 
‘musculoskeletal and connective tissue disorders’ (Figure 4.5). PPVs above 0.8 only occur in the 
large SOCs such as ‘nervous system disorders’ and ‘gastrointestinal disorders’, which are also the 
SOCs with the highest number of AEs in the underlying datasets (Figure 4.5). Otherwise, the PPV 






Figure 4.5 PPVs of target-AE associations across MedDRA SOC of the AE. The highest median 
PPV of 0.56 occurs in ‘blood and lymphatic system disorders’. PPVs above 0.8 only occur in the 
SOCs with the most target-AE associations, such as nervous system and gastrointestinal disorders. 
Boxplots show the IQR including the median and whiskers extend to 1.5 times the IQR. 
4.3.3 Trade-off between Positive Predictive Values and detection of AE-associated 
drugs 
The relationship between the PPV and the fraction of AE-associated drugs that are active at the 
target, which is the sensitivity or the fraction of AE-associated drugs that would be detected by 
bioactivity at the target if used a single predictor of the AE, is analysed in Figure 4.6, showing a 
clear inverse relationship between the two variables. For example, the PPV of the muscarinic M2 
receptor activity for tremor is 0.86, but the fraction of AE-associated drugs of around 0.05 
indicates that only 5% of drugs associated with this AE in the dataset are active at the receptor 
(Figure 4.6). Conversely, activity at dopamine D2 receptor would detect 57% of drugs associated 
with hyperprolactinaemia, but has a false positive rate of 86% (PPV=0.14) (Figure 4.6). 
Specifically, there are few target-AE associations with a fraction of AE-associated drugs that are 
active above 0.5, and at the same time high PPVs (Figure 4.6), which would correspond to a 
simultaneous high sensitivity and a low false positive rate, and be most useful in practice. Thus, 
no single bioactivity serves as a strong indicator of clinical and post-marketing AEs in the dataset 
studied. There are many possible reasons for this – e.g. a low fraction of AE-associated drugs 
would be detected per target if multiple mechanisms involving different targets lead to the same 
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AE, which will be explored further in section 4.3.7 below. On the other hand, low PPVs can result 
from pharmacokinetic behaviour of drugs such as lack of blood-brain barrier crossing, leading to 
certain AEs not being observed in practice.  
 
 
Figure 4.6 Trade-off between the PPV of significant target-AE associations and the fraction of 
AE-associated drugs that are active at the target and would therefore be ‘detected’ by the target 
bioactivity. Activity here is based on the integration of the unbound plasma concentration with 
measured and predicted in vitro bioactivities. Target-AE pairs with high PPVs tend to have low 
fractions of AE-associated drugs that are active, meaning only a small share of all drugs 
associated with the AE would be detected by bioactivity at the target. Alternatively, associations 
with high fractions of AE-associated drugs that are active tend to have low PPVs, indicating a 
high false positive rate for that target-AE pair. CHRM2: Muscarinic acetylcholine receptor M2, 
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PTGS1: Cyclooxygenase-1, CHRM3: Muscarinic acetylcholine receptor M3, ACE: Angiotensin-
converting enzyme, KCNH2: hERG, ADRA1B: a-1b adrenergic receptor, CHRM1: Muscarinic 
acetylcholine receptor M1, DRD2: Dopamine D2 receptor, HTR2A: Serotonin 2a (5-HT2a) 
receptor, HTR2C: Serotonin 2c (5-HT2c) receptor. 
One of the limitations of this analysis that may have resulted in the low PPVs, low fractions of 
AE-associated drugs detected and low recall of previously reported associations is that the analysis 
is primarily based on marketed drugs. These drugs have already undergone safety screening, so the 
termination of problematic candidates early on has biased the data available in such a way that 
strong associations with safety targets, e.g. adverse effects observed in animal studies, may not be 
apparent when studying patient data. Another potential reason for missing previously reported 
effects is the incomplete consideration of dose in the current work due to consideration of the 
therapeutic plasma concentrations only. Effects previously reported in e.g. Bowes et al. (19) 
generally do not list the dose at which effects are expected. This may explain some of the 
discrepancies between the results presented here and previous studies. Another limitation resulting 
from the work being based on data from marketed small molecules for a wide range of indications, 
is that the PPVs do not necessarily apply to other types of drugs such as antibodies or drugs in a 
specific therapeutic class, because the prevalence of AEs may be different. 
 
Few studies have directly reported PPVs of secondary pharmacology targets to compare these 
results to. A previous study by Pollard et al., studying marketed drugs, found a PPV of 1.0 for the 
relationship between hERG and QT interval prolongation when the margin between the in vitro 
hERG IC50 and Cmax was less than 10-fold, which is similar to the threshold in the current work 
(71). The difference between this PPV and the one in the current study (PPV=0.47 for TdP) is 
explained by QT interval prolongation being a risk factor for TdP but TdP being the ultimate 
ventricular arrhythmia (19, 59, 71), since a considerable number of drugs cause QT interval 
prolongation but are not torsadogenic (152). The relationship between hERG and QT 
prolongation is not statistically significant in this work, which is potentially related to QT 
prolongation not being routinely measured in patients, at least for FAERS, whereas the results by 
Pollard et al. are derived from regulatory Thorough QT/QTc Studies which are designed to detect 
this effect (71). 
 
More broadly, the lack of one-to-one translation between in vitro and in vivo effects in this study 
corroborates previous findings, for example those that observed a lack of correlations between 
large-scale in vitro bioactivities and toxicity observed in animal studies (185, 186), and those 
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reporting high false positive rates associated with early screening for targets such as hERG and 
BSEP (52, 71, 152). The reasons behind the challenge to translate in vitro to in vivo effects include 
differences between plasma and tissue concentrations (22, 31, 33), varying protein expression 
across tissues and disease states (22), and interactions between targets and pathways, such as 
transporter and ion channels off-setting each other’s effects (52, 152). Low PPVs and sensitivities 
observed here and a low recall or previously reported associations may be related to these factors 
not being taken into account. After taking into account unbound plasma concentrations in this 
study, the PPVs and LRs for previously reported associations increased (Figure 4.2), thus it is 
similarly possible that as more of the above-mentioned limitations are addressed, the concordance 
between in vitro and in vivo activities would improve, which would become more clear when more 
data becomes available and additional factors are taken into account.  
4.3.4 Presence of established and novel safety targets in current analysis 
Next, the significant targets in the current study were compared with those previously reported. 
In total, this study considered 104 targets out of which 45 were found to have at least one 
statistically significant association to an AE (Figure 4.7 and Table 4.3). 30 out of these 45 targets 
are already included on secondary pharmacology panels that were compiled from previous 
literature (19, 20, 62), so the majority of significant targets in the current study are established 
safety targets (Figure 4.7). At the same time, out of the 91 safety targets from literature, data was 
available for only 40 in the current study, highlighting the lack of publicly available experimental 
data for previously reported safety targets (Figure 4.7). The remaining 15 targets with significant 
associations in the current study, among which nine are members of the carbonic anhydrase (CA) 
family, are not included on published panels (19, 20, 62) (Table 4.3). Most of the significant 
associations with CAs identified in this work originate from the SIDER dataset but CA2 and CA4 
appear in both datasets (Table 4.3). Apart from the CAs and one other novel target, namely 
microtubule-associated protein t, all of the other six novel targets are additional family members 
of proteins already included on current panels such as serotonin, dopamine, and adrenergic 
receptors, e.g. dopamine D3 receptor is not currently included on panels but dopamine D1 is. It 
can be concluded that the current analysis was not able to consider around half of previously 
reported safety targets due to lack of data, and the novel targets in this work include targets 




Figure 4.7 Overview of targets in the study, showing the number of targets considered, those 
that are significantly associated with AEs, and those previously reported on safety target panels. 
For 51 out of 91 safety targets from literature, no data was available. Of the 45 targets with 
significant associations to AEs, 30 are listed on current safety target panels whereas 15 are not 
and thus are potentially novel. CA5B=carbonic anhydrase 5B, DRD2=dopamine D2 receptor, 
DRD3=dopamine D3 receptor. 
With respect to the aim of identifying target-AE associations, the current study is similar to the 
recent study by Ietswaart et al. (159) although their study used a different dataset and methods. 
None of the 15 potentially novel targets from the current work is among the significant results by 
Ietswaart et al. (159), but 15 of the human targets previously reported in published panels were 
retrieved in both the current work and the analysis by Ietswaart et al. (159). In addition, 32 out of 
37 human targets with significant associations to AEs in the study by Ietswaart et al. are present 
on current panels (19, 20, 62). Hence, the results by Ietswaart et al. (159) contain a higher fraction 
of previously reported targets and also identified a different set of potentially novel targets. One 
potential reason for these differences is that the data used by Ietswaart et al. (159) is based on 
screening data by Eurofins, which may focus on safety targets more than the ChEMBL data 
underlying the current study does, and may have already excluded redundancy in terms of multiple 
target family members. In conclusion, the overall set of targets with significant relationships in this 
work differs from a recent study with similar aims but different methods and underlying data. The 
next section will consider the specific AEs from this work in more detail. 
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Table 4.3 All targets in the study that have at least one statistically associated AE. The target class 
is the second level of the ChEMBL target hierarchy if available, otherwise the first level. 
Target Target Class Dataset 
Previously 
reported 
(19, 20, 62) 
Dopamine D5 receptor 
Family A G protein-coupled 
receptor FAERS No 
Dopamine D4 receptor 
Family A G protein-coupled 
receptor FAERS No 
Microtubule-associated protein t Unclassified protein FAERS No 
Dopamine D3 receptor 
Family A G protein-coupled 
receptor Both No 
a-1d adrenergic receptor 
Family A G protein-coupled 
receptor Both No 
Carbonic anhydrase 2 Lyase Both No 
Carbonic anhydrase 4 Lyase Both No 
Serotonin 6 (5-HT6) receptor 
Family A G protein-coupled 
receptor SIDER No 
Carbonic anhydrase 14 Lyase SIDER No 
Carbonic anhydrase 9 Lyase SIDER No 
Carbonic anhydrase 5B Lyase SIDER No 
Carbonic anhydrase 1 Lyase SIDER No 
Carbonic anhydrase 12 Lyase SIDER No 
Carbonic anhydrase 9 Lyase SIDER No 
Carbonic anhydrase 5A Lyase SIDER No 
a-1a adrenergic receptor 
Family A G protein-coupled 
receptor FAERS Yes  
µ opioid receptor 
Family A G protein-coupled 
receptor FAERS Yes 
a -1b adrenergic receptor 
Family A G protein-coupled 
receptor FAERS Yes 
Cyclooxygenase-2 Oxidoreductase FAERS Yes 
Cyclooxygenase-1 Oxidoreductase FAERS Yes 
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Angiotensin-converting enzyme Protease FAERS Yes 
Serotonin transporter Electrochemical transporter Both Yes 
Serotonin 2a (5-HT2a) receptor 
Family A G protein-coupled 
receptor Both Yes 
Serotonin 2b (5-HT2b) receptor 
Family A G protein-coupled 
receptor Both Yes 
Histamine H1 receptor 
Family A G protein-coupled 
receptor Both Yes 
a -2c adrenergic receptor 
Family A G protein-coupled 
receptor Both Yes 
Serotonin 2c (5-HT2c) receptor 
Family A G protein-coupled 
receptor Both Yes 
k opioid receptor 
Family A G protein-coupled 
receptor Both Yes 
d opioid receptor 
Family A G protein-coupled 
receptor Both Yes 
a-2b adrenergic receptor 
Family A G protein-coupled 
receptor Both Yes 
Dopamine D2 receptor 
Family A G protein-coupled 
receptor Both Yes 
Serotonin 7 (5-HT7) receptor 
Family A G protein-coupled 
receptor Both Yes 
hERG Voltage-gated ion channel Both Yes 
Dopamine transporter Electrochemical transporter SIDER Yes 
Norepinephrine transporter Electrochemical transporter SIDER Yes 
Muscarinic acetylcholine receptor 
M1 
Family A G protein-coupled 
receptor SIDER Yes 
Dopamine D1 receptor 
Family A G protein-coupled 
receptor SIDER Yes 
Muscarinic acetylcholine receptor 
M4 
Family A G protein-coupled 
receptor SIDER Yes 
Muscarinic acetylcholine receptor 
M3 
Family A G protein-coupled 
receptor SIDER Yes 
 137 
Muscarinic acetylcholine receptor 
M2 
Family A G protein-coupled 
receptor SIDER Yes 
Type-1 angiotensin II receptor 
Family A G protein-coupled 
receptor SIDER Yes 
a-2a adrenergic receptor 
Family A G protein-coupled 
receptor SIDER Yes 
b-1 adrenergic receptor 
Family A G protein-coupled 
receptor SIDER Yes 
Muscarinic acetylcholine receptor 
M5 
Family A G protein-coupled 
receptor SIDER Yes 
s opioid receptor Membrane receptor SIDER Yes 
4.3.5 Target-AE associations with the highest value-added Positive Predictive 
Values 
To examine the individual target-AE associations with the highest PPVs, Table 4.4 shows the 
significant associations with the highest value-added PPVs in SIDER and FAERS. The table 
focuses on events within the SOCs of ‘nervous system disorders’, ‘vascular disorders’, ‘cardiac 
disorders’, and ‘respiratory, thoracic and mediastinal disorders’, because their link to the function 
of vital organs makes these a high priority in drug safety (19, 64), and ‘hepatobiliary disorders’, 
which is a leading cause of clinical attrition (187). The most highly ranked associations in these 
categories will be discussed in more detail. Full details of the most highly ranked associations in 
any organ system are presented in Appendix 1 for FAERS and Appendix 2 for SIDER. 
 
Based on SIDER, the most predictive target-AE association is between CA5B and cholestatic 
jaundice, a liver disorder, with a value-added PPV of 0.73 (Table 4.4). The CA family of enzymes 
are involved in acid-base balance and CA inhibitors are used clinically in a range of conditions 
including ocular disorders, oedema, and seizures, and they are often not entirely selective across 
CAs (28, 188–190). The association between CA5B and cholestatic jaundice is plausible due to its 
high tissue expression in the mitochondria (191), which is relevant to liver toxicity (192). While no 
previous reports of a direct link between CAs and cholestatic jaundice were found in the literature, 
CA4 and CA12 were identified as protein interactors of targets associated with cholestatic jaundice 
in the study by Duran-Frigola and Aloy, suggesting the existence of additional indirect links via 
the protein-protein interaction network (151).   
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The next most predictive associations concern various muscarinic acetylcholine receptors. In this 
study, the muscarinic receptor M2 is associated with somnolence (value-added PPV=0.68, Table 
4.4), which is in line with acetylcholine being important for wakefulness and the expected effects 
of M2 antagonism (193). In practice, somnolence is a common side effect of muscarinic 
acetylcholine M2 and M3 receptor antagonists such as oxybutynin and tolterodine (194–196). 
Next, the muscarinic acetylcholine receptors M3, M5, M1 and M2 are each associated with tremor 
with similar value-added PPVs around 0.67 (Table 4.4). The link between the muscarinic 
acetylcholine receptor M2 and tremor has been previously reported (19), and the links of multiple 
muscarinic receptors in the current study could either be due to multiple targets being biologically 
related to the effect, or compound promiscuity. To visualise underlying promiscuity in more detail, 
Figure 4.8 shows the extent of overlap in active drugs between targets, showing that muscarinic 
receptors have a high level of overlap in active ligands between each family member, i.e. between 
half and all active ligands are shared. Thus, it is possible that multiple associations of tremor with 
muscarinic receptors is due to this promiscuity. In contrast to the CAs, the muscarinic M1 and M2 
receptors are included on all published safety panels considered, whilst the muscarinic M5 is 
included on the Lynch panel (19, 20, 62). In conclusion, the most predictive target-AE associations 
based on SIDER include a novel link for CA5B, while other associations are previously reported 
and in line with current mechanistic knowledge and previous literature. However, several links may 
be driven by compound promiscuity, which cannot be distinguished from independent biological 
mechanisms based on the current statistical analysis. 
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Table 4.4. Most highly ranked associations between activity at a protein and reported AEs in the SIDER and FAERS datasets, sorted by their value-
added PPVs, and restricted to 'nervous system disorders', 'hepatobiliary disorders', 'cardiac disorders', ‘vascular disorders’, and 'respiratory, thoracic and 
mediastinal disorders'. 
Target Adverse event (AE) 
(MedDRA PT) 
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Figure 4.8 Fraction of active drugs, defined by the ratio of the unbound drug plasma 
concentration over the in vitro bioactivity, shared between targets in the SIDER dataset. The 
fraction corresponds to the target on the y-axis. The number of active compounds at each 
protein is shown in parentheses. Targets often share active ligands, especially within target 
families, but also across families. In contrast, the CAs share ligands within the family but hardly 
so with other targets from other families. 
For the analysis of the FAERS database, the association with the highest value-added PPV is 
between the angiotensin-converting enzyme (ACE), a target only included on the Lynch panel 
(62), and hypovolemic shock, which is circulatory failure due to fluid loss (197) (value-added 
PPV=0.57, Table 4.4). This is consistent with the fact that ACE inhibitors interfere with the renin-
angiotensin system that normally protects against hypovolemia (198). There are case reports in 
literature that have attributed hypovolemic shock to ACE inhibitors (199).  
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The known associations between the d opioid receptor and respiratory depression (62) and 
between the a-1b adrenergic receptor and orthostatic hypotension (62) were successfully retrieved 
in the current analysis with value-added PPVs of 0.42 and 0.40 respectively (Table 4.4). The d 
opioid receptor is included on all considered safety panels and the a-1b adrenergic receptor on 
the Whitebread and Lynch panels (20, 62). Similarly, the association between hERG, one of most 
studied and screened safety targets (19, 71, 152), and torsade de pointes (TdP) is retrieved with a 
value-added PPV of 0.38 (Table 4.4). Only QT prolongation is listed among the compiled 
previously reported associations (19, 20, 62) and it has a different MedDRA HLT (investigations) 
as TdP (ventricular arrhythmias and cardiac arrest), resulting in the association between hERG-
TdP in the current work not being annotated as previously reported (Table 4.4). This highlights 
the challenges in using medical terminologies on a large scale, since descriptions of biological 
effects may not directly match all related AE terms (47).  
 
The next association in the results is between respiratory depression and the k opioid receptor 
(value-added PPV=0.38), a target included on the Bowes and Lynch panels (19, 62). While 
activation of µ opioid and d opioid receptors causes respiratory depression (62, 200), the k opioid 
receptor is believed to lack this effect (200). However, the presence of this association can also be 
explained by compound promiscuity, given the high overlap of shared ligands between the opioid 
receptors in the current study (Figure 4.9). This common profile of active ligands shared between 
the k opioid and d opioid receptors was also identified in the study of secondary pharmacology 
panels by Bendels et al. (65), which suggested deselection of the d opioid in an optimised screening 
panel based on the higher hit rate at the k opioid receptor. In conclusion, the most predictive 






Figure 4.9 Fraction of active drugs, defined by the ratio of the unbound drug plasma 
concentration over the in vitro bioactivity, shared between targets in the FAERS dataset. The 
fraction corresponds to the target on the y-axis. The number of active compounds at each 
protein is shown in parentheses. Targets often share active ligands, both within families, e.g. 
serotonin receptors, and across families, e.g. between serotonin and adrenergic receptors. 
4.3.6 Adverse events associated with novel targets and potential value of these 
associations 
To analyse the potential of novel associations from the current study to provide additional 
information to predict AEs, the novel targets without family members on currently screened 
secondary pharmacology panels are considered first; these include nine carbonic anhydrases and 
microtubule-associated protein t. Table 4.5 lists those targets with significant associations to AEs 
within the high-priority SOCs mentioned earlier. The most prominent are the CAs which are 
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associated to a range of AEs in addition to the link between CA5B-cholestatic jaundice, which 
already appeared in the most highly ranked associations discussed earlier. All the effects associated 
with CAs are unique to this target family, meaning no other targets are associated to the same 
effects in the current study. Based on SIDER, CA5A (PPV=0.56), CA12 (PPV=0.45) and CA9 
(PPV=0.26) are also associated to cholestatic jaundice (Table 4.5), of which CA5A is most 
plausible because of its high liver expression (201). Furthermore, CA9 (PPV=0.31) and CA12 
(PPV=0.24) are associated with hepatic necrosis (Table 4.5), adding further evidence to the link 
between CAs and liver effects. CA5A and CA5B are both associated with paraesthesia (PPV=1.0, 
Table 4.5), which is listed as a side effect of CA inhibitors and has been suggested to be caused by 
CA activity (28, 202). Based on the FAERS analysis, CA4 is associated with hyperammonaemic 
encephalopathy (PPV=0.38, Table 4.5), which is consistent with mechanistic knowledge of CA 
inhibitors on ammonia balance (28). Lastly, CA2 is associated with simple partial seizures, and 
CA5B with pulmonary oedema (Table 4.5), but both are most likely examples of indication bias in 
FAERS because these are indications for CA inhibitors (28, 190). This reflects the observation 
made in chapter 2 that while biases may be reduced by methods such as PSM, they are not fully 
removed and this is useful to consider when interpreting results such as these. Overall, since none 
of the existing panels include any members of the CA family and all the associated AEs are unique 
to this family, the results from this study suggest that CAs might be able to extend the coverage 
of future safety target panels. 
 
The other target without family members on existing panels is microtubule-associated protein t, 
which is associated to liver injury with a PPV=0.28 based on FAERS (Table 4.5). This protein is 
associated with neurotoxicity and is currently not the therapeutic target of any approved drug. 
Normal phosphorylation of microtubule-associated protein t is disturbed by the microcystin group 
of bacterial toxins, which are also associated with hepatotoxicity (203), potentially providing some 
support for the observation from this work. Thus, this link could also be a novel association of 
interest for safety screening. 
 
Next, novel targets that are family members of established safety targets are considered, which 
include the dopamine D3 receptor, dopamine D4 receptor, a-1d adrenergic receptor, and 5-HT6  
receptor. To examine whether these could provide information beyond currently screened targets, 
the strength of association to AEs was compared with that of the currently screened target and 
the same AE. For example, the 5-HT6 receptor, not currently included on any of the considered 
panels, is associated with tremor (PPV= 0.71), but as discussed in the previous section, the 
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muscarinic M3, M5 and M1 receptors are associated with the same effect with  higher PPVs of 
0.88 (Table 4.4). Thus, it is possible that these novel associations, such as 5-HT6-tremor, do not 
provide additional information beyond currently screened targets. The only exception to this 
pattern is the a-1d adrenergic receptor’s association to loss of consciousness with a PPV of 0.54 
based on SIDER, an AE to which no other target is associated in the study. In all other cases, 
novel targets had lower or comparable PPVs to a currently screened target. This shows that 
different targets can provide similar levels of information about the same AE and might be 
redundant in the context of safety target screening if there is a large overlap in active drugs across 
targets. However, the extent of promiscuity will determine whether novel targets can provide 
additional information to improve the detection of AE-associated drugs, which is explored next. 
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Table 4.5 Significant associations of novel targets without family members on current panels with AEs in the SOCs 'nervous system disorders', 
'hepatobiliary disorders', 'cardiac disorders', and 'respiratory, thoracic and mediastinal disorders’. 
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4.3.7 Considering activity against multiple protein targets for the same AE 
improves the detection of AE-associated drugs 
To find targets that provide non-redundant information, the detection of AE-associated drugs 
when using single targets versus using combinations was compared. Where multiple targets are 
associated to the same event, in 38% (FAERS) and 45% (SIDER) of AEs, considering activity at 
either one of multiple targets improves the detection of AE-associated drugs. Generally, 
considering two or three targets associated with the AE leads to a median improvement of 20% 
(FAERS) and 33% (SIDER) in the detection of AE-associated drugs (Figure 4.10). This comes at 
the cost of worsening PPVs by a median 16% (FAERS) and 21% (SIDER) (Figure 4.10). Thus, 
the improvement is greater than the reduction in PPVs. The improvements are due to each of the 
targets identifying different AE-associated drugs. 
 
 
Figure 4.10 Changes in the fraction of AE-associated drugs active at the target (‘detected’) and 
PPV when comparing combinations of targets – i.e. activity at either target – for a given AE to 
the individual targets. Considering activity at multiple targets improves the detection of AE-
associated drugs considerably, at a cost of decreasing PPV. Thus, considering activity against 
multiple targets can help anticipate AEs. 
The combination with the greatest improvement in the detection rate compared to the single target 
is the combination of the b-1 adrenergic receptor and CA5B in relation to orthostatic hypotension 
in case of the SIDER dataset (Figure 4.11A). Both targets individually detect 12% of AE-associated 
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drugs, but this is increased to 25% when considering activity at either one of the targets (Figure 
4.11A). It is not surprising that a CA is involved in the best performing target set, since active 
drugs at the CAs generally overlap little with those against other targets in the study, as shown in 
the promiscuity analysis earlier (Figure 4.8). 
 
 
Figure 4.11 ) PPV and fraction of drugs associated with orthostatic hypotension that are active at 
the b-1 adrenergic receptor (ADRB1) and carbonic anhydrase 5B (CA5B), as individual targets 
and in combination, based on 143 drugs that were measured consistently at both targets. (B) 
PPV and fraction of drugs associated with Neuroleptic Malignant Syndrome that are active at the 
dopamine D2 receptor (DRD2) and norepinephrine transporter (SLC6A2), as individual targets 
and in combination, based on 320 drugs that were measured at both targets. 
The AE with the highest overall percentage of AE-associated drugs detected by a combination of 
proteins is Neuroleptic Malignant Syndrome in the SIDER dataset (Figure 4.11B); considering 
activity at either the dopamine D2 receptor or the norepinephrine transporter detects 69% of AE-
associated drugs with an overall PPV of 0.32. These targets are consistent with currently known 
mechanisms behind Neuroleptic Malignant Syndrome (204). The finding that more AE-associated 
drugs can be identified by using combinations of targets as opposed to single targets is consistent 
with the knowledge that AEs or toxicities can be caused by multiple mechanisms involving 
different targets. Thus, this partially explains the low sensitivity of single targets observed earlier 
(Figure 4.6). Although here only combinations of targets with the ‘or’ operator were explored, 
simultaneous modulation of targets – ‘and’ operator – may also explain some AEs, but would not 




The analysis performed here to identify targets that provide orthogonal, as opposed to redundant 
information, bears similarity to a recent approach used by Bendels et al. (65), who used iterative 
pairwise comparisons of active ligands at different targets to identify redundant versus ‘diverse’ 
assays. In the study, assays with many common active ligands were deselected for an optimised 
panel, whereas targets with low levels of common actives were prioritised for inclusion (65). Their 
work identified targets sharing a common profile of active ligands, prompting deselection of one 
of the targets, whereas the combinations in this work highlight the opposite: targets providing 
complementary information. 
 
In conclusion, in about 40% of AEs in the study, considering activity at each of a set of targets 
associated with the same event can improve the detection of AE-associated drugs by a median 
one-fifth to one-third, with in general lower decreases in PPV, indicating a useful trade-off. 
4.3.8 Types of AEs associated with protein activity and hence potentially detectable 
from safety pharmacology screens 
In order to estimate what fraction of AEs may be detectable from protein-based safety 
pharmacology screens, the fraction of unique AEs in the dataset that have at least one significantly 
associated target was determined. Of all unique AEs, 8.5% in the SIDER dataset and 2.9% in the 
FAERS dataset have one or more significantly associated target. These low percentages are 
partially due to the use of unbound plasma concentrations, which restricted the total amount of 
data available for analysis, since the percentages for the constant cut-off (pChEMBL ³ 6) dataset 
are 44.1% (SIDER) and 19.6% (FAERS). This figure for SIDER is similar to the 51% of AEs 
being related to targets in the study by Kuhn et al. (150). However, based on the trade-off observed 
in this work between PPV and fraction of AE-associated drugs detected, the above numbers are a 
result of trading one for the other, the desirability of which depends on the particular situation. 
 
The fact that the percentage is lower for FAERS could be related to the presence of biases and 
the noisier nature of FAERS reporting (7). FAERS also contains a greater diversity of AEs related 
to a similar number of drugs compared to SIDER, which was discussed in chapter 2, and target-
AE associations are less likely to be detected when only a few drugs are associated, such as to rare 
events (150). The fractions of unique AEs that can be statistically related to targets could be 
considered low compared to the figure of 75% of reported AEs being predictable from 
pharmacology (10, 15), but these latter estimates are based on the frequency of the AE in the 
population, whereas the numbers from this study look at unique AEs.  
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To examine differences in how AEs belonging to different SOC are associated with targets, the 
fraction of unique AEs that is significantly associated with targets was compared with the fraction 
of unique AEs in the underlying dataset of drug-AE associations, which includes AEs that could 
not be statistically related to targets (Figure 4.12). The results show that AEs in some SOCs are 
more frequently associated with targets than AEs from other classes. For example, the largest 
percentage difference is observed for AEs in the ‘metabolism and nutrition disorders’ class, which 
comprise 3.9% (SIDER) and 2.7% (FAERS) of unique AEs in the underlying datasets, but 9.4% 
(SIDER) and 10.3% (FAERS) of AEs statistically associated with targets (Figure 4.12). The next 
largest overrepresented classes are GI, nervous system, and psychiatric disorders in FAERS. These 
results are similar to prominent SOCs in the recent study by Ietswaart et al., who associated 
HLGTs of AEs with protein targets using FAERS, since GI and psychiatric disorders were among 
the largest classes in terms of the corresponding HLGTs being significantly related to activities 
(159). For SIDER, the next largest overrepresented classes are nervous system, ‘blood and 
lymphatic system’, and ‘respiratory, thoracic and mediastinal’ disorders.  
 
The enrichment of ‘metabolism and nutrition disorders’ and GI disorders suggest these are more 
often effects that can be related to pharmacological action, as suggested by familiar examples being 
retrieved in this study, such as cyclooxygenase-1 and gastric ulceration (19), and muscarinic 
acetylcholine receptor M3-mediated dry mouth and constipation (19). In chapter 2, GI disorders 
were also found to have the largest number of drugs associated with them (Figure 2.17), thus 
forming a larger dataset for statistical discovery. AEs in some of the above enriched SOCs also 
ranked highly for correspondence to target phenotypes in the study by Deaton et al. (64), such as 
platelet disorders and nonhaemolytic anaemias (blood and lymphatic system), and glucose 
metabolism disorders (metabolism and nutrition disorders), supporting, from a different angle, the 
observation that AEs in some SOCs may be more easily related to knowledge of the secondary 




Figure 4.12 Relating AEs to targets by SOC, comparing the AEs in the underlying drug-AE 
datasets for SIDER and FAERS to those AEs that are statistically associated with targets in the 
study. AEs in some classes (e.g. ‘metabolism and nutrition disorders’) are more often associated 
with targets, whereas AEs in other classes are present in the dataset but rarely associated with 
targets (e.g. ‘infections and infestations’). 
 
The overrepresentation of nervous system, psychiatric, and respiratory disorders in both FAERS 
and SIDER noted above could be related to the prominent presence of GPCRs in the dataset, 
which frequently target these organ systems and neurotransmission generally (18, 19). In contrast, 
the largest underrepresented class is ‘investigations’, which makes up 5.9% (SIDER) and 9.3% 
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(FAERS) of AEs in the underlying dataset, but only 1.0% (SIDER) and 3.1% (FAERS) of the set 
related to targets (Figure 4.12). AEs in this category are sometimes relatively unspecific such as 
‘blood test abnormal’, which might be a reason for the lack of associations to targets. Similarly, the 
next most underrepresented classes are ‘musculoskeletal and connective tissue disorders’ for 
SIDER and ‘infections and infestations’ in FAERS. Many mechanisms by which drugs can increase 
susceptibility to infections, such as immunosuppression due to cytotoxicity (14), or disruption of 
the gut microbiota (205), are not covered by in vitro pharmacology, explaining their 
underrepresentation. Overall, it can be concluded that target-AE associations are not uniformly 
distributed across SOCs, with classes such as ‘metabolism and nutrition disorders’ and nervous 
system disorders being most frequently related to pharmacological targets. SOCs with few 
significant relationships to targets may represent areas in which there is limited in vitro-in vivo 
concordance based on pharmacological activities, thus these may not be expected to be detectable 
from secondary pharmacology screening. 
4.3.9 Protein activities are frequently associated with different AEs in FAERS and 
SIDER 
To investigate the extent to which FAERS and SIDER are complementary for identifying target-
AE associations, the overlap in AEs associated with the same targets in either dataset was 
calculated (Table 4.6). The highest overlap in unique PTs between the datasets is 7% for the 
dopamine D2 receptor (Table 4.6). Considering the HLT increases the overlap to some extent, but 
apart from hERG, which is associated with ‘ventricular arrhythmias and cardiac arrest’ in both 
datasets, leading to 100% overlap in HLTs, the next highest overlap is still low at only 10% for the 
dopamine D2 receptor (Table 4.6). This means that in the current work, the FAERS and SIDER 
datasets contain nearly completely disjointed sets of AEs for the same targets, thus being highly 
complementary. The complementarity could reflect different AEs being reported in clinical trials 
versus post-marketing phases, for example due to more detailed patient observation in clinical 
trials, or due to or differences in short and long-term drug effects. The latter is also supported by 
the observation that FAERS is the only dataset providing target-AE associations in some SOCs, 
such as neoplasms and ‘pregnancy, puerperium and perinatal conditions’ (Figure 4.12), which 
could be related to long-term use and the more diverse populations exposed in the post-marketing 
phase. Other reasons for differences in the reported AEs are that AEs already listed on a drug 
label are less likely to get reported to post-marketing systems (21), and the inclusion of more 
uncertain reports in FAERS due to lack of causal evidence and submission by patients as opposed 
to healthcare professionals (7, 73). Thus, it is concluded that FAERS and SIDER provide different 
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target-AE associations and could each provide added value for detecting target-AE associations. 
A previous study solely considered AEs reported in both FAERS and SIDER (64), but the results 
from this work suggest this approach would potentially result in a large part of the AE space not 
being considered.   
Table 4.6. Targets with significantly associated AEs, showing the number of unique associated 






















Dopamine D2 receptor 31 15 7.0 10.3 
Dopamine D3 receptor 13 8 5.0 5.3 
Serotonin transporter 6 22 3.7 4.3 
Serotonin 2a (5-HT2a) receptor 9 27 2.9 3.2 
Carbonic anhydrase 5B 27 0 0.0 0.0 
Muscarinic acetylcholine receptor 
M3 
24 0 0.0 0.0 
Norepinephrine transporter 19 0 0.0 0.0 
a-1d adrenergic receptor 18 4 0.0 0.0 
Muscarinic acetylcholine receptor 
M5 
15 0 0.0 0.0 
Muscarinic acetylcholine receptor 
M1 
15 0 0.0 0.0 
Dopamine D1 receptor 15 0 0.0 0.0 
Carbonic anhydrase 5A 15 0 0.0 0.0 
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Histamine H1 receptor 13 16 0.0 0.0 
Serotonin 6 (5-HT6) receptor 11 0 0.0 0.0 
Muscarinic acetylcholine receptor 
M4 
10 0 0.0 0.0 
b-1 adrenergic receptor 9 0 0.0 0.0 
Carbonic anhydrase 12 8 0 0.0 0.0 
Carbonic anhydrase 9 8 0 0.0 0.0 
s opioid receptor 8 0 0.0 0.0 
Carbonic anhydrase 2 5 7 0.0 0.0 
Carbonic anhydrase 1 5 0 0.0 0.0 
a-2c adrenergic receptor 4 13 0.0 0.0 
Serotonin 2c (5-HT2c) receptor 4 12 0.0 0.0 
a-2b adrenergic receptor 3 1 0.0 0.0 
Carbonic anhydrase 4 3 1 0.0 0.0 
Muscarinic acetylcholine receptor 
M2 
3 0 0.0 0.0 
k opioid receptor 2 1 0.0 0.0 
d opioid receptor 2 1 0.0 0.0 
a-2a adrenergic receptor 2 0 0.0 0.0 
Carbonic anhydrase 7 2 0 0.0 0.0 
Serotonin 7 (5-HT7) receptor 1 20 0.0 0.0 
Serotonin 2b (5-HT2b) receptor 1 10 0.0 0.0 
hERG 1 1 0.0 100.0 
Dopamine transporter 1 0 0.0 0.0 
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Type-1 angiotensin II receptor 1 0 0.0 0.0 
Carbonic anhydrase 14 1 0 0.0 0.0 
a-1a adrenergic receptor 0 19 0.0 0.0 
Dopamine D4 receptor 0 14 0.0 0.0 
µ opioid receptor 0 8 0.0 0.0 
a-1b adrenergic receptor 0 7 0.0 0.0 
Cyclooxygenase-2 0 6 0.0 0.0 
Cyclooxygenase-1 0 6 0.0 0.0 
Angiotensin-converting enzyme 0 3 0.0 0.0 
Dopamine D5 receptor 0 1 0.0 0.0 
Microtubule-associated protein t 0 1 0.0 0.0 
 
4.4 Conclusions 
In this chapter, associations between drugs’ pharmacological activities and AEs observed in clinical 
trials and during post-marketing surveillance were identified and quantified.  
 
Taking into account unbound drug plasma concentrations reduced the size of the dataset by about 
half, but increased the PPV and LR of associations reported in previous literature at the cost of 
lower recall. This suggests that adjusting activity calls with unbound plasma concentrations results 
in more precise associations but that recall is currently limited by data availability. 
 
Many of the most predictive associations in the current study are supported by previous literature, 
but some associations appeared to be related to compound promiscuity, which remains a source 
of potential false positive associations in studies of statistical nature. Thus, regarding any statistical 
associations derived in this study, further research would be needed to confirm mechanistic links. 
Key novel findings such as the association of CA5A and CA5B with liver effects would be 
suggested for further investigation and future inclusion in safety target panels. 
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The global assessment of the distribution of predictive values and sensitivity of target-AE 
associations shows that in vitro bioactivities rarely directly translate into in vivo effects based on the 
datasets studied, with predictive values for individual in vitro activities centred around 40%, with 
lower values (25%) applying to FAERS datapoints. A range of limitations of the study, such as 
survivor bias in approved drugs and incomplete consideration of dose, as well as of current 
knowledge and available data, such as tissue distribution of drugs, may be related to these 
observations. The low sensitivity could be partially rescued by considering activity at multiple 
targets associated with the same event, which improved the detection of AE-associated drugs in 
the case of around 40% of AEs at the cost of lower precision. 
 
Furthermore, it was found that significant AE associations are not uniformly distributed across 
SOCs, and AEs in enriched SOCs such as nervous system and GI disorders are more frequently 
associated with pharmacological activities in this study, suggesting they may be more easily 
detectable from secondary pharmacology screening. 
 
Lastly, FAERS and SIDER show a low overlap in terms of AEs and resulting target-AE 





5.1 Summary of contribution 
The aim of this research was to investigate target-AE associations in a systematic way, using 
datasets with improved reliability and accuracy compared to previous work. Therefore, 
confounding factors in the post-marketing drug-AE dataset were controlled with PSM, and drug 
plasma concentrations were integrated with in vitro bioactivity data to improve the in vivo relevance 
of drug-target annotations.  
 
The value in the first part of the work, applying PSM on the FAERS AEOLUS database and 
examining the impact on indication bias, lies in applying this method for bias control, which 
originated in the field of epidemiology, to the area of drug discovery informatics, given only few 
related analyses previously conducted focused on deriving target-AE relationships whilst 
controlling confounding factors. Extending the work by Tatonetti et al. (206), the current work 
constitutes an independent validation of the benefit of using PSM in reducing false associations of 
drugs with drug indications in FAERS. 
 
Next, this work assessed the impact of using unbound drug plasma concentrations on activity calls 
as well as on derived target-AE associations. While existing literature on safety pharmacology 
screening frequently stresses the importance of considering unbound drug plasma concentrations, 
and this being standard practice in risk assessment, this thesis has for the first time brought insights 
into the impact of doing so on a larger scale using publicly available data. The halving of available 
drug-target datapoints by requiring drug plasma data, and the lower overall retrieval of previously 
reported target-AE associations when using adjusted activity calls shows that data availability is 
still a limitation. Nevertheless, the results suggest that using unbound drug plasma concentrations 
results in activity calls that are more useful (higher LRs) for anticipating AEs and have higher 
precision, based on the retrieval of currently known safety targets. Therefore, this work contributes 
insight into the trade-off between the availability and the precision of currently available data.  
 
The target-AE associations computed in this work provide novel suggestions of targets for future 
investigation and possible inclusion on future screening panels, such as CA5A and CA5B in 
relation to liver toxicity. In addition, this work provides a large-scale quantification of target-AE 
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associations which was previously unavailable, presenting the distribution of LRs and predictive 
values of diverse target-AE associations across the dataset. These results help to identify the targets 
most strongly associated with AEs, provide evidence for the design of future safety pharmacology 
panels and provide suggestions for the development of in silico models. The quantified results are 
useful to the interpretation of secondary pharmacology results by providing, based on 
retrospective analysis, an estimate of the probability of in vivo events given a certain bioactivity.  
 
The global assessment of predictive values of target-AE associations in this work has highlighted 
that many targets do not have a perfect association to AEs in vivo, with AEs in some SOCs being 
more frequently related to pharmacological effects than those in other SOCs. The value of these 
results lies in the highlighting of areas in need of future development, such as the lack of complete 
functional bioactivity data (agonism versus antagonism), and the lack of data regarding the 
distribution of drugs across different tissues, which may be a factor in the low sensitivities and 
value-added PPVs observed here. The results are also relevant to developments in predictive 
toxicology, some of which focus on applying machine learning to predict target bioactivities for 
lists of toxicity-related targets or assays (207–209). Such efforts will be most useful if the targets 
modelled are strong indicators of in vivo effects. 
 
Lastly, this work prevents novel findings in two other areas, which are (1) the extent to which 
combinations of targets may be able to increase the detection of AE-associated drugs without 
adding redundancy to targets included in screening and (2) the extent of complementarity between 
FAERS and SIDER. Overall, based on a comparison of the the drug-AE datasets and the 
computed target-AE associations, it was found that FAERS and SIDER have a low overlap of AE 
terms and provide complementary information. 
5.2 Limitations 
Several limitations primarily relating to the underlying data have affected this work. Chapter 2 
discussed the limitations of the FAERS and SIDER datasets in terms of the compiled drug-AE 
relationships, such as the biases affecting FAERS. The datasets used in this work are inevitably 
not fully comprehensive and contain possible false labels. The bioactivity data is affected by 
sparsity and the inclusion of predicted datapoints with their associated errors, thus it is possible 
that the absence or inaccuracy of certain associations in this dataset is related to these limitations. 
Furthermore, there is a lack of comprehensive functional (agonism or antagonism) effects on 
targets and thus this was not included in the work. This may have resulted in the masking of 
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associations only associated with certain functional effects or modes of action. Lastly, chapter 3 
discussed some of the limitations of the drug plasma concentrations, including that they only 
consider the therapeutic range and are not specific to the patients affected by AEs in FAERS or 
SIDER. Overall, these factors affecting the underlying data sources have most likely limited the 
sensitivity and specificity in terms of discovering underlying, causative target-AE relationships in 
this study, and maybe have contributed to low predictive values observed. 
 
Regarding data limitations, a theme that emerged throughout the work is the balance between data 
availability and data quality. For example, attempting to increase the quality of the data by using 
unbound plasma concentrations resulted in a decrease in the number of drug-target datapoints 
available. Similarly, when setting minimum thresholds for the target prediction model performance 
and applicability domain, and a minimum number of drugs in two-by-two tables, less data became 
available and certain target classes were underrepresented such as kinases. The trade-off between 
data quality and quantity represents a recurring limitation in this work of which the impact is 
difficult to evaluate without a gold standard of target-AE associations.  
 
Chapter 4 discussed how the ‘survivor bias’ affecting marketed drugs, as well as the incomplete 
consideration of dose, may explain why some previously reported associations were not observed 
in the current work and other associations may have low predictive values. However, even when 
additional doses would have been considered, there is also considerable inter-individual variation 
in pharmacokinetics that can contribute to ADRs (14, 36). This is one of a wider range of factors 
that were beyond the scope of this study, with others being drug metabolites and patient genetics 
affecting the susceptibility to ADRs (14, 36).  
 
Ultimately, there will also be a limit to the extent to which currently known or predicted specific 
drug-target interactions may be able to explain ADRs, because additional mechanisms that cause 
ADRs, such as immunological reactions (14, 210), are not covered by pharmacological drug-target 
interactions. Furthermore, there are unexplored proteins in the human proteome which may be 
relevant to ADRs but are not yet included in currently available experimental data (211). Lastly, 
the statistical nature of the current work means that the causal nature of suggestions of associations 






5.3 Future outlook 
 
While the amount of bioactivity data in ChEMBL and other resources continues to increase, given 
this is dependent on manual extraction from scientific literature (105), it is not likely that more 
complete matrices of bioactivity data for existing drugs will be available soon. The most obvious 
ways to increase the amount of bioactivity data for analysis would be to consider resources that 
have integrated multiple other bioactivity databases such as ExCAPE-DB (108), which by 
incorporating PubChem includes more data, or by drawing on legacy datasets from Bioprint (69) 
or the pharmaceutical industry (212), although the latter two are not publicly accessible. An 
alternative approach being developed by Lhasa Limited is to train target prediction models on 
private data from multiple companies and then make target predictions on public compounds 
available to other users without sharing the original training data (213, 214). This should result in 
better target predictions models and more predictions being available, given the larger and 
potentially more diverse training set, as was demonstrated in the case of hERG (213, 214). This 
approach could be useful for the study of marketed drugs and would be expected to provide more 
reliable and a greater number of target predictions, although these would be limited to targets that 
have been consistently measured at different companies. 
 
A feasible, natural extension of the current work using public domain data would be to consider 
the Tox21 screening data (111, 153, 215), which has the advantages of being a fully screened matrix 
that includes marketed drugs, and includes assays for the detection of agonism and antagonism 
modes as well as a range of more general stress response pathways. This would address some of 
the limitations of considering pharmacology data only, and potentially expand the range of AEs 
that may be related to in vitro assay activities. Different normalisation procedures have been 
published by a number of institutes involved in generating the Tox21 dataset (215–217), each 
emphasizing different aspects, thus consideration needs to be given to the pre-processing of the 
data before being able to extract the AC50 values from the dataset. A few studies have used the 
dataset to relate targets to different in vivo effects (154, 186) although more have tried to predict in 
vivo toxicities directly (111, 218, 219).  
 
Increasing the amount of drug plasma concentration data by manual extraction from scientific 
literature is laborious, but progress is being made in automated approaches for the prediction of 
drug plasma concentrations, such as the High-Throughput Toxicokinetics (HTTK) package (220). 
The parameters needed to obtain predictions for the steady-state drug plasma concentrations with 
 162 
the HTTK package are the in vitro intrinsic clearance and the unbound drug fraction, which may 
be determined using in vitro assays (220). The HTTK package includes such data derived from 
human-specific in vitro assays for 94 drugs (220), so additional data gathering would be needed to 
use the HTTK models for more drugs. While the HTTK models are less sophisticated than 
physiologically-based pharmacokinetic models based on in vivo data (220), and predictions will be 
less accurate than measured values, it would valuable to examine whether using these high-
throughput style predictions are an improvement over using 1 or 10 µM as a cut-off for activity 
calls in secondary pharmacology screening, which is current practice at early stages (19, 22, 65). A 
recent study found that using the HTTK package improved concordance between in vitro activities 
in ToxCast and in vivo toxicities in rat for a set of 84 chemicals (221). Measured plasma 
concentrations could be supplemented by predicted concentrations, similar to the way target 
predictions were used in chapter 3, and the approach could be evaluated by comparing the resulting 
drug-AE associations, the same way the dataset derived from using a constant cut-off was 
compared to using adjusted activity calls based on the unbound plasma concentrations in chapter 
4. 
 
Another idea for future work is to consider greater variation in plasma concentrations, as opposed 
to the single, therapeutic concentrations used in this work. Additionally the ‘toxic’ concentration 
could be used, which were reported for up to 1,000 drugs and chemicals in the publication by 
Schulz et al. (176) that also provided many therapeutic plasma concentrations used in this work, 
but it might be time-consuming to obtain this data for a larger set of drugs. However, considering 
higher plasma concentrations would represent situations such as drug-drug interactions, inter-
individual variation, and overdose, which are undoubtedly a factor in some ADRs (14, 36), and 
would therefore be valuable to consider. At higher plasma concentrations, drugs can interact with 
more targets, and more AEs may then be related to target activities, which might result in a higher 
retrieval of previously reported target-AE associations as well as help to identify novel 
relationships. It would be useful if the extent of pharmacokinetic variation could be represented 
as a distribution in order to derive different activity calls for different concentrations. The most 
easily accessible relevant data for this would be the range of effective therapeutic plasma 
concentrations, which have been reported for sets of marketed drugs (36, 176). 
 
Given the large jump made between in vitro and in vivo effects in this work, and the many processes 
existing in between that influence their concordance, an interesting recent development are the 
concepts of quantitative adverse outcome pathways (qAOPs), which aim to quantitatively link 
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molecular, cellular and organ biology leading to AEs (222) and quantitative systems toxicology 
(QST), which is defined as “an approach to quantitatively understand the toxic effects of a 
chemical on a living organism, from molecular alterations to phenotypical observations, through 
the integration of computational and experimental methods” (223). Only tens of qAOPs have 
currently been developed (222), and both qAOPs and QST face challenges in data availability (222, 
223). Considerable scientific efforts are needed to comprehensively understand and represent 
toxicity and pharmacological pathways (33, 222, 223), thus this is still years away. However, the 
better we are ultimately able to represent the multitude of processes involved in drugs’ effects and 
pharmacokinetic behaviour, the better we will be able to translate in vitro into in vivo effects and 
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Details for the target-AE associations with the highest Positive Predictive Values (PPVs) in the FAERS dataset based on the adjusted activity calls that 
integrate the unbound drug plasma concentration with measured and predicted in vitro bioactivities. LR=Likelihood Ratio. AE=adverse event. 
SOC=System Organ Class. Only the 50 most highly ranked are shown but the full data is available in the University of Cambridge repository 
(https://doi.org/10.17863/CAM.53868). 
 
























DUODENAL ULCER 455 27 0.3333 0.0047 71.3 1.1e-07 0.82 0.0593 1.00 Gastrointestinal 
Cyclooxygenase-
2 








































640 27 0.1481 0.0114 13.0 4.5e-02 0.36 0.0422 0.99 Renal and 
urinary 
hERG TORSADE DE POINTES 475 40 0.1750 0.0184 9.5 4.6e-02 0.47 0.0842 0.98 Cardiac 
a-1a adrenergic 
receptor 
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MELLITUS 
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MELLITUS 

































310 5 0.6000 0.0164 36.6 3.3e-02 0.38 0.0161 0.98 Nervous system 
a-1b adrenergic 
receptor 
TYPE 1 DIABETES 
MELLITUS 




TYPE 1 DIABETES 
MELLITUS 




TYPE 2 DIABETES 
MELLITUS 




TYPE 2 DIABETES 
MELLITUS 







640 26 0.1538 0.0114 13.5 4.2e-02 0.36 0.0406 0.99 Nervous system 
Dopamine D4 
receptor 















455 12 0.3333 0.0158 21.1 2.1e-02 0.36 0.0264 0.98 Gastrointestinal 
Cyclooxygenase-
1 
































Details for the target-AE associations with the highest Positive Predictive Values (PPVs) in the SIDER dataset based on the adjusted activity calls that 
integrate the unbound drug plasma concentration with measured and predicted in vitro bioactivities. LR=Likelihood Ratio. AE=adverse event. 
SOC=System Organ Class. Only the 50 most highly ranked are shown but the full data is available in the University of Cambridge repository 
(https://doi.org/10.17863/CAM.53868). 
















































PARAESTHESIA 191 80 0.0750 0.0000 inf 3.3e-02 1.00 0.4188 1.00 Nervous system 
Carbonic 
anhydrase 5A 


















































TREMOR 567 114 0.0526 0.0022 23.8 3.4e-02 0.86 0.2011 1.00 Nervous system 
Serotonin 6 (5-
HT6) receptor 




TREMOR 357 71 0.1127 0.0070 16.1 8.1e-03 0.70 0.1989 0.99 Nervous system 
Norepinephrine 
transporter 
TREMOR 508 93 0.0860 0.0096 8.9 1.7e-02 0.67 0.1831 0.99 Nervous system 
Serotonin 6 (5-
HT6) receptor 






























































































DRY MOUTH 546 94 0.0532 0.0044 12.0 4.1e-02 0.71 0.1722 1.00 Gastrointestinal 
a-1d adrenergic 
receptor 
OEDEMA 512 127 0.0709 0.0104 6.8 2.6e-02 0.69 0.2480 0.99 General 
b-1 adrenergic 
receptor 















191 32 0.1250 0.0126 9.9 4.9e-02 0.67 0.1675 0.99 Vascular 
Carbonic 
anhydrase 5A 
PANCREATITIS 216 27 0.1481 0.0106 14.0 3.1e-02 0.67 0.1250 0.99 Gastrointestinal 
Carbonic 
anhydrase 5B 












BLOOD URIC ACID 
INCREASED 





191 12 0.3333 0.0112 29.8 2.8e-03 0.67 0.0628 0.99 Renal and 
urinary 
 
 
 
 
 
 
 
 
